Mitochondrial Medicine: assay development and application with special emphasis on human complex V by Jonckheere, A.I.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/98583
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
M
itochondrial M
edicine: assay developm
ent and application w
ith special em
phasis on hum
an com
plex V
            A
n I. Jonckheere
MITOCHONDRIAL MEDICINE:
assay development and application 
with special emphasis on human complex V
An I. Jonckheere
UITNODIGING
voor het bijwonen van de 
openbare verdediging van 
mijn proefschrift
MITOCHONDRIAL MEDICINE: 
assay development and 
application with special 
emphasis on human complex V
 
op maandag 17 september 
2012
om 10.30 uur precies
Aula Major
Radboud Universiteit Nijmegen
Comeniuslaan 2
6525 HP Nijmegen
Aansluitend bent u van harte 
uitgenodigd op de receptie ter 
plaatse.
An Jonckheere
Zwaluwstraat 155
6541 NV Nijmegen
024-8444501
a.jonckheere@cukz.umcn.nl
Paranimfen: 
Merei Huigsloot
merei.huigsloot@gmail.com
Stefanie Henriet
s.henriet@cukz.umcn.nl
MITOCHONDRIAL MEDICINE: 
 
assay development and application  
with special emphasis on human complex V 
 
 
 
An Jonckheere 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial Medicine: assay development and application with special emphasis on  
human complex V 
Thesis Radboud University Nijmegen with a summary in Dutch 
 
© 2012 Jonckheere, An, Nijmegen, The Netherlands 
 
The research presented in this thesis was performed at the Department of Pediatrics,  
Radboud University Nijmegen Medical Center, The Netherlands. 
 
ISBN 978-94-6191-343-2 
 
Cover: artistic representation of a mitochondrion embedding the five OXPHOS complexes, and 
detailed structure of complex V or ATP synthase. 
 
Cover design and lay-out: An Jonckheere and Paul Van Herck 
 
Printed by Ipskamp Drukkers Nijmegen 
 
 
 
Mitochondrial Medicine: 
 
assay development and application  
with special emphasis on human complex V 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proefschrift 
 
 
 
 
 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op 17 september 2012 
om 10.30 uur precies 
 
 
 
 
 
 
door 
 
 
 
An Isabel Jonckheere 
 
geboren op 15 maart 1976 
te Gent (België) 
Promotor 
Prof. dr. J.A.M. Smeitink 
 
Copromotor 
Dr. R.J.T. Rodenburg 
 
Manuscriptcommissie 
Prof. dr. M.A.A.P. Willemsen (voorzitter) 
Prof. dr. G. Vriend 
Prof. dr. F.A. Wijburg (AMC Amsterdam)  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Zo volmaakt, zoveel geluk en toch nog maar zo klein. 
(uit: Als je slaapt – Glennis Grace) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Aan mijn ouders 
 
Voor Paul 
 
Contents 
 
List of abbreviations           9 
 
Part I   General introduction 
 
Chapter 1  Mitochondria and disease        13 
 
 
Part II   Characterization of human cell lines with mitochondrial  
   dysfunction 
 
Chapter 2  A high-throughput assay to measure oxygen consumption in  
   digitonin-permeabilized cells of patients with mitochondrial 
disorders          29 
 
Chapter 3  Toolbox for mitochondrial biochemical characterization of 
myogenic cell lines from Leigh (-like) patients     51 
 
 
Part III   Complex V in health and disease 
 
Chapter 4  Mitochondrial ATP synthase: architecture, function and  
pathology          75 
 
Chapter 5  A novel mitochondrial ATP8 (MT-ATP8) gene mutation in a  
   patient with apical hypertrophic cardiomyopathy  
   and neuropathy       111 
 
Chapter 6  Restoration of complex V deficiency caused by a novel  
   deletion in the human TMEM70 gene normalizes  
   mitochondrial morphology      131 
 
Chapter 7  Functional assays preceding exome sequencing: a rational  
   strategy        161 
 
 
Part IV  General discussion 
 
Chapter 8  General discussion, future perspectives and conclusions  187 
 
Summary           199 
 
Samenvatting (Dutch summary)        205 
 
Dankwoord/ Acknowledgements        211 
 
Curriculum Vitae          215 
 
List of publications          219 
 
Appendix           223 
 
  
 
 
  
List of abbreviations 
 
 
ANT adenine nucleotide transporter 
ADP adenosine diphosphate 
ATP adenosine triphosphate 
BN blue native 
Bp base pair 
CCCP carbonyl cyanide 3-chlorophenyl hydrazone 
cDNA coding DNA 
C.I - C.V complex I – complex V 
CN clear native 
CO2 carbon dioxide 
CoQ coenzyme Q or ubiquinone 
Cox8 mitochondrial targeting sequence of cytochrome c oxidase subunit 8A 
COX cytochrome c oxidase or complex IV 
CS citrate synthase 
Cyt c cytochrome c 
∆ψm mitochondrial membrane potential 
DNA deoxyribonucleic acid 
FADH2 flavine adenine dinucleotide (reduced form) 
gDNA genomic DNA 
GFP green fluorescent protein 
HEK human embryonic kidney 
HHH-syndrome hyperammonemia-hyperornithinemia-homocitrullinuria - syndrome 
IGA in-gel activity 
kDa kilo Dalton 
MEGS mitochondrial energy-generating system 
MILS maternally inherited Leigh syndrome 
MRI magnetic resonance imaging 
Mt mitochondrial 
mtDNA mitochondrial DNA 
NAD(H) nicotinamide adenine dinucleotide (reduced form) 
NARP neuropathy, ataxia and retinitis pigmentosa 
nDNA nuclear DNA 
OSCP oligomycin sensitivity-conferring protein 
OXPHOS oxidative phosphorylation 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDHc pyruvate dehydrogenase complex 
Pi inorganic phosphate 
POLG polymerase gamma 
RFU relative fluorescence units 
RNA ribonucleic acid 
ROCR relative oxygen consumption rate 
RT-PCR reverse transcriptase PCR 
SDS sodium dodecyl sulphate 
TCA cycle tricarboxylic acid cycle 
TMEM70 transmembrane protein 70 
tRNA transfer RNA 
  
 
  
 
 
 
 
 
 
PART I 
 
 
GENERAL INTRODUCTION 
 
  
  
 
 
  
1 
 
 
 
 
Mitochondria and disease 
  
  
 
Mitochondria and disease 
15 
 
MITOCHONDRIAL BIOLOGY: THE OXPHOS SYSTEM 
 
Mitochondria are subcellular organelles, present in virtually every human cell and essential 
for survival (1). The organelles have a double-membrane and are equipped to produce ATP 
and provide this as the energy source for intracellular metabolic pathways (1-2) (Figure 1). 
Mitochondria are also involved in cell signaling, especially signaling for apoptotic cell death, 
and host other metabolic pathways including the fatty acid β-oxidation and lipid and 
cholesterol synthesis (1).  
 
 
Figure 1 The mitochondrion. 
Mitochondria are enclosed by a double 
membrane. The inner membrane is 
composed of two subdomains: the 
inner boundary membrane and the 
cristae membrane. Cristae are 
invaginations of the inner membrane 
that are connected to the inner 
boundary membrane by narrow tubular 
structures, so-called crista junctions 
(3). 
 
 
 
 
 
 
 
 
 
 
The mitochondrial oxidative phosphorylation (OXPHOS) system is the final biochemical 
pathway in the oxidative production of ATP (4). Enzymes or enzyme complexes directly 
involved in the generation of chemical energy by OXPHOS also comprise the pyruvate 
dehydrogenase complex (PDHc) and the tricarboxylic acid cycle (Figure 2). The OXPHOS 
system consists of five multiprotein complexes (I (EC 1.6.5.3), II (EC 1.3.5.1), III (EC 
1.10.2.2), IV (EC 1.9.3.1), and V (EC 3.6.3.14)) and two electron carriers – coenzyme Q and 
cytochrome c -, embedded in the inner mitochondrial membrane (2, 4). The main function of 
the system is the coordinated transport of electrons and protons, which leads to the 
production of ATP (4). The first two events of respiration, i.e. electron transfer and proton 
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pumping, are carried out by the mitochondrial respiratory chain, composed of the first four 
complexes (C.I-IV) (2, 4).  
Figure 2 The energy metabolism. One of the main functions of mitochondria is to produce 
energy in the form of ATP by fatty acid oxidation, the oxidation of acetyl-CoA in the 
tricarboxylic acid (TCA) cycle, and oxidative phosphorylation (OXPHOS). The TCA cycle 
produces four NADH which are oxidized by complex I and one FADH2 which is oxidized by 
complex II. The redox reactions in complexes I to IV (the respiratory chain) generate a proton 
gradient across the inner mitochondrial membrane. The energy created by this proton 
electrochemical gradient is used by complex V to synthesize ATP from ADP. The OXPHOS 
complexes are, except for complex II, under dual genetic control, the number of subunits 
encoded by the nuclear (n) DNA and the mitochondrial (mt) DNA is indicated. Adapted from 
Zschocke/ Hoffman. Vademecum Metabolicum. 
 
 
Basically, the respiratory chain accepts electrons from NADH (complex I) and FADH2 
(complex II) and subsequently transfers them through a series of oxidation-reduction 
reactions (via coenzyme Q, complex III and cytochrome c) to molecular oxygen to produce 
water (complex IV). Simultaneously this reaction is coupled to the translocation of protons 
across the inner membrane (complex I, III, IV) (5-6). Synthesis of ATP from ADP is the 
second fundamental reaction of the OXPHOS system, a process catalyzed by complex V 
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(ATP synthase) (2). Electron transfer across the respiratory chain and ATP synthesis are 
coupled (2). The respiratory chain works as a proton pump which generates a proton 
gradient and a membrane potential of about -180 mV across the inner membrane (2). 
Complex V uses the energy created by the proton electrochemical gradient to phosphorylate 
ADP to ATP in the mitochondrial matrix (7-8). During this process the proton gradient is 
decreased and this activates respiration, i.e. electron transfer in order to maintain the 
membrane potential (5). 
The formation of the OXPHOS system is under the control of two separate genetic systems, 
the nuclear genome and the mitochondrial genome (mitochondrial DNA (mtDNA)). Four of 
the five OXPHOS complexes (I, III, IV and V) contain both nuclear-encoded and mtDNA-
encoded proteins. Human mtDNA is a circular double stranded molecule of 16.569 base pair 
(bp) and codes for 22 transfer and two ribosomal RNAs, and 13 messenger RNAs (1). 
Transmission of mtDNA occurs through the maternal lineage. There are hundreds to 
thousands of mtDNA molecules per cell, and mostly their sequence will be identical 
(homoplasmy) (1). The coexistence of wild type and mutant mtDNA is called heteroplasmy. 
During mitosis mtDNA molecules are randomly distributed to daughter cells (mitotic 
segregation). This means that the degree of heteroplasmy can change drastically between 
different generations of families, but also between tissues in one affected person, and even 
in one tissue through time. The OXPHOS system malfunctions if a critical number of mutated 
mtDNAs is present. This is called the threshold effect (4). MtDNA remains entirely dependent 
upon the nucleus for provision of enzymes for replication, repair, transcription and translation 
(1). The protein subunits of the OXPHOS complexes are assembled by a set of assembly 
factors, encoded by the nuclear DNA (1). Accordingly, many different mutations in mtDNA- 
and nuclear DNA-encoding subunits, components or regulators of the OXPHOS system can 
produce a broad spectrum of OXPHOS diseases (9-10). Mitochondrial diseases are indeed 
among the most common genetic disorders with a prevalence of at least 1 in 5000 (11). 
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MITOCHONDRIAL BIOCHEMISTRY 
 
Because of the heterogeneous clinical presentation and organ involvement, the diagnosis of 
a mitochondrial disease is, in the group of inborn errors of metabolism, not straightforward. 
Nevertheless, significant progress has been made over the past few years in the diagnostic 
possibilities for OXPHOS defects (12-14). Gold standard in the diagnostic process is a fresh 
muscle biopsy from the M. quadriceps in which the mitochondrial energy-generating system 
(MEGS) capacity is studied. This can be done by measuring oxidation rates of [1-14C]-
pyruvate + malate in the presence and absence of adenosine diphosphate (ADP), [1-
14C]pyruvate + carnitine, and the ATP production rate from oxidation of pyruvate + malate in 
fully coupled muscle mitochondria as described in (13), or by examining mitochondrial 
respiration with oxygen consumption measurements. In addition, complex I to V activities are 
analyzed using spectrophotometry (12), a radiochemical method is used to measure PDHc 
activity (15). Molecular genetic analysis is performed afterwards, oriented on the biochemical 
results. Currently, mtDNA can be analyzed quickly and completely with the Affymetrix Human 
Mitochondrial Resequencing Array 2.0. Also the analysis of many nuclear encoded genes 
(subunits of the respiratory chain complexes, assembly factors, transcription and translation 
genes) can be performed in the diagnostic laboratory. Despite this, the underlying genetic 
defect can hitherto be identified in only 50% of patients with a complex deficiency. This will 
probably be countered using whole genome and whole exome sequencing. Nowadays, these 
techniques are continuously optimized and become cheaper and faster, therefore it is 
expected that they will be implemented in a diagnostic setting on short notice. However, a 
considerable diagnostic challenge concerns the group of patients with a defect in the MEGS 
capacity outside the respiratory chain, complex V and PDHc. In our experience, this group 
forms a large subset of mitochondrial patients (1/3 of the patients in Nijmegen, diagnosed in 
the years 2005-2009 (16)). A mitochondriopathy characterized by isolated MEGS capacity 
disturbances can be primary or secondary. Therefore, it is first necessary to exclude 
secondary MEGS dysfunction in muscle tissue (e.g. as a consequence of disuse or poor 
Mitochondria and disease 
 
19 
 
feeding (17)). Subsequently, it must be aimed to confirm the primary nature of the 
mitochondriopathy. Generally, the approach is two-fold: biochemical and functional studies in 
a second tissue, and genetic analysis. mtDNA mutations are now often found and it has been 
shown that the MEGS capacity has a greater sensitivity than respiratory chain enzymatic 
activities for the detection of rare or new mtDNA mutations, or mtDNA mutations with low 
mutation loads (18). Also the polymerase gamma (POLG) gene (mitochondrial 
deletions/depletion) is commonly screened in this setting. Measurements in a second tissue 
are commonly performed in fibroblasts out of combined skin-muscle biopsies. The respiratory 
chain, complex V and PDHc enzyme activities can routinely be determined. Measuring ATP 
synthesis in fibroblasts has been described (19). Different approaches for measuring the 
oxygen consumption rate are available. Polarographic studies using the Clark-type oxygen 
electrode are well established and can be performed in different cell types and tissues (20). 
The relatively low sample throughput however is a limitation. A more advanced technique 
which measures the changes in oxygen and proton concentrations in the media surrounding 
cells is very informative but requires specialized equipment (21). 
Despite this substantial diagnostic capacity approximately 50% of the patients with a primary 
MEGS dysfunction still remain unsolved. This has been recognized earlier (22). It 
complicates diagnosis, prognosis, supportive treatment and counseling in the clinical setting. 
In PART II of this thesis, we try to address this problem with appropriate additional functional 
studies in different human cell lines. First, we adapt a protocol using quenched-fluorescence 
oxygen sensing (23) to measure mitochondrial respiration in digitonin-permeabilized cells. 
This high-throughput assay can identify patients with mitochondrial dysfunction in different 
cell types. Second, we adapt this oxygen consumption assay and other diagnostic 
biochemical assays to characterize muscle cells. Combined with general (whole genome or 
whole exome sequencing) and more targeted (e.g. homozygosity mapping) genetic studies 
we hope to facilitate the search for genetic defects localized on hitherto unknown loci 
involved in mitochondrial metabolism. Moreover, the application of an extended biochemical 
and genetic toolbox in human cell lines will help to improve the (patho)physiological 
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knowledge of mitochondria and mitochondrial diseases. The study of muscle cells is 
important in this setting since this is a clinically important cell type. Understanding the nature 
of the broad and devastating group of mitochondrial diseases is indispensable for the 
ultimate goal, which is the development of (a) curative therap(y)ies. 
 
 
AIMS 
 
The first aim in this thesis is to expand current tools for biochemical diagnostics in patients 
suspected for a mitochondrial disease (PART II). 
Unraveling the underlying genetic mutation and studying the functional impact of the defect in 
patients with a complex V deficiency is the second goal (PART III). 
 
 
OUTLINE OF THE THESIS 
 
PART I: General introduction 
 
Chapter 1 introduces the OXPHOS system and describes current biochemical and molecular 
tools in mitochondrial diagnostics, which creates the framework for the study of additional 
functional assays in human cell lines (PART II of this thesis). Finally, the aims and outline of 
the thesis are given. 
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PART II: Characterization of human cell lines with mitochondrial dysfunction 
 
Muscle biopsy analysis is regarded as the gold standard in diagnostic workups of patients 
with suspected mitochondrial disorders (12). Cultured fibroblasts are mostly used to confirm 
the defect in a second tissue. The measurement of individual OXPHOS complexes however 
does not always provide sufficient information about the functional state of the complete 
mitochondrial energy-generating system. Therefore, the aim of the study in chapter 2 is to 
adapt a protocol allowing quenched-fluorescence oxygen sensing to be used in the 
diagnostic evaluation of suspected mitochondrial disorders in patient-derived cells. 
 
Fibroblasts are vital cell models for additional functional studies. Limitations however are 
their relatively low mitochondrial activity, the slow growth rate and a poor resemblance with 
muscle tissue. Muscle-derived cell lines can overcome these limitations. Therefore, the aim 
of the study in chapter 3 is two-fold: first, to establish OXPHOS-deficient myogenic cell lines 
and second, to test if several biochemical assays which assess the MEGS as a whole such 
as pyruvate oxidation, ATP production and oxygen consumption, can be adapted for both 
myoblasts and myotubes. 
 
 
PART III: Complex V in health and disease 
 
Mitochondrial ATP production is the main energy source for intracellular metabolic pathways 
(1). The human mitochondrial ATP synthase, or complex V is the 5th multi subunit OXPHOS 
complex. It synthesizes ATP from ADP in the mitochondrial matrix using the energy provided 
by the proton electrochemical gradient (2, 7-8). Complex V comprises 16 subunits. Five of 
them (α, β, γ, δ, and ε) form the F1 sector, situated in the mitochondrial matrix, the other 
subunits (a, c-ring, b, d, F6, OSCP, e, f, g, and A6L) belong to the Fo sector, embedded in the 
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inner mitochondrial membrane (24-25). Only two subunits, a and A6L, are encoded by the 
mtDNA ATP6 and ATP8 genes, respectively (26). The other subunits are nuclear encoded. 
 
In chapter 4, we aim to review complex V with respect to architecture, function, assembly, 
pathology, and current therapeutic options. The structure and, intriguingly, the 
oligomerization of complex V determine its function, the former by the so-called “rotary 
catalysis” (24) and the latter by influencing mitochondrial and cristae morphology (27), as will 
be discussed. 
 
Chapter 5 describes the first patient with a pathogenic mutation in the mitochondrial ATP8 
gene. The clinical phenotype, the pathogenicity of the mutation and the molecular 
pathophysiology are discussed. 
 
Complex V of mammalian mitochondria is arranged in long rows of dimeric supercomplexes 
(27). Ribbons of complex V dimers are responsible for cristae formation, and essential for 
optimal performance of the mitochondrial enzyme (27). In addition, it has been demonstrated 
that transmembrane protein 70 or TMEM70 is required to maintain normal expression levels 
of complex V (28). Although mitochondrial structural abnormalities have been shown to occur 
in complex V deficiencies before, a direct causal relationship has never been shown. 
Therefore, the main goal in chapter 6 is to study mitochondrial morphology in fibroblasts of a 
patient with a deletion in the TMEM70 gene before and after complementation of the genetic 
defect. Comparative genomics is used to study the evolution of the protein and to predict the 
subcellular localization of TMEM70. The latter is checked by immunogold labeling. 
 
In chapter 7, the first two patients with complex V deficiency due to a mutation in the ATP5A1 
gene, coding for complex V subunit α, are described. The whole exome sequencing 
technique is used in the search for the genetic mutation. The powerful combination of 
biochemical and genetic approaches to unravel a mitochondrial defect is demonstrated. 
Mitochondria and disease 
 
23 
 
 
PART IV: General discussion 
 
Chapter 8 provides the general discussion, future perspectives and conclusions regarding 
the different topics in this thesis. 
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ABSTRACT 
 
Background: Muscle biopsy analysis is regarded as the gold standard in diagnostic work-
ups of patients with suspected mitochondrial disorders. Analysis of cultured fibroblasts can 
provide important additional diagnostic information. The measurement of individual OXPHOS 
complexes does not always provide sufficient information about the functional state of the 
complete mitochondrial energy generating system. For this purpose, we optimized a high-
throughput fluorescence-based methodology for oxygen consumption analysis in patient-
derived cells. 
Methods: Mitochondrial respiration in digitonin-permeabilized cells was analyzed in the 
presence of a substrate mix containing pyruvate and malate, using a phosphorescent probe, 
96-wells plates and a fluorescence plate reader. 
Results: In control fibroblasts, a clear stimulation of the pyruvate + malate driven respiration 
by ADP was observed. Known inhibitors of the OXPHOS system and the Krebs cycle 
significantly reduced respiration. In patient fibroblasts with different OXPHOS deficiencies, 
ADP stimulated respiratory activity was decreased in comparison to control cells. In several 
patients with a reduced ATP production rate in muscle tissue but with normal OXPHOS 
enzyme activities, the fibroblasts displayed a reduced respiratory activity. Finally, a clear 
difference between control and complex I deficient transmitochondrial cybrid cells was 
observed. 
Conclusion: These results confirm the validity of the assay as a high-throughput screening 
method for mitochondrial function in digitonin-permeabilized cells. The assay allows primary 
and secondary mitochondrial abnormalities in muscle to be differentiated, of great 
importance with respect to counseling, and also will facilitate the search for new genetic 
defects that lead to mitochondrial disease. 
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INTRODUCTION 
 
Mitochondria play a vital role in cellular energy metabolism. The enzymes of the 
mitochondrial energy-generating system (MEGS) are localized in the mitochondrial matrix 
space (pyruvate dehydrogenase complex (PDHc) and tricarboxylic acid (TCA) or Krebs 
cycle) and in the inner mitochondrial membrane (oxidative phosphorylation (OXPHOS) 
complex) (1). Enzyme analysis of individual OXPHOS complexes in skeletal muscle biopsy 
remains the mainstay of the diagnostic process for patients suspected of mitochondrial 
cytopathy (2). In addition, measurement of the MEGS capacity is a powerful tool for the 
assessment of mitochondrial function. The MEGS capacity can be examined in detail by 
measurement of 14CO2 production rates from oxidation of [1-14C]pyruvate and carboxyl-14C-
labeled TCA cycle intermediates in combination with measurement of ATP production in 
intact mitochondria from a muscle biopsy (1), or by examining mitochondrial respiration via 
oxygen consumption measurements using polarography. These methods have been 
demonstrated to be very valuable in the examination of fresh muscle tissue. For fibroblasts, 
several methods have been described to measure ATP production or oxygen consumption 
(3, 4). Analysis of fibroblasts is useful for several reasons (5), including confirmation of the 
defects observed in muscle, to exclude secondary mitochondrial dysfunction e.g. due to poor 
feeding or disuse (6), and serving as a model system for follow up and functional testing. 
One of the most informative ways of assessing mitochondrial function is by analysis of 
mitochondrial oxygen consumption by polarography using the Clark-type oxygen electrode 
(7). With this method, oxygen consumption can be measured in isolated mitochondria, and in 
intact and detergent-permeabilized cells (8). Although this technique has proven very useful, 
a major limitation can be the relatively low sample throughput. An assay set-up with a higher 
throughput has recently become available, but requires specialized equipment (9). 
Quenched-fluorescence oxygen sensing is an approach which may overcome these 
limitations. This measurement methodology allows the assessment of mitochondrial function 
using conventional instrumentation, thereby combining the high degree of information 
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provided by oxygen consumption analysis with the simplicity, throughput and scaling up 
capabilities of standard microtitre plate assays (10). This approach (10) has previously been 
used to investigate mitochondrial toxicity of drugs in isolated mitochondria (7) and in cultured 
adherent cells (11).  
The aim of our study was to adapt a protocol allowing quenched-fluorescence oxygen 
sensing to be used in the diagnostic evaluation of suspected mitochondrial disorders. We 
demonstrate that this assay provides a fast and non-laborious high-content screening 
method for mitochondrial function in different digitonin-permeabilized cell types.  
Oxygen consumption assay 
33 
 
MATERIALS AND METHODS 
 
This study was carried out in the Netherlands in accordance with the applicable rules 
concerning research ethics committee review (Commissie Mensgebonden Onderzoek Regio 
Arnhem-Nijmegen) and informed consent. 
 
Materials 
 
Pyruvate and oligomycin were purchased from Sigma, malate from Fluka, and ADP from 
Roche. All other chemicals were of the highest purity commercially available. 
Phosphorescent oxygen-sensitive probe, MitoXpress™ (A65N-1), was from Luxcel 
Biosciences. Black body clear bottom 96-well plates (Black Isoplate TC) and black backing 
tape were obtained from Perkin Elmer. 
 
Cell cultures 
 
After informed consent of the patients and their caretakers, skin biopsy specimens were 
obtained for diagnostic purposes and fibroblasts were cultured in E199 medium (Gibco, 
Invitrogen Corporation). Transmitochondrial cybrids were cultured in high-glucose (4.5 g/L) 
Dulbecco's Modified Eagle's Medium (DMEM). Both media were supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin (respectively 100 U/ml and 100 
µg/ml). Before harvesting, fibroblasts were incubated for 48 hours in galactose medium, 
consisting of DMEM without glucose, without pyruvate, with L-glutamine 2 mmol/L (Invitrogen 
Corporation) supplemented with 10% dialyzed FBS, 1mmol/L uridine, 1% 
penicillin/streptomycin and 5.5 mmol/L D-galactose. Cells were harvested and washed twice 
in ice cold 1% FBS in Phosphate Buffered Saline (PBS), and the cell pellet was subsequently 
resuspended at 30% w/v ( = 4-6 x 104 cells/ µl) in ice cold 1% FBS in PBS. 
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Isolation of skeletal muscle mitochondria 
 
Human skeletal muscle was obtained from healthy young adults after informed consent. 
Muscle mitochondria were isolated as described (12). Briefly, the muscle specimens were 
placed in ice-cold 0.25 M sucrose, 2 mmol/L EDTA, 10 mmol/L Tris-HCl, 5x104 U/L heparin 
(SETH)-medium. After chopping, homogenization was performed by hand with a Teflon-glass 
Potter-Elvehjem type homogenizer. The resulting homogenate was centrifuged for 10 
minutes at 600 x g. Mitochondria were isolated from the resulting supernatant by 
centrifugation for 10 minutes at 14000 x g. The mitochondrial pellet was finally taken up in 
SETH-medium. 
 
Fluorescence-based assay of mitochondrial respiration 
 
MitoXpress™ (A65N-1) oxygen probe supplied as dry reagent in a vial, was dissolved in PBS 
to a concentration of 1 µM. Probe fluorescence is quenched by molecular oxygen via a non-
chemical (collisional) mechanism, resulting in an increase in probe signal with decreasing 
concentration of dissolved oxygen due to mitochondrial respiration (10). Measurements were 
performed immediately after harvesting in digitonin-permeabilized non-fractionated cells with 
the addition of substrates. Also isolated fresh human skeletal muscle mitochondria were 
tested. The incubations were pyruvate + malate with or without ADP. The incubation volume 
in each well was 50 µl, containing 5 µl cell suspension (= 2-3 x 105 cells), 100 nM fluorescent 
probe, and a substrate mix consisting of 30 mM potassium phosphate , 75 mmol/L potassium 
chloride, 8 mmol/L Tris, 1.6 mmol/L EDTA, 5 mmol/L MgCl2, 0.2 mmol/L p1,p5-di(adenosine-
5’) pentaphosphate (myo-adenylate kinase inhibitor), 32.6 µmol/L digitonin for the 
permeabilization of the cell membranes, 1 mmol/L pyruvate, 1 mmol/L malate, and where 
indicated 2.0 mmol/L ADP, pH 7.4 (1). To regenerate ADP by creatine kinase in the cell 
preparations, 20 mmol/L creatine was added to all ADP-containing incubations. Compound 
solutions were added to the wells to give the indicated final concentrations. Finally, 100 µl of 
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mineral oil was added to each well to seal the samples from ambient oxygen which would 
otherwise destroy oxygen gradients and compromise assay performance (10), and the plate 
was placed in a time-resolved fluorescence plate reader (Viktor 2, Perkin Elmer) equilibrated 
to a temperature of 37 °C and monitored every 5 minutes over a period of 55 minutes. 
Instrument settings were 340/642 nm excitation/emission filters, a delay time of 30 µs and a 
measurement window of 100 µs, and active temperature control of the microplate 
compartment at 37 °C. After completion of fluorescence measurements, time profiles of 
fluorescence intensity in each well were analyzed using Viktor (Perkin Elmer) and Excel 
(Microsoft) software. All measurements were performed in duplicate and the results 
averaged. The relative oxygen consumption rate (ROCR), reflecting respiratory activity, was 
calculated from the maximal linearly increasing fluorescence intensity slope (Figure 1) to 
compare respiration rates of different samples. The results were normalized for citrate 
synthase (CS) activity (13). 
 
Statistical methods 
 
The different fibroblast groups were tested for the goodness of fit to the normal distribution 
using the Shapiro-Wilk test. The Kruskal-Wallis test was applied to study differences in 
respiration rates between the investigated groups. Differences were considered statistically 
significant if the p-value was lower than 0.05. When overall significance was found, the 
Mann-Whitney test with Bonferroni correction (p-value < 0.0125) was used as a post-hoc test 
to compare each patient group to the control.  
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RESULTS 
 
In order to evaluate the maximal mitochondrial oxygen consumption capacity of the samples, 
measurements were done in non-fractionated digitonin-permeabilized cells under optimal 
substrate concentrations and in the presence of an excess of ADP. Most experiments were 
performed in fibroblasts to be able to exclude secondary mitochondriopathies. Therefore, 
different media were tested (data not shown). Galactose-based medium, which drives the 
cell towards the OXPHOS system for ATP production, thereby increasing the differences 
between control and patient fibroblasts (14, 15), was used for subsequent experiments in 
fibroblasts. Table 1 (see at the end of this article) gives an overview of the cell lines used for 
oxygen consumption measurements in fibroblasts. 
 
Pyruvate-malate driven oxygen consumption rate 
 
In control fibroblasts, pyruvate-malate driven respiration yielded substantially higher 
respiratory activity upon ADP stimulation (Figure 1a), indicating proper functional coupling of 
the mitochondria. This was also clearly seen in isolated mitochondria obtained from control 
fresh muscle biopsies. Muscle showed both a higher respiratory activity rate and a higher 
coupling efficiency than fibroblasts (Figure 1b). 
 
Figure 1 ADP stimulation of pyruvate-malate driven respiration in control fibroblasts (a) and in  
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isolated mitochondria obtained from a control fresh muscle biopsy (b). The relative oxygen 
consumption rate (ROCR) of the linearly increasing fluorescence intensity slope, reflecting 
respiratory activity, is presented by the straight line. (Normalized time profile of fluorescence 
intensity; RFU = relative fluorescence units; CS = citrate synthase; ● = +ADP; ○ = -ADP) 
 
During the measurement, the initial reduction in raw signal reflects plate temperature 
equilibration (11). This is followed by a linear phase of oxygen consumption that can be used 
to analyze mitochondrial respiration. The linear phase of oxygen consumption ends due to 
oxygen exhaustion (10), which can be concluded from results of pyruvate oxidation rate 
measurements following the methods outlined in (1). In cultured control fibroblasts, the 
pyruvate oxidation rate is between 0.1 and 0.15 nmol/min for 5 µl cells. At this rate, 40 
minutes of pyruvate oxidation produces 16-24 nmol of NADH and reduces 8-12 nmol O2, 
whereas the reaction volume of 50 µl at 37 ºC and 1 bar (100 kilopascals) pressure contains 
only 10.7 nmol O2. In control muscle mitochondria the pyruvate oxidation rate is 0.55-0.65 
nmol/min for 5 µl mitochondrial suspension, producing 28-32 nmol NADH and reducing 14-16 
nmol O2 in 12 minutes. The addition of a layer of mineral oil to each sample limited back 
diffusion of oxygen (10). The presence of low rate back diffusion through the mineral oil seal 
and polystyrene plate (oxygen diffuses through polystyrene at considerable rates) 
determined the lower limit of the assay sensitivity, i.e. mitochondrial oxygen consumption 
below this rate cannot be analyzed (10). This is in line with previous observations (7, 11). 
The signal stabilizes when equilibrium is reached between the rates of oxygen consumption 
and back diffusion, so successful analysis in the microplate assay requires an oxygen 
consumption rate sufficient to produce a measurable signal change (10). Due to the back 
diffusion the rates of change of dissolved oxygen measured using this assay are lower than 
the actual mitochondrial oxygen consumption rate. Therefore, they were expressed as 
relative oxygen consumption rate (ROCR) in relative fluorescence units per unit citrate 
synthase (RFU/ U CS). The correlation between initial rates of increase of probe signal and 
the corresponding mitochondrial protein concentration has been demonstrated to be close to 
linear (7), which made it possible to compare respiration rates of different samples by 
analyzing the ROCR of the linearly increasing respiratory activity slope (Figure 1). Control 
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fibroblasts typically exhibit a ROCR above 3 RFU/ U CS (mean ± standard deviation = 5.0 ± 
2.0). It was seen that the oxygen consumption rate can decrease when reaching a higher cell 
culture passage number (Figure 2 and Table 1). 
 
Figure 2 Normalized respiration 
rates showing the influence of the 
passage number on the 
measurements. The oxygen 
consumption rate decreases when 
reaching a higher cell culture 
passage number. (ROCR: relative 
oxygen consumption rate; CS = 
citrate synthase; 8015, 8128 and 
5119 = control fibroblasts) 
 
 
 
 
 
 
 
Effect of inhibitors 
 
To study the sensitivity of the assay, several classical inhibitors of the mitochondrial energy 
generating system were added to control fibroblasts: rotenone (for complex I), antimycin A 
(complex III), azide (complex IV), oligomycin (complex V), atractyloside (adenine nucleotide 
transporter (ANT)), α-hydroxycyanocinnamate (pyruvate carrier), and arsenite (PDHc and α-
ketoglutarate dehydrogenase). Figure 3a shows that all inhibitors significantly reduced 
oxygen consumption. Similar results were obtained with isolated mitochondria from a control 
fresh muscle biopsy (Figure 3b). This indicates that oxygen consumption measured in this 
assay is dependent on a fully functional MEGS system. Moreover, it should be feasible to 
pick up deficiencies in any of its components. 
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Figure 3 Inhibitors of the mitochondrial energy generating system reduce oxygen consumption 
in control fibroblasts (a) and in isolated mitochondria obtained from a control fresh muscle 
biopsy (b). (Normalized time profile of fluorescence intensity; RFU = relative fluorescence 
units; CS = citrate sythase; ● = +ADP + 1 µM rotenone; ○ = +ADP + 1 µM antimycin a; ▼= +ADP 
+ 2 mM azide; ∆ = 0.2 mM oligomycin; ■ = +ADP + 20 µM atractyloside; □ = +ADP + 0.025 mM α-
hydroxycyanocinnamate; ♦ = +ADP + 2 mM arsenite; ◊ = + ADP; ▲ = -ADP) 
 
Diagnostics 
 
Analysis of oxygen consumption in fibroblasts from patients with mitochondriopathies 
 
For diagnostic purposes, it is important that deficiencies in the MEGS system can be 
diagnosed or confirmed in fibroblasts. Therefore, patient fibroblasts with various known 
OXPHOS defects were measured in this assay (Figure 4).  
 
Figure 4 Comparison 
of (mean, where 
applicable) relative 
oxygen consumption 
rates in fibroblasts 
(see Supplemental 
Data Table 1) after 
ADP stimulation using 
the Mann-Whitney test 
with Bonferroni 
correction (p < 0.0125). 
In the presence of 
ADP, complex I and IV 
deficient fibroblasts 
showed a significantly 
lower respiratory 
activity rate compared 
to control cells. There 
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was no significant difference when comparing the controls with the complex V deficient 
fibroblasts. Fibroblasts of patients with a decreased MEGS capacity in fresh muscle show a 
range of activities, varying from normal to clearly reduced. (ROCR: relative oxygen 
consumption rate; CS = citrate synthase; each dot represents one cell line; control = control 
fibroblasts; C.I = complex I deficient fibroblasts; C.IV = complex IV deficient fibroblasts; C.V = 
complex V deficient fibroblasts; other = non-OXPHOS deficient fibroblasts, *: p = 0.001; ^: p = 
0.008; NS = not significant) 
 
Patient cell lines with a high passage number and a low respiratory activity were not included 
in this study to prevent possible bias by aging (see Figure 2). There was an overall 
difference in respiration rates between the groups (Kruskal-Wallis test, p = 0.002). All 
complex I and complex IV deficient fibroblasts showed an ADP-stimulated respiratory activity 
rate below the lowest control value. There was a significant difference between the control 
group and the complex I (p = 0.001) and complex IV (p = 0.008) deficient fibroblasts, and no 
significant difference when comparing the controls with the complex V deficient fibroblasts (p 
= 0.427) (Figure 4). A characteristic feature of the complex V deficient cells was the clear 
stimulation of oxygen consumption by addition of an uncoupler (2 µM carbonyl cyanide 3-
chlorophenyl hydrazone: CCCP) (Figure 5a). This phenomenon was not seen in control cells 
(Figure 5b) or in cells with other OXPHOS enzyme deficiencies (data not shown). These 
data indicate that the fluorescence-based oxygen sensing probe assay is a sensitive tool to 
measure mitochondrial function in fibroblasts. 
 
Figure 5 Complex V deficient fibroblasts showed clearly higher rates after the addition of an 
uncoupler (2 µM carbonyl cyanide 3-chlorophenyl hydrazone or CCCP) (a), a phenomenon not 
seen in control cells (b). (Normalized time profile of fluorescence intensity; RFU = relative 
fluorescence units; CS = citrate synthase; ● = +ADP ○ = -ADP; ▼= +ADP + CCCP; ∆ = -ADP + 
CCCP) 
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For patients with non-OXPHOS related decreases in MEGS capacity in fresh muscle 
biopsies, the oxygen consumption rate would be an important tool to confirm the deficiency 
since traditional OXPHOS enzyme assays are not discriminative. Several fibroblasts cell 
lines from this patient category were included. The level of oxygen consumption upon ADP 
stimulation ranged from control respiratory activity rates to, predominantly, low to very low 
rates (Figure 4). As a group they were not statistically significant (p = 0.089) but 
nevertheless several of the non-OXPHOS related MEGS deficiencies could be confirmed in 
cultured fibroblasts, suggesting that these are most likely caused by (a) primary defect(s). 
 
Cybrid cells 
 
Since transmitochondrial cybrid cells are often used to verify the pathogenicity of 
mitochondrial DNA (mtDNA) mutations, both control and complex I deficient (ND1 mutation) 
cybrid cells were included. The clear difference in respiratory activity between control and 
complex I deficient cybrids (Figure 6; ROCR after ADP stimulation 10.1 and 1.1 RFU/ U CS, 
respectively) shows that the assay can also be used to rapidly screen cybrid clones for 
mitochondrial dysfunction due to mtDNA mutations. 
 
Figure 6 Analysis of oxygen 
consumption in cybrid cells showing a 
clear difference between control and 
complex I deficient transmitochondrial 
cybrid cells. (Normalized time profile of 
fluorescence intensity; RFU = relative 
fluorescence units; CS = citrate 
synthase; cy 73 = control cybrids, cy 
ND1 = complex I deficient cybrids due to 
the mutation m.3460G>A in the MT-ND1 
gene (known LHON mutation); ● = cy 73 
+ADP ○ = cy 73 -ADP; ▼= cy ND1 +ADP; 
∆ = cy ND1 -ADP) 
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DISCUSSION 
 
Despite the availability of many tools to diagnose mitochondrial disease (16, 17), current 
methods are still insufficient for the evaluation of a large subgroup of patients suspected to 
have a mitochondriopathy. Here, we show that quenched-fluorescence oxygen sensing 
provides a fast and efficient additional diagnostic tool that can be used to examine the 
mitochondrial energy generating system in cultured patient-derived cells. 
The assay showed a clear difference between control and patient cell lines: control cells 
showed a substantial increase in oxygen consumption rate upon ADP stimulation, in contrast 
to the patient cell lines. This was illustrated in particular by the cybrid cells. Complex I and IV 
deficient fibroblasts showed a significantly decreased oxygen consumption rate. Complex V 
deficient fibroblasts could be recognized because of a substantial increase after uncoupling. 
Addition of an uncoupler leads to a decrease in the mitochondrial membrane potential which 
subsequently gives rise to a maximal stimulation of the respiratory rate (18). Uncoupling 
makes the oxygen consumption rate independent of complex V and this explains the initial 
increase in complex V deficient cells. It has also been shown that CCCP stimulates 
apoptosis via loss in mitochondrial transmembrane potential and reactive oxygen species 
(ROS) production (19). Cell death, combined with back diffusion of oxygen, could explain the 
subsequent decrease of the respiratory activity slope that was sometimes observed. 
Inhibitors of the entire pathway from pyruvate import to ATP export, and several steps in 
between (the MEGS), reduced oxygen consumption in fibroblasts and in isolated muscle 
mitochondria, confirming that the integrity of the entire OXPHOS machinery can be tested 
successfully both in permeabilized cells and in isolated mitochondria. A peculiar finding was 
a slight loss of inhibition of oligomycin in the fibroblasts after 35 minutes. This was not seen 
in isolated muscle mitochondria. Further research is needed to understand this finding. 
Some cautionary notes must be taken into account when measuring the oxygen consumption 
rate in fibroblasts. It was seen that the rate can decrease when reaching a higher cell culture 
passage number (Figure 2 and Table 1). To get reliable results it is very important to 
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measure cells at an early passage stage and to measure samples in at least two 
independent experiments. Usually, the passage number increases by 1-2 between 
measurements. In case of poor reproducibility of multiple measurements with increasing 
passage number, a possible negative effect of the passage stage should be considered. 
Results should then be distrusted and cells from an earlier passage should be tested, if 
available. 
The assay can also be used to support the search for new defects in mitochondrial energy 
metabolism. In a group of patients with a decreased ATP production in fresh muscle, a 
subgroup could be identified with a clearly reduced oxygen consumption rate, despite normal 
OXPHOS enzymes and PDHc activities. Such data indicate that another still unidentified 
defect in the mitochondrial energy metabolism may be responsible for the reduced oxygen 
consumption rates. This will encourage further studies to uncover new genetic defects 
causing mitochondrial disease. Another subgroup of patients showed normal or near-normal 
oxygen consumption rates in fibroblasts that may be a reflection of a tissue specific 
mitochondriopathy, which is not uncommon, e.g. in case of mtDNA mutations with uneven 
tissue distribution or in case of polymerase gamma (POLG)1 gene mutations. A normal 
oxygen consumption rate in fibroblasts can also be expected when the MEGS dysfunction in 
muscle tissue is secondary (poor feeding, disuse) (6). Differentiating between primary and 
secondary mitochondrial abnormalities is of great importance with respect to counseling. 
Thus, this assay provides a valuable tool in the diagnostics of mitochondrial disorders. 
Advantages of the assay compared to substrate oxidation measurements include its 
simplicity, the requirement of less cell material, and the elimination of the need of an isotope 
laboratory. When comparing oxygen-sensitive fluorescence-based methods to classical 
polarography it has been shown that, due to the low rate of back diffusion, the rates of 
change of dissolved oxygen measured using the microplate approach are lower than the 
consumption rates measured using a sealed polarographic system (7). 
In conclusion, quenched-fluorescence oxygen sensing provides a simple, high-throughput, 
high-content screening method for mitochondrial function in different cell types. It requires a 
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relatively low sample volume and allows for simultaneous testing of multiple assay 
conditions. In addition, this approach is also suitable for the analysis of cell lines with a 
relatively low mitochondrial activity (e.g. fibroblasts). Patients with a primary 
mitochondriopathy that does not affect the complexes of the respiratory chain can be 
identified. In combination with functional studies and other diagnostic assays (for instance 
homozygosity mapping) the availability of this approach will facilitate the search for hitherto 
unknown genetic defects leading to mitochondrial disease. 
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Table 1: Overview of the cell lines used for oxygen consumption measurements in fibroblasts 
 
Cell line Passage 
number 
Activity ROCR 
(normal 3.0-
11.0 RFU/ 
U CS)a 
Mean 
ROCR 
Gene-Mutation 
 
Controls      
9022 11 normal 5.64 
4.09 
- 
9022 12 normal 3.00 - 
9022 13 normal 3.62 - 
8015 12 normal 4.37 
6.94 
- 
8015 16 normal 5.82 - 
8015 18 normal 10.63 - 
7972 11 normal 7.37 
6.22 
- 
7972 16 normal 5.06 - 
8128 10 normal 11.00 
9.50 
- 
8128 20 normal 8.00 - 
6869 x+20 normal 3.15  - 
8088 15 normal 8.79 
7.72 
- 
8088 16 normal 9.29 - 
8088 16 normal 3.99 - 
5119 12 normal 6.59  - 
9481 20 normal 4.15  - 
4752 12 normal 3.87  - 
6855 13 normal 3.42  - 
9966 4 normal 3.79   
9968 7 normal 4.35   
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10004 x+4 normal 3.06   
10047 6 normal 3.55   
      
Complex I 
deficiency 
 Complex I 
(normal 
110-260 
mU/UCOX) 
 
 
 
8328 x+12 26 0.53 
1.04 
NDUFS1-
(del211Q+V228A) 
8328 x+13 26 0.43 NDUFS1-
(del211Q+V228A) 
8328 x+14 26 2.17 NDUFS1-
(del211Q+V228A) 
5737 16 62 0.00 
 
NDUFS4-
VPEEKH167/ 
VEKSIstopb 
5175 16 65 1.12  NDUFS7-V122Mb 
7719 12 59 0.00  ND3-S45P 
9270 x+10 56 0.52  NDUFS7-V122M 
6603 x+14 16 0.57  NDUFS8-R94Cb 
      
Complex IV 
deficiency 
 Complex IV 
(normal 
680-1190 
mU/UCS) 
 
 
 
9353 10 256 0.76   
300 13 427 0.42   
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4987 11 155 2.20 
 
SURF1-
(312insATdelTCTGC
CAGCC)c 
      
Complex V 
deficiency 
 Complex V 
(normal 
209-935 
mU/UCOX) 
 
 
 
8836 12 14 7.06 
4.40 
TMEM70-317-2A>Gd 
8836 14 14 1.41 TMEM70-317-2A>Gd 
8836 16 14 4.72 TMEM70-317-2A>Gd 
8835 x+8 113 0.18   
      
Non-
OXPHOS 
defects 
 ATP+CrPe 
(normal 
42.1-81.2 
nmol/h.mU
CS) 
   
7928 14 15 6.86   
9322 8 6 12.01   
5133 9 8 5.07   
8948 11 21 7.89   
9354 7 8 2.25   
8240 11 12 4.03   
5415 x+9 0 3.43   
6191 12 30 0.47   
9121 x+9 18 1.83   
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9492 x+5 n.d.f 0.59   
9493 x+5 12 0.95   
9158 x+6 10 1.42 
1.77 
 
9158 x+8 10 2.12  
9164 9 11 1.03   
ROCR: relative oxygen consumption rate; RFU: relative fluorescence units; SD: standard deviation; 
COX: cytochrome oxidase; CS: citrate synthase; CrP: phosphocreatine; x: unknown number of 
previous passages, typically 2-4 
a  mean ± SD = 5.0 ± 2.0 (calculated for each cell line, thus taking the mean ROCR where 
applicable) 
b Distelmaier F et al. Brain 2009;132(4):833-42 
c Coenen MJ et al. J Child Neurol 2006;21(6):508-11 
d Cizkova A et al. Nat Genet.2008;40(11):1288-90 
e ATP+CrP: production from pyruvate (Janssen AJ et al. Clin Chem 2006;52 (5):860-71) 
f n.d.: not determined; but severely decreased substrate oxidation rate of [1-14C]pyruvate: 0,61 
(normal 3,61 – 7,48 nmol CO2/h.mUCS) 
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ABSTRACT 
 
Two OXPHOS-deficient myogenic cell lines were established, one containing a mutation in 
the nuclear encoded structural complex I subunit NDUFS7, the other showing a combined 
complex I and IV deficiency of unknown genetic origin. Biochemical assays assessing the 
mitochondrial energy generating system (MEGS), such as pyruvate oxidation, ATP 
production, and oxygen consumption, could be adapted successfully for both myoblasts and 
myotubes. Combined with spectrophotometric enzyme activity measurements and 
immunoblotting, a complete biochemical toolbox is provided for the identification and 
characterization of mitochondrial disorders in muscle cells. This resulted in the first 
description of an isolated complex I deficiency due to a nuclear genetic mutation in muscle 
cells and paves the way for multiple applications, e.g. the study of OXPHOS defects that are 
only expressed in muscle tissue, in-depth research on mitochondrial physiology using 
biological assays in living cells, and targeted pharmacological intervention studies. 
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INTRODUCTION 
 
Most mitochondrial (mt) disorders affect skeletal muscle which has led to the preference of 
using fresh muscle biopsies for diagnostic purposes. Fibroblasts are mostly used to 
investigate the defect in a second tissue (1). They are also important cell models for 
additional functional studies. Limitations of fibroblasts for functional studies are their relatively 
low mitochondrial activity, the slow growth rate and a poor resemblance with muscle tissue. 
For example, a defect in the Polymerase gamma (POLG) gene does not lead to pathologic 
alterations in fibroblasts (2). Muscle-derived cell lines can overcome some of these 
limitations. Cultured myoblasts obtained from satellite cells isolated from fresh muscle 
biopsies grow fast and can be differentiated into myotubes, which display a higher 
mitochondrial activity than myoblasts (3). Myogenic cell cultures, providing a back-up of 
muscle tissue, could also preclude a second muscle biopsy should additional testing be 
required.  
In mitochondrial medicine, myogenic cell lines have been used in the study of combined 
OXPHOS deficiency due to mtDNA mutations to elucidate the relationship between mutation 
load and pathology as well as the mechanism of mtDNA segregation in myogenesis (4-8). To 
study the effect of mtDNA mutations on myogenesis and muscle-specific pathophysiology 
myogenic cybrids (9) and rhabdomyosarcoma cybrids (10) have been used. However, due to 
the possibility of genetic drift of heteroplasmic cell lines as well as the switch to cancer-
derived nuclear genetic control in cybrids, these are not ideal model cell lines to study the 
pathophysiology of a genetic defect in a patient. So far only few myogenic cell lines have 
been established from OXPHOS deficient patients resulting from nuclear DNA mutations. 
These include cytochrome c oxidase – deficient SCO2 mutant cells (11) and two cell lines 
with decreased mitochondrial translation under nuclear genetic control (12). The latter defect 
was only expressed in myotubes and did not result in decreased complex I and IV enzyme 
activities measured in vitro in myoblasts and myotubes (12). Since many mitochondrial 
patients have an isolated complex I deficiency, the establishment of a complex I deficient 
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myogenic cell line could provide vital clues to the development of mitochondriopathy in these 
patients as well as provide a clinically important cell type to test therapeutic agents. 
In the present study, we established two OXPHOS deficient myogenic cell lines. One 
contains a mutation in the nuclear encoded structural complex I subunit NDUFS7. A second 
myoblast cell line showed combined deficiency of complex I and complex IV, which was not 
due to mtDNA mutations or several other genes known to affect mtDNA integrity. These cell 
lines were used to demonstrate a proof-of-principle that several biochemical assays which 
assess the mitochondrial energy generating system (MEGS), such as pyruvate oxidation, 
ATP production, and oxygen consumption, could be adapted for both myoblasts and 
myotubes. 
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PATIENTS AND METHODS 
 
Patients 
 
Patient 1 presented at the age of 14 months with bilateral ptosis. Psychomotor development 
had been unremarkable. Clinical investigation revealed nystagmus, intention tremor and 
head titubation. Cerebral MRI showed symmetrical lesions in the medulla oblongata. Lactic 
acid was elevated in plasma and liquor. A muscle and skin biopsy was performed because of 
the suspicion of a mitochondrial disorder in this patient with a Leigh-like phenotype. 
Myoblasts and myotubes were established out of the muscle biopsy. 
The clinical course initially showed a remission marked by an absence of symptoms. 
However, an acute disease exacerbation occurred at the age of 2 years and 9 months, and 
the patient deceased due to hypoventilation and central apneas, leading to respiratory 
failure. 
Patient 2 was born prematurely at 32 weeks and suffered from multiple apnea and 
bradycardia episodes. He has a developmental retardation and epilepsy. Cerebral MRI 
performed at the age of 6 years showed white matter lesions in both hemispheres and 
periaqueductal, suggesting Leigh syndrome. He developed nocturnal apnea and perceptive 
hearing loss, pointing to central neurological disturbances. A muscle and skin biopsy was 
performed, and muscle cells were isolated. 
At the age of 9 years, the clinical picture is stable. There is a slow developmental 
progression. 
 
Skeletal muscle cell culture 
 
Primary myoblast cultures were established from quadriceps muscle biopsies of the two 
patients and seven controls. Satellite cells were released from the sarcolemma by enzymatic 
digestion as described by Yasin et al. (13) and Shoubridge et al. (14). Cells were separated 
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from debris by using a 100 μm nylon mesh cell strainer (Becton Dickinson, Breda, The 
Netherlands) and pelleted at 290 g for 5 minutes at 4°C. Myoblasts were cultured in growth 
medium consisting of Skeletal Muscle Growth Medium (SKGM® BulletKit®, Lonza, Belgium) 
supplemented with 15% fetal calf serum and penicillin/ streptomycin (respectively 100 U/ml 
and 100 μg/ml). Fibroblast contamination of bulk cultures was minimized by preplating the 
cells on collagen (type I from calf skin at 2 μg/cm2 in phosphate-buffered saline (PBS); 
Sigma, Zwijndrecht, The Netherlands) for 45 minutes and subsequent transfer of non-
adherent cells to a second collagen coated flask (adapted from (15)). Growth medium was 
changed after 24 hours and every 2-3 days thereafter. Purity of cells was analyzed by 
immunocytochemical staining with an antibody against desmin (monoclonal mouse anti-
human desmin, Dako, Glostrup, Denmark) and cultures routinely contained > 90% desmin 
positive cells. Myotubes were generated by culturing the myoblasts for 4-6 days in 
differentiation medium, containing Dulbecco's Modified Eagle's Medium (DMEM) with 1 g/L 
glucose, 4% Ultroser G® (Pall, France), 4 mM L-glutamine (Invitrogen, Breda, The 
Netherlands), and penicillin/streptomycin (respectively 100U/ml and 100 µg/ml). Cells were 
used at passage 3-7. 
In the diagnostic setting in Nijmegen, satellite cells are now isolated from all sufficiently large 
fresh muscle biopsies. Cells are stored frozen directly following enzymatic digestion. 
Myoblast cultures are started when indicated by biochemical and genetic analysis of muscle 
tissue and/ or fibroblasts. To reduce fibroblast contamination, cells are preplated at the first 
passage as described above. 
 
Immunofluorescence 
 
Myoblasts or myotubes were fixed in 4% w/v paraformaldehyde in PBS at pH 7.4, 
permeabilized with 0.1% w/v Triton X100 in PBS and stained with myogenin (F5D, Becton 
Dickinson), myosin heavy chain (MHC, clone MF-20 developed by Fishman DA was obtained 
from the Developmental Studies Hybridoma Bank developed under the auspices of the 
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NICHD and maintained by The University of Iowa, Department of Biology, IA (16)) or desmin 
(clone D33, Dako) primary antibodies. Secondary antibodies used were FITC-conjugated 
goat anti-mouse IgG1, Texas Red- conjugated goat anti-mouse IgG2b (both Mitosciences, 
Eugene, OR), Alexa488-conjugated goat anti-mouse (Invitrogen, Breda, The Netherlands). 
Nuclei were stained with the fluorescent dye Hoechst 33258 (Sigma, Zwijndrecht, The 
Netherlands). 
 
Biochemical assays 
 
Measurement of the MEGS capacity was performed on myoblasts or myotubes collected as 
described for fibroblasts (17). Substrate oxidation and ATP production were subsequently 
determined using the same buffers as in (18) except that 5 μl of cell suspension was used in 
a total reaction volume of 50 μl, which contained 0.04% w/v digitonin (Sigma, Zwijndrecht, 
The Netherlands) to permeabilize the cells, similar to (17). Mitochondrial respiration in 
digitonin-permeabilized cells was analyzed in the presence of a substrate mix containing 
pyruvate and malate, using the phosphorescent probe MitoXpress (Luxcel, Cork, Ireland), 
96-wells plates and a fluorescence plate reader as described (17). The activities of the 
mitochondrial respiratory chain enzymes and complex V were measured 
spectrophotometrically in mitochondria isolated from frozen pellets of myoblasts, myotubes, 
muscle tissue and fibroblasts of the patients according to described protocols (19-21) and 
were expressed in milliunits per unit cytochrome c oxidase (COX) (22) or the mitochondrial 
matrix enzyme citrate synthase (CS) (23). 
 
Blue Native and SDS-PAGE analysis 
 
One-dimensional 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and 5%-15% blue native (BN)-PAGE was performed as described previously (24-25). 
Lanes were loaded with 30 (SDS analysis) or 40 (BN analysis) µg of solubilized 
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mitochondrial protein (26). After electrophoresis, blue native gels were processed further for 
immunoblotting as described by (25). For Western blotting, antibodies used were raised 
against NDUFA9 (complex I; Invitrogen, Breda, The Netherlands), Core 2 (complex III; 
Invitrogen), COX 1 (complex IV; Mitosciences, Eugene, OR, USA), subunit alpha (complex 
V; Mitosciences), CoII-70kDa (complex II, loading control, Mitosciences), myogenin and 
MHC (see 2.3). Secondary antibodies used were peroxidase-conjugated anti-mouse or anti-
rabbit IgGs (Invitrogen). Creatine kinase (CK) isoenzymes were analyzed in 2 μg cell lysate 
using the CK isoenzyme Titan gel-kit (Helena Biosciences, Tyne and Wear, UK).  
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RESULTS 
 
High quality myoblast and myotube cultures established from patient muscle biopsies 
 
For correct interpretation of biochemical measurements in the muscle cell cultures, it is 
important that little to no contaminating fibroblasts are present. The purity of the myoblast 
cultures was determined by staining the cells for the muscle-specific protein desmin. Very 
high purity was seen in all cultures established from fresh muscle biopsies (> 90% desmin 
positive cells) (Figure 1, left). Myoblasts could be differentiated into myotubes as shown by 
fusion of the myoblasts into multinucleated tubes and by the induction of myogenin (green) 
and MHC (red) (Figure 1). 
 
Figure 1 High quality myoblast and myotube cultures were established from patient muscle 
biopsies. Myoblast cultures were stained for desmin (left) and all cultures were > 90% desmin 
positive. Both patient and control myoblasts could be differentiated into myotubes as shown 
by the induction of myogenin (green) and myosin heavy chain (MHC, red). Arrowheads indicate 
striation of MHC, nuclei were stained blue with Hoechst. 
 
Biochemical assays and molecular genetic analysis in muscle tissue and fibroblasts 
 
Analysis of the MEGS capacity revealed that the pyruvate oxidation rate in muscle tissue 
from both patients was severely decreased (1.60 and 1.63 nmol 14CO2/h.mU citrate synthase 
(CS), respectively, normal 3.45-7.99). The ATP production rate from oxidation of pyruvate 
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was also severely decreased (19.8 and 18.4 nmol (ATP+CrP)/ h.mU CS, respectively, 
normal 36-81.7). For patient 1, spectrophotometric analysis showed an isolated complex I 
deficiency in muscle tissue (53 mU/ U CS, normal 100-401) and in fibroblasts (118 mU/ U 
CS, normal 163-599). Genetic analysis revealed compound heterozygous mutations in the 
NDUFS7 gene (c.364G>A and c.449T>C), a structural subunit of complex I. Patient 2 
showed a complex I deficiency in muscle tissue (36 mU/ U CS, normal 100-401) and a 
combined complex I (70 mU/ U CS, normal 163-599) and IV (178 mU/U CS, normal 288-954) 
deficiency in fibroblasts. Complex IV activity in muscle tissue was in the lower normal range 
(886 mU/ U CS, normal 810-3120). Hitherto, genetic analysis (mtDNA, POLG, PUS1, 
MPRS16, GFM1, TSFM) showed no mutations. The activities of the remaining OXPHOS 
enzymes and citrate synthase were normal in both patients. 
 
Biochemical assays in myoblasts and myotubes 
 
To ensure that cultured myoblasts and myotubes can be used as a valid model system for 
complex I (patient 1) or complex I and IV (patient 2) deficiency, they were fully characterized. 
To mimic the biochemical screening used for fresh muscle tissue, we adapted the existing 
MEGS capacity assays (18). Digitonin was added to permeabilize the cells and the total 
reaction volume was reduced. With these modifications functional measurements could be 
performed successfully in muscle cells. Results showed that the pyruvate oxidation rate and 
ATP production rate from oxidation of pyruvate were decreased in the myoblasts of patient 2 
(Figure 2a+2b). The relative oxygen consumption rate was decreased in myoblasts as well 
as myotubes of both patients (Figure 2c).  
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Figure 2 MEGS capacity of cultured 
muscle cells is affected in both patients. 
Pyruvate oxidation rate (a), ATP 
production rate (b) and relative oxygen 
consumption rate (ROCR) (c) were 
determined in myoblasts and myotubes 
of both patients. The ROCR of patient 2 
myoblasts was below the detection limit 
(indicated as ‘n.d.’, not detectable) 
(Controls: n=14 for (a), n=15 for (b), n=15 
for (c) blasts, n=13 for (c) tubes, bars 
represent the 25th and 75th percentile of 
control values; Pyruvate oxidation: 
pyruvate oxidation rate (expressed as 
nmol 14CO2/h.mU CS); ATP production: 
ATP production rate from oxidation of 
pyruvate (expressed as nmol 
(ATP+CrP)/h.mU CS); ROCR: relative 
oxygen consumption rate (expressed as 
relative fluorescence units (RFU)/ U CS)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory chain enzyme activity analysis in myoblasts and myotubes of patient 1 revealed 
an isolated complex I deficiency (Figure 3a). A combined complex I and IV deficiency was 
present in the myoblasts and myotubes of patient 2 (Figure 3a+3b).  
The activities of the remaining OXPHOS enzymes and citrate synthase were normal in both 
patients (data not shown). 
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Figure 3 Cultured muscle cells show isolated complex I deficiency for patient 1 and combined 
complex I and IV deficiency for patient 2. The activity of (a) complex I and (b) complex IV was 
analyzed spectrophotometrically in myoblasts and myotubes and expressed relative to citrate 
synthase activity. (Controls: n=7, bars represent the 25th and 75th percentile of control values; 
CS: citrate synthase; COX: cytochrome c oxidase = complex IV) 
 
Together, the enzymatic activity measurements confirm the isolated complex I deficiency 
found in muscle tissue and fibroblasts of patient 1. For patient 2, the enzymatic activity 
measurements in myoblasts and myotubes match the results found in fibroblasts. The 
complex IV activity in muscle tissue of patient 2 was situated in the lower normal range. In 
conclusion, these data describe the first isolated complex I deficiency due to a nuclear DNA 
mutation demonstrated in cultured muscle cells. They also show that different biochemical 
assays can be applied successfully to fully characterize patient muscle cell lines. 
 
Immunoblotting in myoblasts and myotubes (Figure 4) 
 
In order to obtain more information about the structure and amount of the different 
complexes in relation to their activity, BN-PAGE was performed in myoblasts and myotubes 
of the two patients. 
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Figure 4 Holocomplex I (and IV 
for patient 2) levels are reduced 
in patient myoblasts and 
myotubes. BN-PAGE analysis 
(rows 1-5) of complex I to V of 
the OXPHOS system in patient 
and control myoblasts and 
myotubes. Expression of the 
differentiation markers 
myogenin, MHC and CK-MM was 
analyzed by SDS-PAGE (rows 6-
7) or in-gel activity (row 8), 
respectively. (Con: control; P1: 
patient 1; P2: patient 2; CI: 
complex I; CII: complex II; CIII: 
complex III; CIV: complex IV; CV: 
complex V; MHC: Myosin Heavy 
Chain; CK-MM: muscle fraction 
of creatine kinase). 
 
 
 
 
 
 
 
 
 
 
 
Immunoblotting after BN-PAGE showed a decreased amount of complex I in myoblasts and 
myotubes of patient 1. Holocomplex I and IV were nearly absent in the myoblasts of patient 
2, while the amount of these complexes was strongly decreased in the myotubes. The 
complex III panel showed three bands, the lowest represents complex III, the two slower 
migrating bands represent supercomplexes containing complex III. The middle band is 
absent in myoblasts of patient 2. Most likely, this band represents a supercomplex containing 
complex III and complex IV (27). These results demonstrate that both patients have a 
decreased amount of complex I and that patient 2 also has a decreased amount of complex 
IV in muscle cells, which is in line with the enzymatic activity data measured 
spectrophotometrically. For patient 1, the complex IV band is slightly decreased compared to 
the control. However, the middle band in the complex III panel, representing a supercomplex 
of complex III and complex IV, is normal, which is compatible with the spectrophotometric 
enzyme activity data, showing an isolated complex I deficiency. The differentiation markers 
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myogenin, MHC and the CK muscle fraction (CK-MM) were more pronounced in myotubes 
than in myoblasts. The control cell line showed some differentiation in myoblasts, which was 
also seen during culture (not shown). 
Toolbox for characterization of myogenic cell lines 
65 
 
DISCUSSION 
 
A fresh muscle biopsy is the gold standard for detailed biochemical analysis of the MEGS 
capacity and enzymatic activity measurements in patients suspected for a mitochondrial 
disorder (19). Additional analysis of fibroblasts is useful to confirm the defect observed in 
muscle tissue, to exclude a possible secondary nature of the alterations found in muscle e.g. 
due to poor feeding or disuse (28), and to perform functional assays in a diagnostic follow-up 
or research setting (1, 17). Cultured myoblasts and myotubes, however, could be a 
advantageous alternative since they are directly derived from the gold standard and could 
thus be a source for in-depth research in muscle-derived cells. For this aim, we optimized a 
myoblast culture protocol for diagnostic purposes. The preplating technique (15) was 
adapted to improve the purity of the culture. Different media for the culture of myoblasts and 
myotubes were compared and the ones generating the best cultures were selected. These 
protocol modifications resulted in mostly round myoblasts and fairly differentiated myotubes 
with, overall, a high degree of purity. Limitations of these cultures are the degree of 
differentiation which in vitro cannot reach to the stage of a mature muscle, a variable growth- 
and differentiation rate among different cell lines (data not shown) and the viability of the 
cultures, which is restricted to 8-9 passages. Differences in the degree of fusion and a 
restricted proliferative potential of myoblasts have been observed previously (14). It was also 
stated that cells have to be used at an early passage if fusion to myotubes is wanted (14). 
Immortalization of the muscle cells, as performed in (29) can solve the latter issue. Since the 
biochemical and genetic diagnosis is not yet known when isolating satellite cells from the 
fresh muscle biopsy, it was decided in Nijmegen to further adapt the protocol and to freeze 
satellite cells from fresh muscle biopsies directly following their enzymatic digestion. Starting 
the muscle cell culture after thawing of these frozen fractions did not lead to a loss of quality 
of the cultured cells (data not shown). 
We selected 2 patients with OXPHOS deficiencies demonstrated in muscle tissue and 
fibroblasts to study the muscle-derived cells. For the first time, the entire biochemical toolbox, 
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including pyruvate oxidation and ATP production rates, oxygen consumption, 
spectrophotometric analysis of single enzymes and BN-PAGE, was applied to myogenic 
cells. This resulted, to our knowledge, for the first time in the confirmation of an isolated 
complex I deficiency due to a nuclear genetic mutation in human myoblasts and myotubes 
(patient 1). Patient 2 presented with a combined complex I and IV deficiency in fibroblasts. In 
muscle, complex I was also decreased but the complex IV activity was situated in the lower 
normal range. The complex I and IV deficiencies were also observed in myoblasts and 
myotubes thus confirming the presence of a combined OXPHOS deficiency. Since the 
genetic defect is not known, one can only speculate why the complex IV activity in muscle 
tissue differs to a certain extent from that in fibroblasts and cultured muscle cells. Possibly, a 
developmentally regulated factor important for mitochondrial translation in a late stage of 
muscle cell differentiation could play a role (12).  
The reduction in MEGS function, as demonstrated by several functional assays (pyruvate 
oxidation and ATP production rates, oxygen consumption), correlates with the severity of the 
deficiency found by single enzyme measurements and BN-PAGE. This is illustrated by the 
two patients, patient 1 having a milder defect than patient 2. Furthermore, it was observed 
that the relative oxygen consumption rate is the most sensitive assay, which picked up both 
deficiencies in cultured myoblasts as well as in differentiated myotubes. Decreased pyruvate 
oxidation and ATP production rates were only detected in myoblasts of patient 2. This 
suggests that these two assays are less sensitive in myogenic cells, which may be caused 
by their stem cell properties or by alterations induced by cell culture conditions. 
Another possible application of the functional assays lies in the characterization of the large 
subset of patients with a decreased ATP production without a defect in the OXPHOS 
enzymes in muscle tissue. When these assays show a decrease in energy production in 
cultured muscle cells or fibroblasts of this patient group, it most probably reflects a primary 
mitochondrial disease and not secondary mitochondrial dysfunction. The latter can be 
caused by e.g. poor feeding or inactivity (17, 28, 30) and is characterized by a decreased 
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MEGS capacity solely in fresh muscle tissue which can normalize in muscle tissue taken 
after clinical improvement. 
Altogether, this study indicates that the myoblast and myotube cell model together with the 
biochemical assays provide a complete toolbox for the identification and characterization of 
mitochondrial disorders in a clinically important cell type. The fact that the muscle cells are 
primary, non-immortalized or otherwise genetically modified makes them more genuine than, 
for example, myoD transformed fibroblasts (31). This paves the way for multiple applications. 
These cells could be suited to study tissue specific OXPHOS defects that are only expressed 
in muscle tissue and not in fibroblasts. The physiology of mitochondrial disease can be 
studied more thoroughly by applying known biological assays like Reactive Oxygen Species 
(ROS) measurements, membrane potential and calcium uptake measurements in living 
muscle cells (32-36). A better knowledge of the pathophysiology of mitochondrial disease 
can help to develop targeted pharmacological intervention studies, which could be tested in 
vitro using the cultured muscle cells. Moreover, the myoblasts containing a mutation in 
NDUFS7 could serve as a model to test whether cells with mutated structural subunits are 
susceptible for therapy. 
Chapter 3 
68 
 
Funding 
This work was supported by a grant from the Prinses Beatrix Fonds [grant number OP-05-04] 
to AIJ and JS and grant IGE05003 from Senternovem to MH. The authors confirm 
independence from the sponsors; the content of the article has not been influenced by the 
sponsors. 
 
Conflicts of interest 
None. 
 
The study has been carried out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees (Commissie Mensgebonden Onderzoek 
Regio Arnhem-Nijmegen) and informed consent. 
 
 
REFERENCES 
 
1. van den Heuvel LP, Smeitink JA, Rodenburg RJ. Biochemical examination of 
fibroblasts in the diagnosis and research of oxidative phosphorylation (OXPHOS) defects. 
Mitochondrion. 2004 Sep;4(5-6):395-401. 
2. de Vries MC, Rodenburg RJ, Morava E, van Kaauwen EP, ter Laak H, Mullaart RA, et 
al. Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders 
due to polymerase gamma (POLG1) mutations. Eur J Pediatr. 2007 Mar;166(3):229-34. 
3. Barbieri E, Battistelli M, Casadei L, Vallorani L, Piccoli G, Guescini M, et al. 
Morphofunctional and Biochemical Approaches for Studying Mitochondrial Changes during 
Myoblasts Differentiation. J Aging Res. 2011;2011:845379. 
4. Rorbach J, Yusoff AA, Tuppen H, Abg-Kamaludin DP, Chrzanowska-Lightowlers ZM, 
Taylor RW, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially 
restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids 
Res. 2008 May;36(9):3065-74. 
Toolbox for characterization of myogenic cell lines 
69 
 
5. Pye D, Watt DJ, Walker C, Lightowlers RN, Turnbull DM. Identification of the RAG-1 
as a suitable mouse model for mitochondrial DNA disease. Neuromuscul Disord. 2004 
May;14(5):329-36. 
6. Boulet L, Karpati G, Shoubridge EA. Distribution and threshold expression of the 
tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red 
fibers (MERRF). Am J Hum Genet. 1992 Dec;51(6):1187-200. 
7. Suomalainen A, Majander A, Pihko H, Peltonen L, Syvanen AC. Quantification of 
tRNA3243(Leu) point mutation of mitochondrial DNA in MELAS patients and its effects on 
mitochondrial transcription. Hum Mol Genet. 1993 May;2(5):525-34. 
8. Sasarman F, Antonicka H, Shoubridge EA. The A3243G tRNALeu(UUR) MELAS 
mutation causes amino acid misincorporation and a combined respiratory chain assembly 
defect partially suppressed by overexpression of EFTu and EFG2. Hum Mol Genet. 2008 
Dec 1;17(23):3697-707. 
9. Sobreira C, King MP, Davidson MM, Park H, Koga Y, Miranda AF. Long-term analysis 
of differentiation in human myoblasts repopulated with mitochondria harboring mtDNA 
mutations. Biochem Biophys Res Commun. 1999 Dec 9;266(1):179-86. 
10. Vergani L, Malena A, Sabatelli P, Loro E, Cavallini L, Magalhaes P, et al. Cultured 
muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants. Brain. 
2007 Oct;130(Pt 10):2715-24. 
11. Jaksch M, Paret C, Stucka R, Horn N, Muller-Hocker J, Horvath R, et al. Cytochrome 
c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper-binding 
protein, is rescued by copper in human myoblasts. Hum Mol Genet. 2001 Dec 
15;10(26):3025-35. 
12. Sasarman F, Karpati G, Shoubridge EA. Nuclear genetic control of mitochondrial 
translation in skeletal muscle revealed in patients with mitochondrial myopathy. Hum Mol 
Genet. 2002 Jul 1;11(14):1669-81. 
13. Yasin R, Van Beers G, Nurse KC, Al-Ani S, Landon DN, Thompson EJ. A quantitative 
technique for growing human adult skeletal muscle in culture starting from mononucleated 
cells. J Neurol Sci. 1977 Jul;32(3):347-60. 
14. Shoubridge EA, Johns T, Boulet L. Use of myoblast cultures to study mitochondrial 
myopathies. Methods Enzymol. 1996;264:465-75. 
15. Yaffe D. Retention of differentiation potentialities during prolonged cultivation of 
myogenic cells. Proc Natl Acad Sci U S A. 1968 Oct;61(2):477-83. 
16. Bader D, Masaki T, Fischman DA. Immunochemical analysis of myosin heavy chain 
during avian myogenesis in vivo and in vitro. J Cell Biol. 1982 Dec;95(3):763-70. 
Chapter 3 
70 
 
17. Jonckheere AI, Huigsloot M, Janssen AJ, Kappen AJ, Smeitink JA, Rodenburg RJ. 
High-throughput assay to measure oxygen consumption in digitonin-permeabilized cells of 
patients with mitochondrial disorders. Clin Chem. 2010 Mar;56(3):424-31. 
18. Janssen AJ, Trijbels FJ, Sengers RC, Wintjes LT, Ruitenbeek W, Smeitink JA, et al. 
Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic 
procedure and application to human pathology. Clin Chem. 2006 May;52(5):860-71. 
19. Janssen AJ, Smeitink JA, van den Heuvel LP. Some practical aspects of providing a 
diagnostic service for respiratory chain defects. Ann Clin Biochem. 2003 Jan;40(Pt 1):3-8. 
20. Janssen AJ, Trijbels FJ, Sengers RC, Smeitink JA, van den Heuvel LP, Wintjes LT, et 
al. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and 
cultured fibroblasts. Clin Chem. 2007 Apr;53(4):729-34. 
21. Jonckheere AI, Hogeveen M, Nijtmans LG, van den Brand MA, Janssen AJ, Diepstra 
JH, et al. A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic 
cardiomyopathy and neuropathy. J Med Genet. 2008 Mar;45(3):129-33. 
22. Cooperstein SJ, Lazarow A. A microspectrophotometric method for the determination 
of cytochrome oxidase. J Biol Chem. 1951 Apr;189(2):665-70. 
23. Srere PA. Citrate synthase 1969. 
24. Schagger H, von Jagow G. Blue native electrophoresis for isolation of membrane 
protein complexes in enzymatically active form. Anal Biochem. 1991 Dec;199(2):223-31. 
25. Nijtmans LG, Henderson NS, Holt IJ. Blue Native electrophoresis to study 
mitochondrial and other protein complexes. Methods. 2002 Apr;26(4):327-34. 
26. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. 
Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76-85. 
27. Huigsloot M, Nijtmans LG, Szklarczyk R, Baars MJ, van den Brand MA, 
Hendriksfranssen MG, et al. A mutation in C2orf64 causes impaired cytochrome c oxidase 
assembly and mitochondrial cardiomyopathy. Am J Hum Genet. 2011 Apr 8;88(4):488-93. 
28. Morava E, Rodenburg R, van Essen HZ, De Vries M, Smeitink J. Dietary intervention 
and oxidative phosphorylation capacity. J Inherit Metab Dis. 2006 Aug;29(4):589. 
29. Lochmuller H, Johns T, Shoubridge EA. Expression of the E6 and E7 genes of human 
papillomavirus (HPV16) extends the life span of human myoblasts. Exp Cell Res. 1999 Apr 
10;248(1):186-93. 
30. Jonckheere AI, Huigsloot M, Janssen AJ, Kappen AJ, Smeitink JA, Rodenburg RJ. 
High-throughput assay to measure oxygen consumption in digitonin-permeabilized cells of 
patients with mitochondrial disorders. Clinical chemistry.  Mar;56(3):424-31. 
31. Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, Holtzer H. MyoD converts 
primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial 
Toolbox for characterization of myogenic cell lines 
71 
 
cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad 
Sci U S A. 1990 Oct;87(20):7988-92. 
32. Distelmaier F, Koopman WJ, Testa ER, de Jong AS, Swarts HG, Mayatepek E, et al. 
Life cell quantification of mitochondrial membrane potential at the single organelle level. 
Cytometry A. 2008 Feb;73(2):129-38. 
33. Koopman WJ, Distelmaier F, Esseling JJ, Smeitink JA, Willems PH. Computer-
assisted live cell analysis of mitochondrial membrane potential, morphology and calcium 
handling. Methods. 2008 Dec;46(4):304-11. 
34. Distelmaier F, Visch HJ, Smeitink JA, Mayatepek E, Koopman WJ, Willems PH. The 
antioxidant Trolox restores mitochondrial membrane potential and Ca2+ -stimulated ATP 
production in human complex I deficiency. J Mol Med. 2009 May;87(5):515-22. 
35. Koopman WJ, Verkaart S, van Emst-de Vries SE, Grefte S, Smeitink JA, Willems PH. 
Simultaneous quantification of oxidative stress and cell spreading using 5-(and-6)-
chloromethyl-2',7'-dichlorofluorescein. Cytometry A. 2006 Dec 1;69(12):1184-92. 
36. Verkaart S, Koopman WJ, van Emst-de Vries SE, Nijtmans LG, van den Heuvel LW, 
Smeitink JA, et al. Superoxide production is inversely related to complex I activity in inherited 
complex I deficiency. Biochim Biophys Acta. 2007 Mar;1772(3):373-81. 
 
 
  
 
 
  
 
 
 
 
 
PART III 
 
 
COMPLEX V IN HEALTH AND DISEASE 
  
  
 
  
4 
 
 
 
 
Mitochondrial ATP synthase: architecture, 
function and pathology 
 
 
 
An I. Jonckheere, Jan A.M. Smeitink, Richard J.T. Rodenburg 
 
 
Adapted from: J Inherit Metab Dis 2012; 35(2):211-25 
Chapter 4 
76 
 
ABSTRACT 
 
Human mitochondrial (mt) ATP synthase, or complex V consists of two functional domains: 
F1, situated in the mitochondrial matrix, and Fo, located in the inner mitochondrial membrane. 
Complex V uses the energy created by the proton electrochemical gradient to phosphorylate 
ADP to ATP. This review covers the architecture, function and assembly of complex V. The 
role of complex V di-and oligomerization and its relation with mitochondrial morphology is 
discussed. Finally, pathology related to complex V deficiency and current therapeutic 
strategies are highlighted. 
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Mitochondrial ATP production is the main energy source for intracellular metabolic pathways 
(1). The human mitochondrial (mt) ATP synthase, or complex V (EC 3.6.3.14) is the 5th multi 
subunit oxidative phosphorylation (OXPHOS) complex. It synthesizes ATP from ADP in the 
mitochondrial matrix using the energy provided by the proton electrochemical gradient (2-4). 
To date, numerous mutations in the mtDNA encoded subunits a and A6L have been found, 
next to mutations in a structural subunit (subunit epsilon, (5)), an assembly factor (ATP12, 
(6)) and an ancillary factor (TMEM70, (7)) which are nuclear-encoded. Most of these 
mutations give rise to severe mitochondrial disease phenotypes, ranging from NARP 
(Neuropathy, Ataxia, and Retinitis Pigmentosa) or MILS (Maternally Inherited Leigh 
Syndrome) for subunit a mutations to neonatal mitochondrial encephalo(cardio)myopathy 
and dysmorphic features in patients with an ATP12 or TMEM70 gene mutation (6-7). In this 
article, we have aimed to review the 5th OXPHOS complex with respect to architecture, 
function, assembly, pathology, current therapeutic options and future perspectives. The 
structure and, intriguingly, the oligomerization of complex V determine its function, the former 
by the so-called “rotary catalysis” (8) and the latter by influencing mitochondrial and cristae 
morphology (9), as will be discussed below. 
 
 
ATP synthase: architecture (Figure 1) 
 
ATP synthase consists of two well defined protein entities: the F1 sector, a soluble portion 
situated in the mitochondrial matrix, and the Fo sector, bound to the inner mitochondrial 
membrane. F1 is composed of three copies of each of subunits α and β, and one each of 
subunits γ, δ and ε. F1 subunits γ, δ and ε constitute the central stalk of complex V. Fo 
consists of a subunit c-ring (probably comprising eight copies, as shown in bovine 
mitochondria (10)) and one copy each of subunits a, b, d, F6 and the oligomycin sensitivity-
conferring protein (OSCP). Subunits b, d, F6 and OSCP form the peripheral stalk which lies 
to one side of the complex. A number of additional subunits (e, f, g, and A6L), all spanning 
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the membrane, are associated with Fo (8, 11). Two of the Fo subunits, subunit a and subunit 
A6L are encoded by the mtDNA ATP6 and ATP8 genes, respectively (12). The detailed 
structure of most of the bovine mitochondrial complex V subunits, which will not be covered 
in this review, has been resolved by X-ray crystallography by John Walker and his group 
(see, among others, (11, 13-19)). 
 
 
 
 
Figure 1 Human mitochondrial ATP synthase, 
or complex V, consists of two functional 
domains, F1 and Fo. F1 comprises 5 different 
subunits (three α, three β, and one γ, δ and ε) 
and is situated in the mitochondrial matrix. Fo 
contains subunits c, a, b, d, F6, OSCP and the 
accessory subunits e, f, g and A6L. F1 
subunits γ, δ and ε constitute the central stalk 
of complex V. Subunits b, d, F6 and OSCP 
form the peripheral stalk. Protons pass from 
the intermembrane space to the matrix 
through Fo, which transfers the energy created 
by the proton electrochemical gradient to F1, 
where ADP is phosphorylated to ATP. One β 
subunit is taken out to visualize the central 
stalk. 
 
 
 
For comparison, the subunit composition of human, yeast and E. coli ATP synthase is 
presented in Table 1 (10, 20). 
 
Table 1: Subunit composition of human, yeast and E. coli ATP synthase (10, 20). 
  
Stoichiometry 
Bacteria Mitochondria 
E. coli S. cerevisiae H. sapiens 
F1 3 α α α 
 3 β β β 
 1 γ γ γ 
 1 ε δ δ 
 1 - ε ε 
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 1 δ OSCP OSCP 
Fo 1 a 6 a 
 1 - 8 A6L 
 10-15 c10-12 910 c8 
 1-2 b2 4 b 
 1 - d d 
 1 - h F6 
 1 - f f 
 t.b.d. - e e 
 t.b.d. - g g 
 1 - i - 
 1 - k - 
Regulators 1 - Inh1p IF1 
 t.b.d. - Stf1p - 
 t.b.d. - Stf2p - 
t.b.d.: to be determined 
 
How structure relates to function: the rotary F1Fo ATP synthase 
 
The function of ATP synthase is to synthesize ATP from ADP and inorganic phosphate (Pi) in 
the F1 sector. This is possible due to energy derived from a gradient of protons which cross 
the inner mitochondrial membrane from the intermembrane space into the matrix through the 
Fo portion of the enzyme. The proton gradient establishes a proton-motive force, which has 
two components: a pH differential and an electrical membrane potential (∆ψm) (21). The 
released energy causes rotation of two rotary motors: the ring of c subunits in Fo (22) 
(relative to subunit a), along with subunits γ, δ and ε in F1 (23), to which it is attached. 
Protons pass Fo via subunit a to the c-ring (24). Rotation of subunit γ within the F1 α3β3 
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hexamer provides energy for ATP synthesis. This is called “rotary catalysis” (8) and can be 
explained by the “binding-change” mechanism, first proposed by Boyer (25). This mechanism 
describes ATP synthesis and ATP hydrolysis at the catalytic sites, located in each of the 
three β subunits, at the interface with an adjacent α subunit. In the case of ATP synthesis, 
each site switches cooperatively through conformations in which ADP and Pi bind, ATP is 
formed, and then released. ATP hydrolysis uses the same pathway, but in reverse (26). 
These transitions are caused by rotation of the γ subunit. The α3β3 hexamer must remain 
fixed relative to subunit a during catalysis, this occurs through the peripheral stalk. Complex 
V can therefore mechanically be divided into “rotor” (c-ring, γ, δ, ε) and “stator” (α3β3, a, b, d, 
F6, OSCP) components (8). 
Oligomycin is an inhibitor of proton translocation in ATP synthase, putatively binding the Fo 
subunits a and c (27). 
F1Fo ATP synthases, or F-type ATPases, belong to a bigger rotor protein family, consisting of 
F-, V-, and A-type ATPases (28-29). The different ATPases are categorized on the basis of 
their function and taxonomic origin. They are related in both structure and mechanism (30). 
F-type ATPases synthesize ATP, but are also capable of the reversed reaction and can 
hydrolyze ATP. Vacuolar or V-type ATPases use the energy derived from ATP hydrolysis to 
pump protons through membranes (28). V-ATPases are localized to intracellular membranes 
where they acidify intracellular compartments (e.g. lysosomes). They also lie in the plasma 
membrane, to transport protons out of highly specialized cells, like kidney cells or osteoclasts 
(30). Eukaryotes contain both F- and V-ATPases. In contrast, archaea typically contain only 
one complex which is evolutionarily closer to V-ATPases, called A-ATPase/synthase (28). A-
ATPases are structurally simpler than F- or V-ATPases, but functionally more versatile, 
performing both ATP synthesis and ATP hydrolysis (28). F-type ATP synthases contain only 
one peripheral stalk, while A- and V-ATPases have two and three peripheral stalks, 
respectively, each made of an E-G heterodimer (28). 
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Proteins related to mammalian ATP synthase 
 
Coupling factors: the Inhibitor Protein IF1 and Factor B 
 
In normally respiring mitochondria, ∆ψm is high (estimated at between 150 and 180 mV 
negative to the cytosol), favoring ATP synthesis by F1Fo ATP synthase (21). However, when 
mitochondrial respiration is compromised and ∆ψm falls below a threshold, F1Fo ATP 
synthase can reverse, hydrolyzing ATP to pump protons through the membrane. Since 
depletion of ATP precipitates cell death, wasteful hydrolysis of ATP is not desirable, and 
must be prevented during inhibition of respiration (8). This regulation is carried out by the 
inhibitor protein IF1, which inhibits mitochondrial F1-ATPase activity (31) in a pH-dependent 
manner (32). The active form predominates at pH values < 6.5 (33). IF1 conserves ATP at the 
expense of ∆ψm, which has been shown to be protective to cells during ischemia (21, 34). IF1 
acts as a homodimer, binding to two F1-ATPase sectors via subunits β and γ. IF1 has no 
prokaryotic counterpart but is highly conserved through evolution in eukaryotic species, 
which indicates its functional importance (21). Remarkably, an increased IF1 expression - as 
found in certain tumors and cancer cells – will inhibit both the synthetic and hydrolytic 
activities of complex V (35). 
 
Factor B, which has no prokaryotic homologue nor a counterpart in Saccharomyces 
cerevisiae, appears to bind to Fo on the matrix side (36). It seems to have a regulatory 
function, like IF1. In addition to the classic proton-translocating pathway in Fo, situated at the 
interface of subunit a and the c-ring, it has been proposed that the membrane sector Fo of 
animal mitochondria could harbor a second, latent proton-translocating pathway, to the 
assembly of which supernumerary subunits e, f, g, and A6L, as well as the ADP/ATP carrier 
could contribute their transmembrane segments (37). It has further been proposed that factor 
B occludes the latent proton-translocating pathway (37). Doing so, factor B blocks a proton 
leak, keeping ∆ψm high and thus favoring ATP synthase activity (37). 
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Assembly factors: ATP11 and ATP12 
 
ATP11 and ATP12 bind to unassembled β and α subunits, respectively, by shielding their 
hydrophobic surfaces (38-39). In the absence of these assembly factors, the α-F1 and β-F1 
aggregate within large inclusion bodies in the mitochondrial matrix (40-41). 
 
TMEM70 
 
Transmembrane protein 70 (TMEM70) has been shown to be localized in mitochondria (42). 
The N-terminal part of the cytosolic 29 kDa precursor is cleaved to a 21 kDa mature 
mitochondrial protein (43). Analysis of submitochondrial fractions has shown that TMEM70 is 
associated with the inner mitochondrial membrane (43). It has been demonstrated that 
TMEM70 is required to maintain normal expression levels and activity of complex V (7). It 
however does not interact directly with holocomplex V (43). A transient binding to complex V 
assembly intermediates has been proposed (44). Since TMEM70 is a low abundant 
mitochondrial protein, like the ATP11 and ATP12 assembly factors, a regulatory role of 
TMEM70 in complex V biogenesis has been suggested (43). Further studies are necessary 
to clarify the exact mechanism by which TMEM70 defects lead to complex V deficiency. 
 
Proteins associated with mammalian ATP synthase 
 
Two ATP synthase-associated membrane proteins were identified a few years ago (45). Both 
proteins had been identified earlier in a different context. The first one is a 6.8-kDa 
mitochondrial proteolipid (MLQ protein), the second one has been denoted as diabetes-
associated protein in insulin-sensitive tissue (DAPIT) (AGP protein). It has been shown 
recently that DAPIT has a role in maintaining ATP synthase amount in mitochondria and 
Mitochondrial ATP synthase 
83 
 
therefore possibly can influence cellular energy metabolism (46). The functional role of the 
6.8-kDa proteolipid as ATP synthase-associated protein still has to be elucidated (45). 
 
 
Complex V assembly 
 
Current knowledge about the assembly of ATP synthase is mainly based on research 
performed on assembly-deficient yeast mutants (20). Nevertheless complex V assembly 
remains puzzling and partially hypothetical because the biogenesis of ATP synthase is not 
easily studied biochemically (47). This is due to rapid turnover of subunits of Fo and the stator 
in these yeast mutants (47). This problem has been addressed lately by labeling and tracking 
the mitochondrial gene products of Fo in isolated mitochondria (48). 
It is known that the assembly of F1, the stator and the c-ring occurs separately, but the 
assembly sequence of subunits into the different modules and the sequence between the 
modules is not entirely clear (49-50). Using Clear Native Polyacrylamide Gel Electrophoresis 
(CN-PAGE), performed with milder detergents than Blue Native PAGE (BN-PAGE), it has 
been shown in human mitochondria lacking mtDNA (and therefore subunits a and A6L) that 
ATP synthase can assemble into a complex with a mass of 550 kDa (49). This is a little bit 
smaller than holocomplex V (597 kDa), suggesting that the only subunits lacking in the 550 
kDa complex are subunit a (24.8 kDa) and A6L (8 kDa), and possibly the small associated 
proteins AGP and MLQ (49). This implies that the so-called F1-z complex (or V* (3)) contains 
the c-ring and that it is a breakdown product of the 550 kDa complex under the harsher 
conditions of BN-PAGE instead of an assembly intermediate (49). Based on these findings 
and on previous yeast work (reviewed in (20, 47)) a proposal regarding the assembly of 
mammalian ATP synthase has been made: assembly of the c-ring followed by binding of F1, 
the stator arm, and finally of subunits a and A6L (49) (Figure 2).  
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Figure 2 Complex V assembly and dimerization. The current working model is based on 
assembly of the c-ring followed by binding of F1, the stator arm, and finally of subunits a and 
A6L. Two ATP synthase monomers dimerize via the Fo sector, where subunits a, e, g, b and 
A6L stabilize the monomer-monomer interface. 
 
 
A recent yeast study indicated that ATP synthase is formed from three different modules: the 
c-ring, F1 and the Atp6p/Atp8p complex (48). It is proposed that ATP synthase assembly in 
yeast involves two separate pathways (F1/Atp9p and Atp6p/Atp8p/2 stator subunits/Atp10p 
chaperone) that converge at the end stage (48). The final addition of the mitochondrial 
encoded subunits to mammalian complex V is in line with the yeast studies describing that 
the expression of yeast subunits 6 and 8 is translationally regulated by the F1 sector (48, 51). 
Therefore a balanced output can be achieved between the nuclear encoded and mtDNA 
encoded subunits. The role of complex V subunits in the assembly process has been 
studied. The peripheral stalk is important for the stability of the c-ring/F1 complex (47). It has 
been described that subunit A6L provides a physical link between the proton channel and the 
other subunits of the peripheral stalk (52). F1 subunit ε is indispensable for the assembly of 
holocomplex V (53). More specifically, subunit ε plays a role in the biosynthesis and 
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assembly of the F1 sector and seems to be involved in the incorporation of subunit c to the 
rotor structure of ATP synthase (5). Subunit c isoforms (P1, P2, and P3) are not functionally 
interchangeable since their targeting peptides have different roles, varying from 
mitochondrial import to the regulation of the assembly and function of other OXPHOS 
complexes (54). On the contrary, an example of over engineering is the F1 subunit γ, which 
only needs its N-terminal helix together with subunit δ in an upward position to catalyze ATP 
synthesis (55-56). 
 
 
Complex V di- and oligomerization 
 
An important role of subunits a and A6L is the stabilization of holocomplex V (49). It has 
been shown that ATP synthase is organized in dimers and higher oligomers (24, 57-62). The 
interaction between two ATP synthase monomers mainly takes place via the Fo sector 
(Figure 2). It has been suggested that subunit a forms the most important basis for 
dimerization since it has a high number of predicted transmembrane helices (24). Next to 
subunit a, subunits of the stator stalk and accessory subunits (e, g, b, and A6L) stabilize the 
monomer-monomer interface (24, 49, 63). Another protein that has a role in the stabilization 
of di- and oligomers is IF1. Mature IF1 is only bound to di- and oligomeric ATP synthase in 
mammals (49). IF1 links two ATP synthases via the F1 sector (8).  
Monocomplex V is fully capable of ATP synthesis. Nevertheless forming di- and oligomers 
has been proven to be beneficial to the cell. First, di- and oligomers provide stabilization of 
complex V, which is continuously subject to dynamic rotor/ stator interactions and can 
therefore be dissociated more easily (64). Secondly, oligomerization of complex V facilitates 
ATP synthesis (9). This happens because dimer ribbons of ATP synthase shape the inner 
mitochondrial membrane (9). Because of the angular association of two monomers, 
dimerization leads to bending of the inner mitochondrial membrane, creating protrusions of 
the membrane in the matrix, called mitochondrial cristae. Clustering of ATP synthase dimers 
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at the apex of the cristae creates a strong local positive curvature which generates a proton 
trap. This facilitates ATP synthesis (9). IF1 contributes to this mechanism and is therefore 
beneficial during ischemia, since ATP synthesis can be preserved when mitochondrial 
respiration is compromised (21, 34). 
 
 
Complex V and mitochondrial morphology 
 
The association of ATP synthase dimers as generating the tubular cristae has been 
hypothesized by Allen (65). The link between dimerization of mitochondrial ATP synthase, 
through subunits e, g, and –as described just recently, subunits i, k, and the biogenesis of 
cristae has been provided by studying yeast cells (62, 66-67). Due to cristae formation, the 
inner mitochondrial membrane can be divided into the inner boundary membrane and the 
cristae membrane. The cristae are connected to the inner boundary membrane by narrow 
structures, called crista junctions. In yeast, it has been suggested that the formation of 
cristae and crista junctions in mitochondria depends on antagonism between Fcj1 (formation 
of crista junction 1) and subunits e/g (68). IF1 contributes to cristae formation (34). Other 
components such as prohibitins or OPA1 or others yet to be identified also could contribute 
to crista junction and cristae tip formation (68-69). 
It has been shown in yeast that in the absence of complex V dimerization (by depleting 
subunits e and g) normal cristae formation is hampered, resulting in onion-like structures 
(66). Inhibition of F1 synthesis in yeast leads to an absence of cristae (41, 66). Another yeast 
study describes that the lack of Atp6p rather than an ATP production deficit modifies the 
overall structure of the mitochondria (70). Taken together, the complex V structure and not its 
enzymatic activity seems to modify cristae morphology, which is in agreement with the 
necessity of ATP synthase dimerization for mitochondrial cristae formation (9, 34, 66).  
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Complex V deficiency 
 
Complex V deficiency is one of the rarer OXPHOS deficiencies. Based on the results of 
mitochondrial biochemical diagnostics in Nijmegen in the years 2005-2009, complex I, IV and 
combined enzyme deficiencies are encountered most frequently (8%, 5% and 7%, 
respectively of 1,406 fresh muscle samples examined), followed by complex III (3%), 
complex II (2%) and complex V (1%) (71).  
 
Biochemical diagnosis 
 
Measurement of the mitochondrial energy-generating system (MEGS) capacity in fresh 
muscle tissue is a powerful tool to assess mitochondrial function and to detect deficiencies of 
complex V and other OXPHOS complexes. The MEGS capacity can be examined in detail by 
measurement of 14CO2 production rates from oxidation of [1-14C]pyruvate and carboxyl-14C-
labeled TCA cycle intermediates in combination with measurement of ATP production in 
intact mitochondria from a muscle biopsy (72), or by examining mitochondrial respiration by 
measuring oxygen consumption in digitonin-permeabilized cells (73). A reduced pyruvate 
oxidation rate that is normalized by addition of an uncoupler, e.g. carbonyl cyanide 3-
chlorophenyl hydrazone (CCCP), indicates a defect in complex V, the adenine nucleotide 
transporter, or the phosphate carrier (71). Enzyme analysis of complex V (mtATPase) in 
skeletal muscle biopsy and in cultured fibroblasts remains the mainstay of the diagnostic 
process (74). In Nijmegen, mtATPase activity is measured spectrophotometrically in isolated 
mitochondria from fresh muscle tissue and fibroblasts as described (71): a solution of 980 µl 
containing 250 mM sucrose, 50 mM KCl, 30 mM phosphate buffer pH 7.4, 25 mM phosphate 
buffer pH 8.0, 0.1 mM phosphoenolpyruvate, 5 mg/L Ap5A, 0.3% BSA, 0.2 mM EGTA, 3 mM 
ATP, 7.5 mM MgCl2, 250 µM NADH, 2.5 U/ml lactate dehydrogenase, and 1.5 U/ml pyruvate 
kinase is incubated for 10 min at 37°C. A mitochondrial suspension is freeze-thawed three 
times and 20 µl is added to the reaction mixture, mixed and transferred to a cuvette, after 
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which the absorption at 340 nm is measured for 8 min. Simultaneously, the absorption is 
measured in a second cuvette after addition of 1 µl of an 8 mg/ml oligomycin solution in 
ethanol to the mitochondrial suspension and the reaction mixture. The oligomycin-sensitive 
activity of complex V is calculated using an ε340 for NADH of 6.22x103 L/mol.cm and is 
expressed in units (the amount of enzyme required to convert 1 µmol NADH per min) per unit 
cytochrome oxidase (COX) (75) activity. Analysis of complex V in frozen tissue is considered 
to be less reliable than in fresh muscle tissue ((76), and personal experience (data not 
shown)). In addition, BN-PAGE followed by western blotting (77-78) and in-gel activity 
measurements of ATP hydrolysis (78) can be performed to assess the amount and activity of 
complex V. BN-PAGE can also provide information about the assembly of complex V (7, 79). 
 
Molecular genetics 
 
Hitherto, complex V mutations have been described in the mtDNA encoded ATP6 (MT-
ATP6) and ATP8 (MT-ATP8) genes. ATP synthase deficiency due to the nuclear encoded 
ATP12 and TMEM70 genes has also been described (6-7). Interestingly, only one mutation 
has hitherto been described in a nuclear encoded structural complex V subunit, ATP5E (5). 
 
ATP synthase subunit a; MT-ATP6 (MIM ID +516060) 
 
Mutations in MT-ATP6 were the first complex V genetic defects to be reported (80) and have 
been described most frequently to date. The classical clinical picture is found in 
m.8993T>G/C and m.9176T>G/C mutations and covers a spectrum which varies between 
isolated ataxia, NARP, bilateral striatal necrosis, to Leigh or Leigh-like syndromes 
(www.mitomap.org). Also other clinical features have been associated with MT-ATP6 
mutations (www.mitomap.org). Below, an overview of a part of the hitherto described 
mutations in this gene is given, i.e. the mutations that have been well studied in humans and 
in yeast and those that, in our opinion, add interesting information regarding the clinical 
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expression of mitochondrial complex V diseases. They have been outlined in relation to their 
clinical picture. 
m.8993T>G. This mutation leads to NARP (typically < 90-95% heteroplasmy) or MILS (when 
> 95% heteroplasmy). Biochemically a decreased ATPase activity (measured 
spectrophotometrically) and a severely decreased ATP production rate (until 70% when > 
90% heteroplasmy) is observed (81-87). Subunit a has two functions: (i) it conducts protons 
from the inner mitochondrial membrane to the matrix, which (ii) leads to the rotation of the 
ring of c-subunits that contacts subunit a in the membrane. The resulting mechanical energy 
is used to induce conformational changes at the level of the catalytic sites in the F1 extra-
membrane domain that favor ATP synthesis (81, 88). The m.8993T>G point mutation leads 
to p.Leu156Arg. Leu156 is highly conserved in eukaryotes (81, 89) and is situated in the 
region of subunit a that regulates proton translocation coupled to rotation of the c-ring (20, 
81). The introduction of a positively charged amino acid (arginine) instead of the hydrophobic 
leucine causes a structural change that has been shown to affect rotation of the c-ring (81). 
The proton flux through Fo is slower, but not blocked (81). Furthermore, it has been shown 
that ATP synthase still assembles and oligomerizes correctly. This is confirmed by an intact 
oligomycin sensitivity (90), a property that is lost when enzyme structure is severely altered 
(91-92). The assembly of F1 with Fo has only been shown to be delayed because of a slower 
subunit a synthesis or an increased subunit a instability and degradation (93). Taken 
together, the severe impairment of ATP synthesis is due to functional inhibition in a correctly 
assembled ATP synthase (90).  
m.8993T>C. The clinical picture is similar to the m.8993T>G mutation, but is generally milder 
(87, 94-96). The mutation results in p.Leu156Pro. Opposite to the positive charged arginine 
in the m.8993T>G mutation, proline is a non-charged amino acid. Biochemically, ATP 
synthesis is not severely affected (81). So this does not fully explain the NARP or MILS 
phenotypes seen in patients. It has been shown that the m.8993T>C mutation favors 
Reactive Oxygen Species (ROS) production, which is believed to be the major pathogenic 
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mechanism (81). ROS plays a major role in the pathogenesis of neurological diseases 
related to mitochondrial dysfunction (97-98). 
m.9176T>G/C. The clinical picture is characterized by familial bilateral striatal necrosis 
(FBSN) and Leigh syndrome (99-100). A hereditary spastic paraplegia-like disorder has been 
described in a family carrying the homoplasmic m.9176T>C mutation (101). The mutations 
also change a highly conserved hydrophobic leucine residue into arginine (m.9176T>G) or 
proline (m.9176T>C) at position 217 of the protein. Position 217 of subunit a also lies in 
proximity to the c-ring (70). It has been shown in human cells with a high degree of 
heteroplasmy that the m.9176T>G mutation severely decreases the rate of ATP production 
(102). In yeast carrying the m.9176T>G mutation, it has been described that that 
incorporation of subunit a into ATP synthase was almost completely prevented (70). This 
resulted in a disturbed assembly which profoundly altered mitochondrial morphology (70). 
This finding is in contrast to the m.8993T>G mutation, where the assembly is not altered (as 
mentioned before). Taken together, the pathogenicity of m.9176T>G may not be limited to a 
bio-energetic deficiency, but may also be attributed to an altered mitochondrial and cristae 
morphology (70). Also the m.9176T>C mutation has been studied in yeast, only showing a 
mild decrease in ATP production (88). There is a poor correlation between genotype and 
phenotype for the m.9176T>C mutation (88). Additional determinants may be responsible 
and are a plausible explanation for this finding. One of these determinants has been 
proposed to be the higher degree of oligomycin vulnerability in the mutant than in wild type 
(88).  
In tightly coupled mitochondria the oxygen consumption rate and ATP synthesis depend on 
each other (103). Therefore it is not very surprising to see a decreased respiratory activity in 
many ATP synthase defective mutants (103). In several yeast models with NARP-MILS 
mutations (atp6-p.Leu183Pro (104), atp6-p.Leu183Arg (105), atp6-p.Leu247Arg (70), atp6-
p.Leu247Pro (88), and ∆atp6 (103)), it has been shown that there is a linear correlation 
between ATP synthase activity and complex IV activity (88). So it appears that complex IV is 
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an important target for the co-regulation of electron transfer and ATP synthesis in 
mitochondria (88).  
m.9035T>C, m.9185T>C, m.9191T>C, m.8851T>C. These mutations are illustrations of 
variants of the earlier described NARP-MILS clinical spectrum. m.9035T>C has been found 
in a family with maternally transmitted cognitive developmental delay, learning disability, and 
progressive ataxia (106). Mutant cybrids had less than half of the steady-state content of 
ATP and a substantial higher basal level of Reactive Oxygen Species (ROS) (106). 
m.9185T>C (p.Leu220Pro) results in a phenotype varying from mild learning difficulties and 
foot deformities, ataxia, an acute neurological presentation with complete recovery, to Leigh 
syndrome (107-108). m.9191T>C (p.Leu222Pro) has been described in a patient with Leigh 
syndrome (108). The pathogenic mechanism of the m.9185T>C and m.9191T>C mutations 
is unknown, but they are situated in a highly conserved region of the protein. The observed 
phenotypical differences are proposed to result from additional genetic and/or environmental 
modifying factors (107). A patient suffering from bilateral striatal necrosis and harboring a 
m.8851T>C mutation has also been described (109). This phenotype is less severe than 
found in typical Leigh disease (109).  
∆TA9205. This mutation has been reported in a patient with seizures and lactic acidemia 
(110). ∆TA9205 is situated at the junction between the two genes MT-ATP6 and MTCO3 
(which codes for COX3, a complex IV subunit). It removes the termination codon from 
RNA14, the bi-cistronic RNA unit encoding MT-ATP8 and MT-ATP6, which has been shown 
to cause a decrease in the steady-state level of the mutated RNA14 (111). The level of 
RNA15, the RNA transcribed from MTCO3, is not affected (111). This mutation illustrates 
how a mtDNA mutation can influence the turnover of a human mitochondrial mRNA.  
Modifiers. Phenotypical variations between patients harboring the same mtDNA mutation 
have classically been attributed to mtDNA heteroplasmy. However, a discrepancy between 
the levels of mutant mtDNA and disease severity is sometimes observed (93). The mtDNA 
background has been shown to play an important role in modulating the biochemical defects 
and clinical outcome (93). MT-ATP6 mutations m.8741T>G and m.8795A>G have been 
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shown to be protective factors for the m.8993T>G MILS mutation (112). A MT-ATP6 
polymorphism, m.9055G>A, significantly reduces the risk of Parkinson disease, especially in 
women (113). The mitochondrial haplogroup J has been shown to be associated with 
longevity and protection against certain diseases (101). Vice versa, respiratory chain defects 
upstream of ATP synthase contribute to ATP synthesis impairment, worsening the 
biochemical and clinical phenotype e.g. of m.8993T>G/C and m.9176T>G mutations (93). 
The germ-line mutation m.8932C>T has, together with somatic mtDNA mutations in the 
cytochrome oxidase subunit I (COI) gene, been associated with prostate cancer (114-115). 
The mtDNA variants m.8836T>G, m.9016A>G, m.9101T>C, m.9139G>A have been linked 
with patients who had Leber Hereditary Optic Neuropathy (LHON) or LHON-like optic 
neuropathies (116-119). Hence, mtDNA background can explain the biochemical and clinical 
variations observed between patients with the same mutation and a comparable mutation 
load. This also illustrates the role of mtDNA variants in the complexity of mtDNA disease 
expression. In general, phenotypic variability is proposed to be the result of interactions 
between the casual genes, genetic background or modifier genes (mitochondrial or nuclear), 
and probably environmental factors (120). 
 
ATP synthase subunit A6L; MT-ATP8 (MIM ID +516070) 
 
m.8528T>C. This homoplasmic mutation has been found in four unrelated patients who 
presented as infants with isolated hypertrophic cardiomyopathy and congestive heart failure, 
evolving to multisystem disease (121). Electron microscopy of muscle tissue showed 
increased variation in size and shape of mitochondria with dense parallel cristae in one 
patient (121). For A6L, m.8528T>C (p. Trp55Arg) is a pathogenic missense mutation, 
replacing a hydrophobic tryptophan into a basic arginine in a conserved region of the subunit. 
In subunit a, the nucleotide alteration results in the change of the initiation methionine to 
threonine, but the effect of this mutation on the function of this subunit is not clear (121).  
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m.8411A>G. The de novo mutation with 97% heteroplasmy has been described in a patient 
with psychomotor delay, epilepsy, tetraplegia, congenital deafness, central blindness and 
swallowing difficulties (122). He died at the age of 10 years. Brain MRI showed involvement 
of the interpeduncular nucleus, the central tegmental tract, the white matter and the 
cerebellum. This leucodystrophy phenotype differs from the other mutations described in MT-
ATP8, where cardiac involvement predominates. Leucodystrophy has been described in two 
siblings with Leigh syndrome harboring the m.9176T>C mutation in MT-ATP6 (123). It should 
be noted that complex V enzyme analysis was not performed in this patient (122), and 
therefore the pathogenicity of the m.8411A>G mutation has not been firmly established yet. 
 
ATP12 (MIM ID *608918) 
 
A homozygous T>A mutation, changing an evolutionary conserved tryptophan to an arginine 
at position 94 (p.Trp94Arg) of the nuclear encoded complex V assembly gene ATP12 has 
been found in a patient who presented with a severe neonatal encephalopathy and 
dysmorphic features, evolving to basal ganglia atrophy within months and death at the age of 
14 months (6, 124). The mutation resulted in a severely decreased complex V amount and 
activity. It was hypothesized that the change of a neutral polar amino acid (tryptophan) into a 
basic one (arginine) resulted in an ATP12 protein that was no longer able to mediate F1 
assembly (6). Later, it has been shown in a yeast model that the p.Trp94Arg mutation 
decreases the solubility of the protein, implying that the primary impact of the mutation was a 
change in physical rather than functional parameters (124). Mitochondrial morphology has 
been studied in fibroblasts, but no alterations compared to control cells could be observed 
(124). 
 
TMEM70 (MIM ID *612418) 
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The TMEM70 gene encodes a mitochondrial protein, transmembrane protein 70. A common 
splice site mutation and an isolated frameshift mutation have been described in the TMEM70 
gene particularly in a homogeneous ethnic group (Romanies), with a clinical phenotype 
characterized by neonatal mitochondrial encephalocardiomyopathy, lactic acidosis and 
dysmorphic features (7). The description of four novel mutations in the TMEM70 gene has 
confirmed and expanded this classical clinical picture with early onset cataract, 
gastrointestinal dysfunction, congenital hypertonia and a fetal presentation of the syndrome 
(125). One patient with a milder clinical phenotype carrying the common splice site mutation 
and a missense variant has also been described (126). This phenotype corroborates with two 
reported patients who are compound heterozygous for the common splice site mutation and 
a frame-shift mutation in exon 1 (44, 127). It was shown that TMEM70 is required to maintain 
normal expression levels of complex V (7). The exact mechanism behind this remains to be 
elucidated, although it has been suggested that TMEM70 is involved in complex V 
biogenesis (7). 
 
ATP synthase subunit epsilon; ATP5E (MIM ID *606153) 
 
Recently, a homozygous missense mutation c.35A>G (p.Tyr12Cys) has been described in 
exon 2 of the ATP5E gene (5). The patient was a 22 year old woman presenting with 
neonatal onset, lactic acidosis, 3-methylglutaconic aciduria, and mild mental retardation. She 
developed peripheral neuropathy (5). The mutation caused a decrease in the amount and 
activity of holocomplex V. Remarkably, subunit c was found to accumulate, in contrast to the 
other investigated complex V subunits, and in contrast to what was found in patients with a 
mutation in the TMEM70 (127) and ATP12 (6) genes (5). Using pulse-chase experiments, 
this study pointed to the crucial role of subunit ε in the biosynthesis and assembly of the F1 
part of ATP synthase. Moreover, subunit ε seems to be involved in the incorporation of 
subunit c into the rotor (5). 
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Therapy 
 
Current available treatment options for patients with mitochondrial diseases are mainly 
supportive. Therefore, a lot of effort is put into the search for both pharmacological and 
genetic approaches to cure this devastating group of disorders (for reviews, see (128-130)). 
Focusing here on complex V deficiency, current research has mainly covered the therapy of 
mtDNA mutations. 
 
Antioxidants 
 
As mentioned above, complex V mutations can increase ROS production which is 
deleterious for the cell. The antioxidants N-acetylcysteine (NAC) and dihydrolipoic acid 
(DHLPA) have therefore been tested in fibroblasts harboring 97% m.8993T>G mutant 
mtDNA. It has been shown that they significantly improved mitochondrial respiration and ATP 
synthesis in these cells (131). 
 
Substrates: α-Ketoglutarate/Aspartate 
 
In yeast studies, it has been suggested that forcing substrate-level phosphorylation to work 
overtime may counteract the energy crisis due to OXPHOS impairment (132).  
For the application of this approach in OXPHOS-deficient human cells, exogenous 
substrates capable of stimulating the Krebs cycle flux while at the same time removing the 
excess of reduced nicotinamide adenine dinucleotide (NADH) have been chosen (133). It 
has been demonstrated that homoplasmic cybrids harboring the m.8893T>G mutation were 
protected from cell death and had an ATP content similar to controls after supplementation of 
the culture medium with α-ketoglutarate and aspartate (133). 
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Affecting heteroplasmy of the mtDNA (gene-shifting) 
 
This genetic approach aims to force a shift in heteroplasmy, reducing the ratio of mutant to 
wild-type genomes (also called gene-shifting) (128). Various methods can be applied to 
achieve this goal.  
Allotopic expression. Here, a normal version of a mutant mtDNA-encoded protein is 
imported into the nucleus. For example, MT-ATP6 can be converted from the mitochondrial 
into the nuclear genetic code (128, 134). To be transported to the mitochondrion, it has to be 
provided with a mitochondrial targeting signal, of which the genetic sequence can be 
borrowed from another mtDNA-encoded protein. The biochemical defect in cybrid cell lines 
harboring the m.8993T>G mutation has been corrected successfully using this strategy 
(134).  
Xenotopic expression. The correction here implies the transfection of mammalian cells with 
either mitochondrial or nuclear genes from other organisms encoding the protein of interest 
(128). This has also been applied to human cybrids harboring the m.8993T>G mutation by 
expressing the nDNA encoded ATPase6 protein of the alga Clamydomonas reinhardtii, 
which already possessed the mitochondrial targeting sequence since it is nuclear encoded 
(135). Also this approach could correct the biochemical defect in these cells (135).  
Restriction endonucleases. These are specific proteins that cut mutant mtDNA but not wild 
type mtDNA (128). For example, the m.8993T>G mutation creates a unique cleavage site for 
the restriction endonuclease SmaI. The gene for SmaI was fused to a mitochondrial targeting 
sequence and expressed in heteroplasmic mutant cybrid cells, which lost mutant mtDNA and 
recovered biochemically (136-137).  
Oligomycin. It has been shown that culturing heteroplasmic m.8993T>G cybrid cells in 
medium containing oligomycin (complex V inhibitor) and galactose (which forces the cells to 
rely on oxidative metabolism for ATP production) allowed for the selection of wild type over 
mutant mtDNA (138).  
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Germline therapy 
 
It has been proposed that nuclear transfer techniques may be an approach for the prevention 
of transmission of human mtDNA disease (139-140). Briefly, this means that the pronucleus 
of an oocyte, or zygote, of a woman carrying mutated mtDNA could be transferred to a donor 
enucleated oocyte, or zygote, carrying wild type mtDNA (128, 141). In that way, the offspring 
will carry all the nuclear – and physiognomonic - traits of the parents, but not the mutated 
mtDNA of the mother (128). Two successful approaches have recently been described. 
Metaphase II spindle transfer between unfertilized metaphase II oocytes. It has been 
demonstrated in mature non-human primate oocytes (Macaca mulatta) that the mitochondrial 
genome can be efficiently replaced by spindle-chromosomal complex transfer from one egg 
to an enucleated, mitochondrial-replete egg (142). Subsequently, it was possible to have 
normal fertilization and embryo development. The offspring was healthy (142). 
Pronuclear transfer between zygotes. This is essentially the same procedure, except that 
the nuclear material, both the male and female pronucleus, is removed after fertilization 
(142). It has been shown that transfer of pronuclei between abnormally fertilized human 
zygotes resulted in minimal carry-over of donor zygote mtDNA and is compatible with onward 
development of the blastocyst stage in vitro (141). 
 
There have been few randomized controlled trials for the treatment of mitochondrial disease 
(143). To date, there is no clear evidence supporting the use of pharmacological agents, 
non-pharmacological treatments (vitamins and food supplements), and physical training in 
patients with mitochondrial disorders (143). Although very promising, all genetic techniques 
are still in an experimental phase and different technical, ethical and safety issues still have 
to be solved (20, 128, 141-142). Nevertheless, they do allow cautious optimism for the future. 
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Prenatal and preimplantation diagnosis 
 
Since current therapeutic options for mitochondrial diseases are insufficient, the possibility of 
prenatal diagnosis for fetuses at risk is a valuable alternative. If it concerns a known nuclear 
genetic defect, the mutation can directly be searched for in fetal tissue. If the complex V 
deficiency is caused by a mtDNA defect (in MT-ATP6 or MT-ATP8), prenatal diagnosis is 
complicated by several factors. First, the correlation between mutant mtDNA load and 
disease severity is poor in many mtDNA diseases. Second, the heteroplasmy level differs 
between tissues and in one tissue through time (144). In this context, the m.8993 mutation 
(NARP mutation) is an exception. There is a correlation between mutant mtDNA load and 
disease severity (144). Moreover, it has been shown that the placental/ amniotic mutant 
loads do reflect the NARP mutant mtDNA load in the whole fetus (145-146). Finally, is 
suggested that the heteroplasmy level remains stable after 10 weeks of gestation (146). A 
mutation load <30% gave rise to healthy children at 2-7 years of age, while the correlation 
between an intermediate mutant load (> 30% and < 80%) and disease severity still needs to 
be assessed (146). Hitherto termination of pregnancy has been preferred in case of 
intermediate mutant loads (146). Remarkably, the intermediate mutant loads question the 
observation that the m.8993T>G mutation has a skewed segregation during oogenesis (147). 
Post-zygotic drift might explain this discrepancy (146). Current options for women with MT-
ATP6 or MT-ATP8 mutations can be oocyte donation or preimplantation genetic diagnosis 
(PGD), since the different heteroplasmy levels between tissues are not yet present in 
blastomeres (144, 148-149). The interpretation of PGD results nevertheless demands a 
known correlation between mutation load and clinical phenotype. In addition, caution is 
warranted since some pathogenic mutations could exhibit different segregation behavior 
(149). In case the genetic examination of an index case has revealed no mutations in both 
mtDNA and nDNA, prenatal diagnosis could still be possible. In Nijmegen, complex V activity 
can be measured spectrophotometrically in native chorionic villi, cultured chorionic cells or 
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cultured amniotic cells if there is a clear isolated complex V deficiency in fibroblasts and 
muscle tissue (or other tissue) of the index patient (71, 150). 
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ABSTRACT 
 
Purpose: To elucidate the biochemical and molecular genetic defect in a 16-year-old patient 
presenting with apical hypertrophic cardiomyopathy and neuropathy suspected for a 
mitochondrial disorder.  
Methods: Measurement of the mitochondrial energy-generating system (MEGS) capacity in 
muscle and enzyme analysis in muscle and fibroblasts were performed. Relevant parts of the 
mitochondrial DNA were analyzed by sequencing. Transmitochondrial cybrids were obtained 
by fusion of 143B206 TK- rho zero cells with patient-derived enucleated fibroblasts. 
Immunoblotting techniques were applied to study the complex V assembly. 
Results: A homoplasmic nonsense mutation m.8529G>A (p.Trp55X) was detected in the 
mitochondrial ATP8 gene in the patient’s fibroblasts and muscle tissue. A decreased 
complex V activity was measured in the patient’s fibroblasts and muscle tissue, and was 
confirmed in cybrid clones containing patient derived mitochondrial DNA. Immunoblotting 
after Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) revealed a lack of 
holocomplex V and increased amounts of subcomplexes of mitochondrial ATP synthase. In-
gel activity assay of ATP hydrolysis showed activity of free F1-ATPase in the patient’s muscle 
tissue and cybrid clones. 
Conclusion: We describe the first pathogenic mutation in the mitochondrial ATP8 gene, 
resulting in an improper assembly and a decreased activity of the complex V holoenzyme.  
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INTRODUCTION 
Mitochondrial (mt) ATP synthase, or complex V (EC 3.6.3.14), uses the proton gradient 
provided by the activity of the respiratory chain enzymes complexes I, III and IV for ATP 
synthesis, thereby generating over 95% of cellular ATP (1). Complex V is a multisubunit 
complex consisting of two functional domains, F1 and Fo, connected by a stalk. The F1 
domain contains 5 different subunits (3 alpha’s, 3 beta’s, and one gamma, delta, and 
epsilon), is situated in the mitochondrial matrix and acts as the catalytic domain. The Fo 
domain is embedded in the mitochondrial inner membrane and consists of 8 subunits 
(a,b,c,d,e,f,g and A6L). The stalk contains the subunits OSCP, F6, b and d (2). Protons pass 
from the intermembrane space to the matrix through Fo, which transfers the energy created 
by the proton electrochemical gradient to F1, where ADP is phosphorylated to ATP (2-3). It 
has been proposed that a shaft (“rotor” consisting of the ring of 10 c subunits, plus the 
subunits gamma, delta and epsilon that form the central stalk) linked to Fo rotates relative to 
the catalytic subunits (3 alpha, 3 beta) of F1, thereby sequentially changing the conformation 
of these subunits, creating the “binding change mechanism of energy coupling” proposed by 
Boyer (4-6). Two of the Fo subunits, subunit a (or subunit 6) and subunit A6L (or subunit 8) 
are encoded by the mtDNA ATP6 and ATP8 genes, respectively (7). Hitherto mtDNA 
complex V mutations have only been described in the mitochondrial ATP6 gene (MT-ATP6). 
The point mutations m.8993T>G/C are the most frequently encountered MT-ATP6 mutations 
and, depending on the degree of heteroplasmy, mainly lead to the clinical picture of NARP 
(Neuropathy, Ataxia, and Retinitis Pigmentosa) or, more severe, MILS (Maternally Inherited 
Leigh Syndrome) (1, 8). ATP synthase deficiency due to nuclear genetic defects has also 
been described (1, 9). To our knowledge pathogenic mutations in the mitochondrial ATP8 
gene have not been published before. Here we describe a 16-year-old patient presenting 
with apical hypertrophic cardiomyopathy and neuropathy. Biochemical analysis performed in 
muscle tissue and fibroblasts showed an isolated complex V deficiency. MtDNA mutation 
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analysis revealed a pathogenic nonsense mutation in MT-ATP8. We studied the molecular 
pathophysiology of this novel mtDNA mutation using transmitochondrial cybrid cells. 
 
CASE HISTORY 
The patient is the third child of healthy, non-consanguineous Caucasian parents. His older 
brother and sister are healthy. The family history is unremarkable. His motor development 
has been slower than the sibs since infancy. He walked independently at the age of 1 ½ - 2 
years, and learned to ride a bicycle at the age of 7-8 years. During childhood, he fell easily, 
and his gross motor skills were clumsy. According to the parents his speech development 
was delayed but turned to normal after an adenotomy at the age of 4 years. He is wearing 
glasses since the age of 3 years for hypermetropia and astigmatism, and one eye was 
temporarily covered because of amblyopia. At the age of 9-10 years the balance problems 
became prominent. Since then he also mentions decreased muscle strength, walking 
problems, and tingling in the extremities. These symptoms appear to be progressive. 
Exercise intolerance, shortness of breath (dyspnea) during exercise and angina were also 
common symptoms. The clinical examination at the age of 16 years revealed a slender 
young man. His speech was dysarthric. He had an ataxic walking pattern and revealed a 
clear Trendelenburg sign. Decreased tendon reflexes and a Babinski sign bilaterally were 
present. A moderate external ophthalmoplegia was noted. The metabolic tests performed at 
the age of 14 years revealed normal blood lactic acid concentrations, with increased lactic 
acid in the cerebrospinal fluid (4000 µmol/l, normal values 1350-1900 µmol/l). The organic 
acid pattern in urine was normal. The ophthalmologic evaluation confirmed the astigmatism 
and hypermetropia, and showed no signs of retinitis pigmentosa. Audiology was normal. The 
MRI of the brain did not demonstrate any abnormalities besides a cisterna magna. 
Neuropsychological evaluation revealed a moderate learning disorder. Cardiac evaluation 
showed an extensive left ventricular hypertrophy on the ECG, without signs of arrhythmia. 
Echocardiography was abnormal: left ventricular hypertrophy was concentrated around the 
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apex of the left ventricle (Figure 1) with discrete asymmetric hypertrophy of the echogenic 
interventricular septum and without left ventricular outflow tract obstruction. A small atrial 
septal defect with left to right shunt was detected. A sensor and motor axonal polyneuropathy 
was seen on an electromyogram at the age of 16 years: the sensible potentials were not 
evocable in the sural nerve bilaterally, and there were slightly delayed motor nerve 
conduction velocities with decreased amplitudes in the peroneal and tibial nerves. Finally a 
muscle (M. quadriceps femoris) and skin biopsy was performed. 
 
Figure 1 Echocardiography 
showing apical left ventricular 
hypertrophy. LA = Left Atrium; 
RA = Right Atrium; LV = Left 
Ventricle; RV = Right Ventricle. 
The arrows indicate the 
myocardial hypertrophy. 
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METHODS 
Cell cultures  
Fibroblasts were cultured in M199 medium (Gibco®, Invitrogen Corporation) supplemented 
with 10% fetal calf serum and penicillin/streptomycin (respectively 100U/ml and 100 µg/ml). 
Transmitochondrial cybrids were obtained by fusion of 143B206 TK- rho zero cells with 
control or patient-derived enucleated fibroblasts as described before (10). Seven 
independent colonies (clones) of the patient transmitochondrial cybrid cell line were randomly 
picked for further study. For the control cybrid cell line the colonies were pooled, resulting in 
a clone mixture. 
Biochemical assays 
Measurement of MEGS capacity was performed as described before (11). The complex V (or 
mtATPase) activity was measured spectrophotometrically in mitochondria isolated from 
frozen pellets of the patient and control cybrids as described (8): a solution of 980 µl 
containing 250 mM sucrose, 50 mM KCl, 50 mM K2HPO4, 50 mM KH2PO4, 1 mM 
phosphoenolpyruvic acid, 11 nM P1-P5-di(adenosine-5’) pentaphosphate, 0.2 mM EGTA, 5 
mM ATP, 5 mM MgCl2, 0.2 mM oubaine, 2 µM carbonyl cyanide 3-chlorophenyl hydrazone 
(CCCP), 250 µM NADH, 1.25 µM rotenone, 2.5 U/ml lactate dehydrogenase, and 1.5 U/ml 
pyruvate kinase was incubated for 10 min at 30°C. A mitochondrial suspension was freeze-
thawed three times and 20 µl was added to the reaction mixture, mixed and transferred to a 
cuvette, after which the absorption at 340 nm was measured for 8 min. Subsequently, 1 µl of 
a 8 mg/ml oligomycin solution in ethanol was added and the absorption was measured for 
another 8 min. The oligomycin-sensitive activity of complex V was calculated using an ε340 for 
NADH of 6.22x103 L/mol.cm and was expressed in units (the amount of enzyme required to 
convert 1 µmol NADH per min) per unit cytochrome oxidase (COX) (12) and the 
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mitochondrial matrix enzyme citrate synthase (CS) (13) activities, respectively. The activities 
of the mitochondrial respiratory chain enzymes were measured spectrophotometrically in 
muscle tissue and fibroblasts of our patient according to described protocols (14-15). 
Molecular genetic analysis 
Total DNA from frozen skeletal muscle tissue and from cultured fibroblasts was extracted 
using the Gentra genomic isolation kit according the protocol of the manufacturer (Biozym, 
Landgraaf, The Netherlands). Major DNA deletions or other rearrangements in the mtDNA 
were screened for using standard long template PCR. The presence of the MELAS 
m.3243A>G, MERFF m.8344A>G and Leigh/NARP m.8993T>G/C point mutations was 
investigated using Pyrosequencing™ technology as described previously (8, 16). Sequence 
analysis of PCR amplified products of the mtDNA encoded tRNAGln, tRNAGly, tRNAIle, 
tRNALeu(cun), tRNALeu(uur), tRNALys, tRNASer(agy), mitochondrial ATP6 and ATP8 genes was 
performed on an ABI3730 automatic capillary sequencer using BigDye® terminator 
chemistry (Applied Biosystems). Primers used for amplification of tRNA genes are available 
upon request. MT-ATP6 and MT-ATP8 were PCR amplified as 3 overlapping fragments (a, b 
and c) using the following primers: For-a: 5’-cggtcaatgctctgaaatctgtg-3’; Rev-a: 5’-
gagatatttggaggtggggatc-3’; For-b: 5’-ctgttcgcttcattcattgcc-3’; Rev-b: 5’-gtggcgcttccaattaggtg-
3’; For-c: 5’-cccacttcttaccacaaggc-3’; Rev-c: 5’-gtgctttctcgtgttacatcg-3’. PCR conditions were 
92 ºC for 30 seconds, 55 ºC for 30 seconds and 72 ºC for 60 seconds for a total of 35 cycles. 
Subsequently, mtDNA was analyzed in the patient and control cybrids looking for the 
nonsense mutation m.8529G>A following the protocol described above. 
Complex V assembly and activity 
BN-PAGE, blotting and complex V in-gel activity was performed as described (17-18) loading 
60 µg of protein (19) of OXPHOS complexes isolated from a mitoplast fraction of the patient 
and control cybrids and muscle homogenates. For Western blotting, monoclonal antibodies 
Chapter 5 
118 
 
against mitochondrial ATP synthase subunit alpha and CoII-70 kDa (complex II) (Invitrogen, 
Breda, The Netherlands) were used. For the complex V in-gel activity assay the gel was 
incubated overnight at room temperature with the following solution: 35 mM Tris, 270 mM 
glycine, 14 mM MgSO4, 0.2% Pb(NO3)2, and 8 mM ATP, pH 7.8 (18). 
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RESULTS  
Biochemical assays 
Measurement of MEGS capacity in muscle tissue showed a decreased pyruvate oxidation 
rate, which improved after addition of CCCP, which could point to a complex V defect (11). 
The ATP production rate from oxidation of pyruvate was decreased. Spectrophotometric 
analysis confirmed the decreased complex V (mtATPase) activity in muscle tissue and in 
fibroblasts. The activities of the respiratory chain enzymes and CS were normal. (Table 1) 
 
Table 1: Measurement of MEGS capacity in muscle tissue and enzymatic analysis of the 
activities of complex V (mtATPase), the respiratory chain enzymes and CS in muscle tissue 
and fibroblasts. 
 
 Muscle tissue Fibroblasts 
[1-14C]Pyruvate + malate 
(nmol 14CO2/h.mU CS; normal 3.45-7.99) 
2.25 n.d. 
[1-14C]Pyruvate + malate-ADP + CCCP 
(nmol 14CO2/h.mU CS; normal 3.76-8.37) 
4.39 n.d. 
ATP production rate 
(nmol (ATP+CrP)/h.mU CS; normal 36-81.7) 
22 n.d. 
   
Complex V 54 mU/UCOX 
(normal 169-482) 
122 mU/UCOX 
(normal 209-935) 
Complex I 73 mU/UCS  
(normal 70-251) 
223 mU/UCOX 
(normal 110-260) 
Complex II 518 mU/UCS 
(normal 335-749) 
812 mU/UCOX 
(normal 536-1027)
Complex III 3438 mU/UCS 
(normal 2200-6610) 
1998 mU/UCOX 
(normal 1270-
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2620) 
Complex IV 2134 mU/UCS 
(normal 810-3120) 
797 mU/UCS 
(normal 680-1190)
CS 231 mU /mg 
(normal 37.4-162) 
398 mU/mg 
(normal 144-257) 
MEGS: mitochondrial energy-generating system; CCCP: carbonyl cyanide 3-chlorophenyl hydrazone; 
COX: cytochrome oxidase; CS: citrate synthase; n.d.: not determined. 
Molecular genetic analysis 
The diagnosis of a mitochondriopathy was further substantiated by mutation analysis of 
mtDNA from muscle tissue and fibroblasts, showing a homoplasmic (>90%) nonsense 
mutation m.8529G>A (p.Trp55X) in the mitochondrial ATP8 gene. The mutation is located in 
an overlap region of MT-ATP6 and 8 (nucleotides m.8527-8572). It results in a silent change 
in MT-ATP6 (Met1Met; ATG>ATA), whereas it introduces a premature stopcodon in the C-
terminal domain of MT-ATP8, which is a conserved region (20) (Figure 2). This probably 
results in a truncated protein lacking the last 14 amino acids.  
 
Figure 2 The C-terminal domain of mt ATP synthase subunit 8 is a conserved region in 
mammals. p.Trp55X indicates the mutation site at the protein level. 
 
Cell biological consequences 
DNA analysis in the cybrid cells confirmed the presence of the mitochondrial nonsense 
mutation m.8529G>A in each of the clones containing patient-derived mtDNA. Sequence 
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analysis showed that all clones were homoplasmic for the mutation. The control cybrid cell 
line showed no mutation (Figure 3). 
 
Figure 3 Molecular genetic analysis of the cybrid clones containing patient-derived mtDNA 
reveals the mt nonsense mutation m.8529G>A (arrow). Top row: control cybrid cell line; 
subsequent row: patient cybrid clone. Sequence analysis shows that all the clones are 
homoplasmic for the mutation (data not shown). 
 
Enzymatic analysis of complex V was performed in the patient cybrid clones and in the 
control cybrid clone mixture. A distinctly decreased activity was found in the patient cell line 
relative to the control (Table 2). CS and COX activities were normal in the patient and control 
cybrids (data not shown).  
Table 2: Enzymatic analysis of the complex V (mtATPase) activity in cybrids. 
 Complex V/COX (mU/U COX) Complex V/CS (mU/U CS) 
Control cybrid clone 
mixture 
2.0 0.3 
Patient cybrid clone 1 0.45 0.09 
Patient cybrid clone 2 0.08 0.02 
Patient cybrid clone 3 0 0 
Patient cybrid clone 4 0.56 0.09 
Patient cybrid clone 5 0 0 
Patient cybrid clone 6 0.87 0.07 
Patient cybrid clone 7 0.23 0.07 
COX: cytochrome oxidase; CS: citrate synthase 
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A higher range of residual activities in individual cybrids is seen when normalized to the COX 
activity because the COX assay has a broader normal range than the CS assay.  
 
Immunoblotting after BN-PAGE (Figure 4) with anti-ATP synthase subunit alpha antibody 
clearly revealed a lack of holocomplex V and increased amounts of subcomplexes of 
mitochondrial ATP synthase in the patient cybrid clones and muscle homogenate. This was 
not found in the control cybrid and control muscle which only showed the complex V 
holoenzyme and dimer. The subcomplexes most likely are the F1-ATPase and the 
subcomplex V*, as denoted before (2, 21). 
 
 
Figure 4 Immunoblotting after BN-PAGE shows increased amounts of subcomplexes of mt ATP 
synthase in the patient cybrid clones and muscle. The control cybrid and muscle only show the 
complex V holoenzyme and dimer. Antibodies used are against ATP synthase subunit alpha 
and CoII-70 kDa (complex II, loading control). Lane 1: control cybrid cell line (coCy); lanes 2-8: 
patient cybrid clones (1->7); lane 9: patient muscle homogenate (ptMu); lane 10: control muscle 
homogenate (coMu). 
 
 
The in-gel activity assay of ATP hydrolysis showed activity of free F1-ATPase in the patient 
cybrid clones and muscle. The holoenzyme showed no activity in neither the patient nor 
control samples (Figure 5).  
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Figure 5 The in-gel activity (IGA) assay of ATP hydrolysis shows activity of free F1-ATPase in 
the patient cybrid clones and muscle. Lane 1: control cybrid cell line (coCy); lanes 2-8: patient 
cybrid clones (1->7); lane 9: patient muscle homogenate (ptMu); lane 10: control muscle 
homogenate (coMu). 
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DISCUSSION 
Clinical phenotype 
To our knowledge we describe the first pathogenic mutation in the mitochondrial ATP8 gene. 
It has been stated before that the clinical phenotype of complex V deficiency due to nuclear 
genetic defects (hypertrophic cardiomyopathy, hypotonia, facial dysmorphism and 
microcephaly) markedly differs from the severe central system changes observed in NARP 
or MILS (1). The clinical phenotype of our patient is characterized by signs and symptoms 
that have mainly been described both in mitochondrial (neuropathy, ataxia) and nuclear 
(hypertrophic cardiomyopathy) complex V defects. Hypertrophic cardiomyopathy can 
manifest with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte 
disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal 
contours/morphologies with extremely varying clinical course (22). The apical variant-
hypertrophic cardiomyopathy reported here represents a genotype-phenotype relationship 
that has not been described before. Taken together, this indicates that the clinical variability 
among the patient group carrying mitochondrial complex V mutations is greater than 
previously assumed. 
Pathogenicity 
Our results strongly suggest that the MT-ATP8 mutation is the cause of the complex V 
deficiency in our patient. Several lines of evidence point to this. (I) The mutation leads to a 
premature stopcodon situated in the C-teminal region of subunit 8. (II) The C-terminal 
domain of mt ATP synthase subunit 8 is a conserved region in yeast (20) and in mammals 
(www.mitomap.org) (Figure 2) (III) Hitherto no polymorphisms have been described at the 
position of the mutation (23). (IV) The mutation is homoplasmic (>90%) in muscle tissue and 
fibroblasts and in both tissues the complex V activity is clearly decreased (Table 1). (V) 
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Transmitochondrial cybrids retained the complex V deficiency, confirming the mitochondrial 
origin of the pathogenic mutation. 
Molecular pathophysiology 
Immunoblotting after BN-PAGE showed a lack of holocomplex V and increased amounts of 
subcomplexes and the in-gel activity assay revealed an isolated activity of F1-ATPase in the 
cybrids and in muscle. The results of the in-gel activity assay of ATP hydrolysis probably 
point to the free rotation capacity of the F1 subcomplex in the patient. It was reported that F1 
can be detected as a single entity (2) and that it retains ATP hydrolysis activity (21). The 
higher in-gel ATP hydrolysis activity of F1-ATPase has been described before (21). It was 
suggested that subunits of the Fo portion of ATP synthase restrict in-gel ATP hydrolysis (21), 
which results in an apparently low activity of the holocomplex in this assay. Whereas the in-
gel activity assay showed an isolated F1-ATPase activity, the spectrophotometric assay 
demonstrated a very low FoF1-ATPase activity. The enzymatic assay measures the 
oligomycin-sensitive activity of complex V (8). This is the result of the subtraction of the 
mtATPase holoenzyme activity and the activity after addition of oligomycin, an inhibitor of 
proton translocation in mtATPase (24). Although the ATPase activity in the absence of 
oligomycin was in the same order of magnitude in our patient as in controls, the activity in the 
patient was not sensitive to oligomycin inhibition, whereas in control cells, usually a 90% 
inhibition is seen. In fact, detachment of the F1 from the Fo subcomplex – as seen on the BN 
gel data of the patient cybrid clones and muscle homogenate- leads to a decrease in 
oligomycin-sensitive complex V activity. ATP hydrolysis by F1 takes place, but without the 
coupling of ATP hydrolysis to extrusion of protons through Fo, the sensitivity to oligomycin is 
no longer evident (24). 
How can the increased amounts of subcomplexes of complex V be explained? It has been 
described that subunit 8, which is unique to mtATPase of fungi and mammals, consists of 
three functional domains: the N-terminus, a central transmembrane hydrophobic domain and 
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the C-terminus localized to the mitochondrial matrix side (25-26). In yeast, the positively 
charged C-terminal region has been shown to be required for assembly of yeast subunit 8 
(Y8) into the Fo-sector (27). Since Y8 interacts with other subunits in the assembly of the Fo-
sector – subunit 6 assembly into mtATPase requires the presence of assembled Y8 in the 
enzyme complex (28)- it could be postulated that mutations in the C-terminal region – as 
present in our patient: p.Trp55X, subunit 8 having 68 residues- are associated with a 
decreased complex V assembly, which appears to be similar to the effect of human MT-
ATP6 mutations (21). Our immunoblotting results confirm this hypothesis.  
The impaired complex V assembly very likely has a repercussion on the function of the 
holoenzyme, as was demonstrated in our patient by enzymatic analysis. Impaired subunit 6 
assembly into the Fo-sector possibly plays a role. It has been described that subunit 6 has 
two functions: first, it leads the protons through a hydrophilic half-channel into the matrix, and 
secondly, it turns the rotor for ATP synthesis (29). The MT-ATP6 m.8993T>G mutation 
interferes with the rotation of the ring of c subunits, and therefore it uncouples ADP 
phosphorylation in F1 from proton transfer through Fo (29). The assembly problem is most 
likely not the sole pathogenic factor. It is also likely that the subunit 8 protein is decreased 
due to the nature of the mutation in our patient, namely a premature stopcodon, most likely 
resulting in a truncated protein. In that case a direct negative effect on the function of the 
enzyme could be assumed. It has indeed been described in yeast that Y8 also plays an 
important role in determining the mtATPase activity (25). In particular, the hydrophobic 
nature of amino acids in the center of the transmembrane domain of Y8 is essential for 
coupling proton transport through Fo to ATP synthesis on F1 (25). Thus, Y8 may take part in 
conformational changes that occur between the Fo- and F1-sectors of the enzyme during 
catalysis (25). However, further investigation is warranted in order to elucidate this latter 
issue. 
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ABSTRACT 
 
We report a fragmented mitochondrial network and swollen and irregularly shaped 
mitochondria with partial to complete loss of the cristae in fibroblasts of a patient with a novel 
TMEM70 gene deletion, which could be completely restored by complementation of the 
TMEM70 genetic defect. Comparative genomics analysis predicted the topology of TMEM70 
in the inner mitochondrial membrane, which could be confirmed by immunogold labeling 
experiments, and showed that the TMEM70 gene is not restricted to higher multi-cellular 
eukaryotes. This study demonstrates that the role of complex V in mitochondrial cristae 
morphology applies to human mitochondrial disease pathology. 
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INTRODUCTION 
 
Complex V (or the mitochondrial (mt) ATP synthase, EC 3.6.3.14), uses the proton gradient 
to generate ATP during oxidative phosphorylation. Complex V is a multisubunit complex 
consisting of two functional domains, F1 and Fo, connected by two stalks. The catalytic F1 
domain is composed of subunits α, β, γ, δ, ε and a loosely attached IF1 inhibitor protein. The 
membrane-embedded Fo domain consists of an additional ten subunits, a (or subunit 6), b, c, 
d, e, f, g, OSCP, A6L (or subunit 8), and F6 and functions as a proton channel (1-2). 
Subunits 6 and 8 of the Fo domain are encoded by the mtDNA genes MT-ATP6 and MT-
ATP8, respectively. All other complex V subunits are encoded by the nuclear DNA. 
Mitochondria are enclosed by a double membrane. The inner membrane is composed of two 
subdomains: the inner boundary membrane and the cristae membrane. Cristae are 
invaginations of the inner membrane that are connected to the inner boundary membrane by 
narrow tubular structures, so-called crista junctions (3). It has been shown that complex V of 
mammalian mitochondria is arranged in long rows of dimeric supercomplexes (4). Ribbons of 
complex V dimers are common to all eukaryotes (4). The role of complex V dimers in the 
formation of tubular cristae has been hypothesized by Allen (5). The link between the 
dimerization of mitochondrial complex V, through subunits e, g, and –as described just 
recently- subunits i, k, and the biogenesis of cristae has been provided by studying yeast 
cells (6-7). Complex V oligomers are found either on the crest of lamellae, or along the length 
of tubular cristae and introduce a positive curvature to the inner mitochondrial membrane (4). 
In a recent yeast study, this effect has been shown to be attributed to the action of subunit e 
and subunit g (8). Moreover, it has been suggested that the formation of cristae and crista 
junctions in mitochondria depends on antagonism between Fcj1 (formation of crista junction 
protein 1) and subunits e and g (8). In HeLa cells, it has been shown that IF1 overexpression 
increases mitochondrial cristae formation and dimerization of complex V (9). Other 
components such as prohibitins or OPA1 or others yet to be identified also could contribute 
to crista junction and cristae tip formation (8, 10). Complex V mutations have been described 
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in MT-ATP6 (see, amongst many others, (11)), in MT-ATP8 (12), in the nuclear encoded F1-
specific assembly gene ATP12 (13), and in the nuclear encoded structural subunit ε (ATP5E) 
(14). A common splice site mutation and an isolated frameshift mutation were described in 
the TMEM70 gene particularly in a homogeneous ethnic group (Romanies), and it has been 
shown that TMEM70 is required to maintain normal expression levels of complex V (15). The 
TMEM70 gene, located on chromosome 8q21.11, consists of three exons and encodes a 
260 amino acid (AA) protein, transmembrane protein 70. GFP-tagged TMEM70 has been 
shown to be localized in mitochondria (16). The exact molecular function of the TMEM70 
protein is not known at present (2), although it has been suggested that TMEM70 is involved 
in complex V biogenesis (15). TMEM70 homologues have been found in genomes of multi-
cellular eukaryotes and plants, while it has been described to be absent from yeast and other 
fungi (2). 
 
CASE HISTORY 
 
The boy, born at 40 weeks, was the third child of healthy consanguineous Iraqi parents with 
unremarkable family history. Two older siblings are healthy. Prenatal ultrasound revealed 
fetal ascites and oligohydramnion. He was small for gestational age (birth weight 2090 g, 
length 47 cm, head circumference 33 cm). Postnatal echocardiography was normal. He 
presented on day four of life with feeding difficulties and fever. Lactic acidosis was diagnosed 
(base excess -14.5 mmol/l) with a blood lactate of 13.9 mmol/l (normal < 2). Also 
hyperammonemia (557 µg/dl, normal < 45) occurred. Plasma amino acid analysis revealed 
elevation of ornithine (651 µmol/l, normal 0-235) and alanine (971 µmol/l, normal < 450). In 
urine, excretion of homocitrulline was observed, together suggesting presence of 
hyperammonemia-hyperornithinemia-homocitrullinuria (HHH)- syndrome. After 
supplementation of sodium-benzoate and L-arginine and protein restriction, the clinical 
condition stabilized and hyperammonemia resolved. However, lactic acidosis and 
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hyperalaninemia persisted, suggesting mitochondrial impairment. During follow-up lactate 
was between 3.5 and 7.8 mmol/l. 
In the first months of life, hypertrophic cardiomyopathy developed. During follow-up motor 
and especially speech development was impaired. Cerebral magnetic resonance 
spectroscopy revealed an increased lactate peak within the basal ganglia and the white 
matter region as well as an increased choline peak. 
All symptoms were initially interpreted as either a primary mitochondrial disease or HHH-
syndrome with secondary mitochondrial impairment. After HHH –syndrome was excluded by 
molecular analysis, skin and muscle biopsies were performed in order to investigate a 
primary mitochondrial enzyme defect. Currently, at the age of 6 years, the cardiomyopathy 
has remained stable under treatment with calcium antagonists. The child’s development is 
progressive but he retains a distinctive motor and mental retardation. He has an ataxic gait 
and ptosis. 
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MATERIALS AND METHODS 
 
Cell cultures 
 
Fibroblasts were cultured in medium 199 (Gibco®, Invitrogen Corporation) supplemented 
with 10% fetal calf serum and penicillin/streptomycin (respectively 100 U/ml and 100 µg/ml). 
The amphotropic packaging cell line PA317 (# CRL-9078, LGC, Middlesex, UK) and Flp-In T-
REx293 cells (Invitrogen) were grown in Dulbecco's Modified Eagle's Medium (DMEM) 
containing 4.5 g/L glucose, 10% fetal calf serum and penicillin/streptomycin (respectively 100 
U/ml and 100 µg/ml). Inducible cell lines were selected on 5 μg/ml blasticidin (Invitrogen) and 
200 μg/ml hygromycin (Calbiochem), and expression of the transgene was induced by 
addition of 1 μg/ml doxycycline (Sigma Aldrich) for 24 hours. 
 
Biochemical assays 
 
Measurement of the mitochondrial energy-generating system (MEGS) capacity was 
performed as described before (17). The complex V (or mtATPase) activity was measured 
spectrophotometrically in mitochondria isolated from frozen pellets of the patient and control 
fibroblasts as described (11). The activities of the mitochondrial respiratory chain enzymes 
and citrate synthase (CS) were measured spectrophotometrically in muscle tissue and 
fibroblasts of the patient according to described protocols (18-19). 
 
Molecular genetic analysis 
 
Total DNA from blood and cultured fibroblasts was extracted using the salting out procedure 
for human DNA extraction (20). The coding region in genomic DNA of the TMEM70 gene 
was polymerase chain reaction (PCR) amplified using three primer pairs (Table 1a). PCR 
conditions were 95°C for 5 minutes (denaturation), 92°C for 45 seconds, 60°C for 45 
TMEM70 gene deletion 
137 
 
seconds and 72°C for 45 seconds for a total of 35 cycles. Major deletions in genomic DNA 
were screened for by long template PCR (Expand Long Template PCR system, Roche, 
Germany) using new primers (Table 1a). PCR conditions were 95°C for three minutes 
(denaturation), 93°C for 10 seconds, 60°C for 30 seconds, 68°C for seven minutes, for a total 
of 9 cycles followed by 93°C for 10 seconds, 60°C for 30 seconds, 68°C for seven minutes, 
plus 20 seconds each cycle for a total of 24 cycles. Sequence analysis of PCR amplified 
products was performed on an ABI3730 automatic capillary sequencer using BigDye® 
terminator chemistry (Applied Biosystems, Nieuwerkerk a/d Ijssel, The Netherlands). RNA 
from the patient cultured fibroblasts was extracted as described (20). Reverse Transcriptase 
PCR (RT-PCR) was performed to produce cDNA followed by PCR amplification (Table 1b). 
Sequence analysis was subsequently performed as described above. 
Table 1a: Primers for PCR amplification of the genomic DNA 
Exon(s) Forward primer Reverse primer Comment 
1 5'-GGCATGCGCCACTTGTGCG-3' 5'-GCTGGGGCTCCCCAGGCC-3' Conventional 
PCR 
2 5'-AGGTTAGTTGACCATAATGATCCCTG-
3' 
5'-ACGTCTTGTAATTAAGGGATGCCA-3' Conventional 
PCR 
3a* 5'-GCAGATTTCCTGCCTGGAGAGG-3' 5'-TCTGGAATCTTCACATCATTCTGGTG-3' Conventional 
PCR 
3b* 5'-TGATTGGCCTTACATTTCTGCCA-3' 5'-AACAATCAGTCACTAACGGAATGCAA-
3' 
Conventional 
PCR 
2 5'-GGATTGGCAAACCTGGTTAAAA-3' 5'-GGCTGAGGCAGGAAAATCCTT-3' Long-template 
PCR 
*Exon 3 of TMEM70 is PCR amplified in two overlapping fragments (a and b). 
 
Table 1b: Primers for PCR amplification of the cDNA 
Fragment Forward primer Reverse primer
1 5'-GGCAGTCGGGTGGGAAGCC-3' 5'-ACCCGGACGCCGGAGAAGG-3' 
2 5'-CCTTCTCCGGCGTCCGGGT-3' 5'-CAGTCACTAACGGAATGCAAAAG-3' 
3 5'-GGTGATCACCCCAGTGCTGC-3' 5'-CAGTCACTAACGGAATGCAAAAG-3' 
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Complex V assembly and activity 
 
Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE), blotting and in-gel activity of 
ATP hydrolysis was performed as described (21). Gel lanes were loaded with 40 µg of 
protein (22) of OXPHOS complexes isolated from a mitoplast fraction of the patient and 
control fibroblasts. For Western blotting, monoclonal antibodies against mitochondrial 
complex V subunit alpha and CoII-70 kDa (complex II) (Invitrogen, Breda, The Netherlands) 
were used. For the in-gel activity assay of ATP hydrolysis the gel was incubated overnight at 
room temperature with the following solution: 35 mM Tris, 270 mM glycine, 14 mM MgSO4, 
0.2% Pb(NO3)2, and 8 mM ATP, pH 7.8 (21). 
 
Cloning of human TMEM70 gene, generation of inducible cell lines, and retroviral 
complementation 
 
Human full length TMEM70 cDNA clone IOH40588 (Imagenes, Berlin, Germany) (without 
stop codon) flanked by Gateway AttB sites was amplified by PCR according to the 
manufacturer’s protocol and cloned into pDONR201 by the use of Gateway BP Clonase II 
Enzyme Mix. The pDONR201-TMEM70-vector was recombined with the AcGFP1-destination 
vector by use of the LR Clonase II Enzyme Mix (Invitrogen). The obtained constructs were 
transfected into Flp-In T-REx293 cells (Invitrogen) by using SuperFect Transfection Reagent 
(QIAGEN) according to the manufacturer’s manual. The inducible COX8 leader sequence 
(first 210 base-pairs of sequence NM_00004074)-GFP cell line has been described 
previously (23). For complementation, the TMEM70 cDNA clone IOH40588 was cloned into 
the GATEWAY retroviral destination vector pDS_FBneo (# MBA-295, LGC, Middlesex, UK). 
pDS_FBneo retroviral vector with or without TMEM70 was used to transfect the amphotropic 
packaging cell line PA317 using Lipofectamine 2000 according to the manufacturer’s 
protocol (Invitrogen, Breda, The Netherlands) (24). At 24 hours after transfection, fresh 
medium was added and supernatants containing retroviral particles were collected at 40 
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hours after transfection and filtered through a 0.45 µm filter. Fibroblasts in 75 cm2 flasks were 
incubated for 24 hours with a 1:1 mixture of growth medium and virus-containing medium in 
the presence of 4 µg/ml polybrene (24). The medium was then changed to selection medium 
consisting of 199 medium supplemented with 15 % fetal calf serum, penicillin/streptomycin 
(respectively 100 U/ml and 100 µg/ml) and 500 µg/ml geneticin (G418, PAA, Pasching, 
Austria). Cells were selected for at least 14 days. G418-resistant cells were used for 
biochemical analyses within 5 passages after transduction. 
 
Immunogold labeling 
 
Cells were fixed in 1% formaldehyde and 0,01% glutaraldehyde in 0,1M PHEM buffer for 1 h 
at RT. Next, cells were pelleted in 10% gelatin and post-fixed in 1% formaldehyde for another 
24 h. Ultra-thin cryosections were prepared on a Leica EMFCS, incubated with a homemade 
polyclonal antiserum raised against GFP (25) followed by incubation with protein A complex 
to 10 nm gold particles according to standard procedures (26). Sections were observed in a 
JEOL 1010 electron microscope. 
 
Quantitative mitochondrial morphology and membrane potential assessment 
 
Mitochondrial morphology and membrane potential was quantified in single living cells using 
tetramethyl rhodamine methyl ester (TMRM; Invitrogen, Breda, The Netherlands) staining 
and videomicroscopy applying a protocol described previously (27), with some adaptations. 
To prevent retrovirus contaminations, cells were cultured for three days and imaged in 35 
mm glass bottom dishes with a 22 mm glass aperture (WillCo Wells BV, Amsterdam, The 
Netherlands). Immediately after loading and washing, the dishes were sealed using paraffin. 
The TMRM loading solution was prepared using 1 µl of a 20 µM “working” stock solution in 
DMSO in 1 ml of medium 199. Image acquisition was performed using a Zeiss 40x/1.3 NA 
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fluor objective instead of a Zeiss 63x/1.25 NA Plan NeoFluar objective. Statistical 
significances were assessed by a Student’s two-population, independent t-test. 
 
Electron microscopy 
 
Trypsinized fibroblast suspensions in culture medium were centrifuged for 10 minutes at 120 
g. The medium was carefully removed and 2% glutaraldehyde buffered with 0.1 M sodium 
cacodylate pH 7.4 was gently added. After at least 4 hours fixation the pellets were very 
carefully taken of and post-fixed in 1% osmium tetroxide in Palade’s buffer pH 7.4 with 1% 
potassium hexacyanoferrat(III)-trihydrate and after dehydration in ethanol and propylene 
oxide, embedded in Epon. Semi-thin, 1µm thick transverse sections were stained with 1% 
toluidine blue. Ultrathin sections were stained with uranyl acetate and lead citrate and 
examined in a JEOL 1200. Electron microscopy was solely performed in fibroblasts because 
muscle tissue of the patients was no longer available. 
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RESULTS 
 
Biochemical assays 
 
Measurement of the MEGS capacity in muscle tissue showed both a severely decreased 
pyruvate oxidation rate and ATP production rate from oxidation of pyruvate (Table 2). 
Spectrophotometric analysis showed an undetectable complex V (mtATPase) activity in 
muscle tissue (0 mU/U Cytochrome Oxidase (COX), normal 169-482) and a combined 
deficiency of complex V (113 mU/U COX, normal 209-935) and complex I (60 mU/U COX, 
normal 110-260) in fibroblasts. The activities of the respiratory chain enzymes complex II, III, 
and IV, and citrate synthase (CS) were normal (Table 2). 
 
Table 2: Measurement of MEGS capacity in muscle tissue and enzymatic analysis of the 
activities of complex V (mtATPase), the respiratory chain enzymes and CS in muscle tissue 
and fibroblasts. 
 
 Muscle tissue Fibroblasts 
[1-14C]Pyruvate + malate * 0.68 (3.45-7.99) n.d. 
ATP production rate ** 3.3 (36-81.7) n.d. 
   
Complex V, mU/U COX 0 (169-482) 113 (209-935) 
Complex I, mU/U CS (m), mU/U COX (f) 75 (70-251) 60 (110-260) 
Complex II, mU/U CS (m), mU/U COX (f) 394 (335-749) 635 (536-1027) 
Complex III, mU/U CS (m), mU/U COX (f) 3800 (2200-6610) 2175 (1270-2620) 
Complex IV, mU/U CS 2049 (810-3120) 762 (680-1190) 
CS, mU/mg 298 (37.4-162) 114 (144-257) 
MEGS: mitochondrial energy-generating system; COX: cytochrome oxidase; CS: citrate synthase; 
n.d.: not determined ; m : muscle tissue ; f : fibroblasts. 
Figures in brackets are normal ranges. 
*Expressed as nmol 14CO2/h.mU CS 
**Expressed as nmol (ATP+CrP)/h.mU CS 
 
Chapter 6 
142 
 
Molecular genetic analysis 
 
Homozygosity mapping revealed several homozygous regions, including a 9.2 cM region on 
chromosome 8q13.3-21.13, that includes the TMEM70 gene (data not shown). PCR of the 
coding region of the TMEM70 gene showed a normal fragment for exon 1 and exon 3 but no 
fragment for exon 2. Fragments of known sizes for all three exons were seen in control DNA 
and in DNA of the parents (Figure 1a). Long template PCR from exon 1 to 3 resulted in a 
smaller fragment in the patient’s DNA compared to control DNA. Long template PCR on DNA 
samples of the parents showed two fragments, one with the same size as the control, the 
other with the same size as the patient (Figure 1b). Taken together, these observations 
suggest the presence of a homozygous deletion in the patient’s TMEM70 gene, for which the 
parents are heterozygous carriers. This was confirmed by sequence analysis of the long 
template PCR product, which showed a homozygous 1353 base pair deletion containing 
exon 2 (g. 2436-3789) in the TMEM70 gene of the patient (Figure 1c). To evaluate the effect 
of the deletion on the TMEM70 transcript, the patient’s cDNA was analyzed, revealing a 
smaller transcript compared to wild type TMEM70 cDNA (Figure 1d). Sequence analysis of 
the patient’s cDNA confirmed that exon 2 was deleted from the transcript, resulting in a 
mRNA consisting of exon 1 spliced to exon 3 (Figure 1e). No mutations were found in exons 
1 and 3. At the protein level, this is an in-frame deletion resulting in a theoretical protein of 
226 AA, missing 34 AA (AA 71-105) encoded by exon 2. 
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Figure 1 Molecular genetic analysis of the TMEM70 gene in fibroblasts. (a) PCR of the coding 
region in genomic DNA shows no fragment for exon 2 in the patient, in contrast to the control 
and both parents. (F: father; M: mother; P: index patient; -: negative control; +: wild type). (b) 
Long template PCR in genomic DNA shows a smaller fragment in the patient compared to wild 
type DNA. DNA of the parents shows two fragments, which points to heterozygosity. (F: father; 
M: mother; P: index patient; -: negative control; +: wild type). (c) Genomic sequence analysis of 
the patient’s DNA reveals a homozygous 1353 base pair deletion (g. 2436-3789) containing 
exon 2. (d) Reverse Transcriptase PCR shows a smaller product in the patient for the fragment 
containing all three exons (1F+3R). Fragments of normal size are present for exon 1 (1F+1R) 
and for exon 3 (3F+3R). (F: forward primer, R: reverse primer, see Table 1b; P: patient; -: 
negative control; +: wild type). (e) cDNA sequence analysis confirms a deletion of exon 2 in the 
patient. 
 
 
Complementation of complex V deficiency by wild type TMEM70  
 
Immunoblotting after BN-PAGE (Figure 2a) with anti-complex V subunit alpha antibody was 
performed on protein extracts from fibroblasts of the patient, two controls and a patient 
harboring the previously described homozygous c.317-2A>G mutation (15, 28). The blot 
clearly revealed a nearly absent holocomplex V in the patient samples, in contrast to the 
Chapter 6 
144 
 
control samples. The in-gel activity assay of ATP hydrolysis showed activity in both controls, 
but not in the patient samples (Figure 2b). 
To confirm that deletion of TMEM70 exon 2 caused the strong reduction of complex V 
holocomplex amount and activity, both index patient and control fibroblasts were retrovirally 
transduced with human full length TMEM70. Complementation of patient fibroblasts with wild 
type TMEM70 induced a normalization of fully assembled complex V on BN-PAGE (Figure 
2c). Moreover, in-gel activity of ATP hydrolysis at the position of complex V in the gel was 
detectable in extracts from the TMEM70-complemented patient cell line at a similar level as 
in the control (Figure 2d). 
 
 
 
Figure 2 Complementation of the TMEM70 gene defect in fibroblasts. (a) Immunoblotting after 
BN-PAGE shows a nearly absent holocomplex V in the fibroblasts of the patients, in contrast to 
the control samples. (b) The in-gel activity assay of ATP hydrolysis demonstrates activity in 
both controls, but not in the fibroblasts of the patients. (8835: index patient; 8836: patient with 
homozygous c.317-2A>G mutation in the TMEM70 gene). (c) Immunoblotting after BN-PAGE 
shows a normalization of the concentration of the fully assembled complex V in the 
complemented fibroblasts of the index patient. (d) In-gel activity assay of ATP hydrolysis 
demonstrates activity in the control and in the complemented index patient cell line. (Lane 1: 
control; lane 2: control + pDS_FBneo; lane 3: control + pDS_FBneo + TMEM70 gene; lane 4: 
index patient; lane 5: index patient + pDS_FBneo; lane 6: index patient + pDS_FBneo + 
TMEM70 gene). Antibodies used are against complex V subunit alpha and CoII-70 kDa 
(complex II, loading control).  
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TMEM70 comparative genomics 
 
To shed more light on the evolution and function of TMEM70 we analyzed its sequence and 
relevant genomics data. Profile based homology detection using PSI-Blast (5 iterations, E < 
0.001) shows that orthologs of TMEM70 are not only present in multicelullar species and in 
the closest single cell relative of the metazoa, the choanoflagellate Monosiga brevicollis (15). 
The gene is also present in fungi (Schizosaccharomyces pombe), plants (Arabidopsis 
thaliana) and even stramenopiles (Phytophthora infestans) (Figure 3a). This indicates that 
TMEM70 was already present in the ancestor of all eukaryotes. Consistent with its function in 
respiration, TMEM70 cannot be found in obligatory anaerobic species. However, it does not 
specifically co-occur with complex V, as it is also absent from many species that do have 
complex V, like Saccharomyces cerevisiae. Most genomics data on TMEM70 are consistent 
with a role in OXPHOS. Orthologs of TMEM70 have been identified in the proteomic analysis 
of Caenorhabditis elegans mitochondria (29) as well as in the fluorescent-tag study of 
Schizosaccharomyces pombe - organelles (30). Furthermore, large-scale co-expression 
studies of mammalian cells (31-33) show that three nuclear encoded subunits of complex V 
genes (ATP5J, ATP5C1, ATP5A1) are among the top 10 genes that co-express with 
TMEM70. 
TMEM70 has been predicted to have two transmembrane regions located in the well-
conserved part of the protein (15). Based on a multiple sequence alignment and a 
consensus-based tool for the prediction of transmembrane topology (MetaTM, (34)), the N- 
and the C-terminus are predicted to be located in the mitochondrial matrix, with the region 
between the two transmembrane regions located in the inter-membrane space (Figure 3b). 
The deletion observed in the patient overlaps with the predicted transmembrane region 
(Figure 3a). 
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Figure 3 TMEM70 comparative genomics. (a) Alignment of the human TMEM70 protein with 
orthologs from eukaryotic crown groups (animals, fungi, plants, chromalveolates) suggests the 
early origin of the protein. Predicted mitochondrial targeting signal (MTS), transmembrane 
regions (TM), as well as the exon deleted in the index patient (DEL) are marked. (b) Likely 
topology of TMEM70 in the inner mitochondrial membrane. Transmembrane topology was 
predicted with MetaTM (34). 
 
Immunogold labeling 
 
Immunogold labeling of Flp-In T-Rex293-TMEM70-GFP cells after incubation with an 
antibody against GFP demonstrated that TMEM70 is localized in mitochondria predominantly 
in the cristae membrane (Figure 4a+b). As a control, the localization of the COX8 leader 
sequence attached to GFP, a known matrix-soluble protein (23), was found predominantly in 
the mitochondrial matrix (Figure 4c). 
Figure 4 Immunogold labeling. 
(a+b) Immunogold labeling of Flp-
In T-REx293-TMEM70-GFP cells 
after incubation with antibody 
against GFP shows that TMEM70 
is localized in mitochondria 
predominantly in the cristae 
membrane and is absent from the 
mitochondrial matrix (asterix). (c) 
In contrast, immunogold staining 
of the COX8 leader sequence 
attached to GFP, a known matrix-
soluble protein, shows that this 
construct is present in the 
mitochondrial matrix (asterix). (d) 
The negative control, Flp-In T-
REx293 cells without GFP-tag, 
shows no label. Scale bar is 0.5 
μm. 
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Live cell mitochondrial morphology and membrane potential 
 
The mitochondrial network is fragmented in TMEM70 patient fibroblasts (Figure 5a). This 
was demonstrated by quantification of mitochondrial morphology, revealing that TMEM70 
patient fibroblasts contained mitochondria with a reduced aspect ratio ('AR', Figure 5b) and a 
reduced length and degree of branching ('F', Figure 5c). This was paralleled by an increased 
number of mitochondria per cell ('Nc', Figure 5d). The mitochondrial network parameters 
were reversed after complementation with wild type TMEM70 (Figure 5b,c,d). In addition, it 
was demonstrated that the mitochondrial membrane potential in patient cells is increased. 
This was also reversed by complementation (Figure 5e), which is in agreement with 
previously published observations (15). 
For the parameters TMRM intensity and mitochondrial form factor, the relatively strong effect 
of complementation of patient cells with wild type TMEM70 was probably due to the relatively 
high levels of expression caused by the retroviral promoter that drives expression of 
TMEM70 in the complemented cells. In summary, these observations show that TMEM70 
affects mitochondrial network parameters, indicating a role of TMEM70 in mitochondrial 
morphology. 
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Figure 5 Live cell mitochondrial morphology and membrane potential (a) The mitochondrial 
network is fragmented in TMEM70 patient fibroblasts (8835: index patient; 8836: patient with 
homozygous c.317-2A>G mutation in the TMEM70 gene). (b+c+d) Quantitative mitochondrial 
morphology assessment. (b) Mitochondrial aspect ratio (AR), being the ratio between 
mitochondrial length and width, in control cells, patient cells (8835, 8836) and complemented 
patient cells (8835 + empty: index patient + pDS_FBneo, 8835 + TMEM70: index patient + 
pDS_FBneo + TMEM70 gene). (c) Mitochondrial form factor (F), being a combined measure of 
mitochondrial length and degree of branching, in control cells, patient cells (8835, 8836) and 
complemented patient cells (8835 + empty, 8835 + TMEM70). (d) The number of mitochondria 
per cell in control cells, patient cells (8835, 8836) and complemented patient cells (8835 + 
empty, 8835 + TMEM70). (e) Mitochondrial membrane potential, expressed by TMRM intensity, 
in control cells, patient cells (8835, 8836) and complemented patient cells (8835 + empty, 8835 + 
TMEM70). All data were expressed as % of the average control value (i.e. that measured the 
control in cell line) measured on the same day. Numerals indicate the number of cells (panel B) 
analyzed in four independent experiments. Statistics: ***(p<0.001), **(p<0.01) and *(p<0.05) 
relative to control. 
 
 
Electron microscopy 
 
Mitochondria in fibroblasts of the index case (Figure 6a) and in cases with complex V 
deficiency due to TMEM70 c.317-2A>G (Figure 6b) and MT-ATP8 8529G>A (Figure 6c) 
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mutations were consistently swollen and irregularly shaped with disruption of the central part 
to complete loss of the cristae. Fibroblasts with a MT-ATP6 8993T>G mutation 
predominantly showed normal cristae (Figure 6d). The mitochondrial morphology of the 
fibroblasts with the TMEM70 defect normalized after complementation with wild type 
TMEM70 (Figure 6f). 
 
Figure 6 Electron microscopy in fibroblasts of patients with complex V deficiency compared to 
control cells and complemented cells. Mitochondria in fibroblasts of the index case (a, scale 
bar: 0.5 µm) and in cases with complex V deficiency due to TMEM70 c.317-2A>G (b, scale bar: 
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0.2 µm) and MT-ATP8 8529G>A (c, scale bar: 0.2 µm) mutations are swollen and irregularly 
shaped with disruption of the central part to complete loss of the cristae. Fibroblasts with a 
MT-ATP6 8993T>G mutation predominantly show normal cristae (d, scale bar: 0.5 µm). Control 
fibroblasts show normal shaped mitochondria (e, scale bar: 0.5 µm). Fibroblasts of the index 
patient complemented with wild type TMEM70 show normal mitochondria (f, scale bar: 0.5 μm). 
(m: mitochondrion; v: vacuole; n: nucleus). 
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DISCUSSION 
 
Clinical phenotype 
 
The patient described in this report shares common clinical features with the Gypsy patients 
harboring the common splice site mutation c.317-2A>G in the TMEM70 gene described 
before (15). He presented during the first week of life with lactic acidosis and 
hyperammonemia. Later, he developed non-progressive hypertrophic cardiomyopathy and 
psychomotor delay. The description of four novel mutations in the TMEM70 gene has 
confirmed and expanded this classical clinical picture with early onset cataract, 
gastrointestinal dysfunction, congenital hypertonia and a fetal presentation of the syndrome 
(35). A milder clinical course has been found in a patient who was compound heterozygous 
for the c.317-2A>G and a c.494G>A mutation (36). These clinical features differ from those 
in a patient with a mutation in the nuclear encoded complex V assembly gene ATP12, 
presenting with a severe encephalopathy and basal ganglia involvement (13). Patients with 
mtDNA mutations in MT-ATP6 usually show central nervous system involvement, presenting 
with neuropathy, ataxia, and retinitis pigmentosa (NARP), maternally inherited Leigh 
syndrome (MILS), or bilateral striatal necrosis (2). Apical hypertrophic cardiomyopathy and 
neuropathy has been found in a case harboring a MT-ATP8 mutation (12). Recently, the first 
case of complex V deficiency due to a mutation in the nuclear encoded structural subunit ε 
has been described (14). This 22 year old patient presented with neonatal onset, lactic 
acidosis, 3-methylglutaconic aciduria, mild mental retardation and developed peripheral 
neuropathy (14). Taken together, the clinical picture described here resembles that of 
previously described Gypsy patients with a defect in the TMEM70 gene. 
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Pathogenicity 
 
In addition to the fact that the clinical symptoms resemble those of the previously described 
Romany patients with TMEM70 gene mutations (15), several additional lines of evidence 
point to the pathogenicity of the novel TMEM70 deletion described here. Both parents are 
heterozygous carriers of the deletion. The homozygous deletion in the patient leads to loss of 
exon 2 from the full length transcript which includes the first 5 amino acids of a conserved 
DUF1301 domain and the first 3 amino acids of the putative transmembrane region 1 
(www.ensembl.org). This results in a severely decreased amount and activity of holocomplex 
V. Complementation of the TMEM70 gene defect normalized the amount of complex V, the 
in-gel activity of ATP hydrolysis and the mitochondrial morphology in the patient fibroblasts. 
 
Immunogold labeling confirms TMEM70 localization to the inner mitochondrial 
membrane 
 
The exact localization of TMEM70 within mitochondria by immunogold labeling experiments 
has not been described before. The results confirm both the prediction that was based on the 
comparative genomics data presented in this report, and the recently described observations 
in submitochondrial fractions (37). The apparent localization of TMEM70 in the mitochondrial 
cristae membrane corresponds to the location of complex V and supports the involvement of 
TMEM70 in complex V biogenesis, as has been proposed before (38). 
 
Mitochondrial morphology 
 
The role of complex V in mitochondrial cristae formation has previously been studied in yeast 
(6, 8, 39-42) and in animal tissue (4). In yeast, it has been shown that in the absence of 
dimerization of complex V, the organization of the tubular cristae is abolished and the inner 
membrane is produced in an uncontrolled fashion, resulting in onion-shaped structures (6). 
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The importance of mitochondrial cristae morphology has been investigated in beef heart and 
rat liver (4). Ribbons of complex V dimers are responsible for cristae formation, and are 
essential for optimal performance of complex V (4). Although mitochondrial structural 
abnormalities have been shown to occur in complex V deficiencies before, a direct causal 
relationship has never been demonstrated. In this study, we show that the mitochondrial 
abnormalities that are present in fibroblasts with a TMEM70 genetic defect causing complex 
V deficiency, can be completely restored by complementation with wild type TMEM70. 
Electron microscopy observations showed similar mitochondrial structural abnormalities in 
fibroblasts of patients with complex V deficiency caused by different genetic defects. 
Fibroblasts carrying a TMEM70 defect contain swollen and irregularly shaped mitochondria 
with disruption of the central part to complete loss of the cristae. This was also seen in 
fibroblasts of patients with complex V deficiency harboring the TMEM70 c.317-2A>G and 
MT-ATP8 8529G>A mutations, respectively. By contrast, fibroblasts of a patient with a MT-
ATP6 8993T>G mutation predominantly showed normal cristae. Previous findings in yeast 
have shown mitochondria with an absence of cristae in mutants in which F1 synthesis had 
been virtually abolished (6, 41). It has also been described in yeast that the lack of Atp6p 
protein, rather than an ATP synthesis deficit, modifies the overall structure of mitochondria 
(43). In addition, it has been shown that the MT-ATP6 8993T>G mutation does not impair 
F1Fo assembly and oligomerization in human fibroblasts (44). The MT-ATP8 8529G>A 
mutation gives rise to an improper assembly of the complex V holoenzyme (12). It has also 
been assumed that subunits e/g and a/A6L have dimer/oligomer stabilizing effects that are 
additive (45). Mutations in the TMEM70 gene lead to a nearly absent holocomplex V. Taken 
together, it is the complex V structure rather than its enzymatic activity that seems to modify 
cristae morphology. This is in agreement with the necessity of complex V dimerization for 
mitochondrial cristae formation (4, 6, 9). It could be argued that the role of complex V in 
cristae morphology is at odds with the high mitochondrial cristae density in brown adipose 
tissue (BAT), which has relatively low amounts of complex V protein (46-48). However, the 
structure of complex V in BAT is normal (49-50), which is a prerequisite for dimerization. We 
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postulate that these complex V dimers, in spite of the relatively low levels, are sufficient to 
lead to a high cristae density in BAT, in particular in the presence of mitogenic stimuli, such 
as cold exposure or norepinephrine (47, 51). Quantitative mitochondrial morphology 
assessment in fibroblasts of the TMEM70-deletion patient and of the patient harboring the 
TMEM70 c.317-2A>G mutation revealed a disruption of the mitochondrial network. Although 
mitochondrial enzyme deficiencies are not systematically associated with fragmentation of 
the mitochondrial network (52-53), these data show that TMEM70 gene mutations affecting 
complex V structure result in mitochondrial network fragmentation. Complex V structure, 
mitochondrial morphology and the mitochondrial network were restored by complementation 
of the fibroblasts of the index patient with wild type TMEM70, which proves the causal 
relationship between TMEM70, human complex V integrity, and mitochondrial morphology, 
as has been recently suggested (38). This demonstrates that the previously established role 
of complex V in mitochondrial cristae morphology is highly relevant to human complex V 
pathology. The role of complex V in mitochondrial cristae biogenesis differs from other 
complexes of the respiratory chain, where a mutation leads to secondary loss of cristae due 
to degeneration of the mitochondria (54-55). 
 
Implications 
 
Hitherto, in most genotyped cases a substitution (c.317-2A>G) has been found (2, 15, 36). In 
addition, four novel TMEM70 mutations were described, confirming the distinct clinical 
phenotype caused by mutations in this gene (35). This report describes the first pathogenic 
deletion in the TMEM70 gene, further extending the mutation spectrum of this gene and 
confirming the classical clinical phenotype and pan-ethnicity of the disorder. Comparative 
genomics data point to the functional importance of conserved transmembrane regions of 
TMEM70 in the evolution of eukaryotes. The predicted localization in the inner mitochondrial 
membrane corresponds to the immunogold labeling data. The complementation study 
demonstrates a causal relationship between TMEM70, complex V structure and 
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mitochondrial morphology in human fibroblasts. This proves that the role of complex V in 
mitochondrial cristae morphology that has been previously studied in yeast and in animal 
tissues applies to human complex V pathology. 
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ABSTRACT 
 
Whole exome sequencing (WES) is a powerful tool to detect novel pathogenic mutations. 
The interpretation of WES data however remains challenging. Here, we present two siblings 
with a severe neonatal encephalopathy caused by complex V deficiency. WES analysis 
revealed a heterozygous mutation the ATP5A1 gene, coding for complex V subunit α, in the 
two patients, but also in their father. Due to the pathogenic susceptibility of the mutation, 
cDNA was checked and revealed a homozygous mutation in the patients, while father 
remained heterozygous. Complementation with wild type ATP5A1 restored complex V, 
confirming the pathogenicity of the mutation. At protein level, there is a disturbed interaction 
of the α subunit with the β subunit of complex V, which interferes with the stability of the 
complex. In summary, we describe the first human complex V ATP5A1 mutation and 
demonstrate the value of functional assays preceding and following WES analysis. 
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INTRODUCTION 
 
To date, mitochondrial (mt) ATP synthase (complex V) deficiencies have been described in 
the mtDNA encoded ATP6 (MT-ATP6) (MIM +516060) and ATP8 (MT-ATP8) (MIM +516070) 
genes (www.mitomap.org). ATP synthase deficiency due to the nuclear encoded ATP12 
(MIM 604273) and TMEM70 (MIM 612418) genes has also been reported (1-2). Interestingly, 
only one mutation has hitherto been found in a nuclear encoded structural complex V subunit 
(3), ATP5E (MIM 606153). Most of these genes however are not routinely screened in a 
diagnostic setting since complex V deficiency is not a common OXPHOS deficiency and 
since there is a large set of candidate genes (4). 
Recent advances in next-generation sequencing can counter the latter issue. Since most 
Mendelian disorders are caused by exonic mutations or splice-site mutations, whole exome 
sequencing (WES) can be applied to detect genetic defects underlying monogenic inherited 
disorders (5). On one hand, WES can be initiated “blindly” based only on a clinical 
phenotype. The interpretation of millions of genomic variants however is very challenging. 
Bioinformatics analysis tools and filter criteria (6-7) are used to identify causative mutations. 
For instance, when a recessive mode of inheritance is suspected, only the genes carrying 
homozygous or compound heterozygous variants are selected (6-7). On the other hand, 
biochemical data can be used to guide WES analysis. The latter approach has been applied 
in this study, describing two siblings with severe neonatal encephalopathy and an isolated 
complex V deficiency. WES was subsequently performed to uncover the genetic defect. We 
show that WES data have to be interpreted with caution in certain cases and that 
mitochondrial biochemistry preceding WES analysis can be very helpful to do so. 
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PATIENTS AND METHODS 
 
Patients 
 
We report two patients from a Dutch non-consanguineous family with the same clinical 
phenotype. Pregnancy and delivery were uneventful in both cases. They both died in the first 
weeks of life due to a severe encephalopathy characterized by intractable seizures (apnoeic 
spells). Clinical examination showed no dysmorphic features or organomegaly. Neurologic 
examination at day one revealed irritability, a high-pitched cry, a horizontal and vertical 
nystagmus, abnormal primitive reflexes, and tonus dysregulation. Brain MRI demonstrated a 
progressive and severe encephalopathy characterized by hyperdense thalami and 
subcortical densities in the eldest sibling. The EEG showed abnormal slow waves in the right 
hemisphere. Postmortem anatomopathological examination revealed extensive cerebral 
damage: the cerebellum was too small, the consistency of the occipital lobe was weakened. 
There was a cystic degeneration of the white matter, especially occipital and temporoparietal. 
Also the pons and the brain stem were damaged. The lungs were hypoplastic, there were 
small renal cysts, and skeletal muscle contained small lipid droplets. The cerebral, renal and 
skeletal muscle lesions indicated a mitochondrial disease. The MRI of the younger patient 
was characterized by progressive frontal and parieto-occipital damage including the posterior 
limb of the internal capsule (PLIC), the pyramidal tract and basal ganglia, mainly in the right 
hemisphere. Also the cerebellum and pons were damaged. Metabolic screening in blood, 
urine and liquor showed no abnormalities in both cases. 
 
Cell cultures 
 
Fibroblasts were cultured in medium 199 (Gibco®, Invitrogen Corporation) supplemented 
with 10% fetal calf serum and penicillin/streptomycin (respectively 100 U/ml and 100 µg/ml). 
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293FT cells (Invitrogen, Breda, The Netherlands) were grown in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 4.5 g/L glucose, 10% fetal calf serum, 4 mM L-glutamine, 1 mM 
MEM sodium pyruvate, 0.1 mM MEM non-essential amino acids, 1% penicillin/streptomycin, 
and 500 μg/ml geneticin (G418). During transfection, the medium does not contain 
penicillin/streptomycin and geneticin (according to Invitrogen recommendations).  
 
Biochemical assays 
 
Mitochondrial respiration in digitonin-permeabilized cells was analyzed in the presence of a 
substrate mix containing pyruvate and malate, using the phosphorescent probe MitoXpress 
(Luxcel, Cork, Ireland), 96-wells plates and a fluorescence plate reader as described (8). The 
complex V (or mtATPase) activity was measured spectrophotometrically in mitochondria 
isolated from patient and control fibroblasts as described (9). The activities of the 
mitochondrial respiratory chain enzymes and citrate synthase (CS) were measured 
spectrophotometrically in fibroblasts of the patients according to described protocols (4, 10-
11). 
 
Complex V assembly and activity 
 
One-dimensional (1D) 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), 5%-15% blue native (BN)-PAGE and two-dimensional (2D) 10% SDS-PAGE after 
BN-PAGE were performed as described previously (12-13). Lanes were loaded with 30 (SDS 
analysis) or 40 (BN analysis) µg of solubilized mitochondrial protein (14). After 
electrophoresis, gels were processed further for immunoblotting as described by (13). For 
Western blotting, antibodies used were raised against V5 (Invitrogen), mitochondrial complex 
V subunit alpha, beta, OSCP, d; complex I subunit NDUFA9, complex IV subunit IV, complex 
III subunit core 2, and CoII-70 kDa (complex II) (MitoSciences). For the in-gel activity assay 
of ATP hydrolysis the gel was incubated overnight at room temperature with the following 
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solution: 35 mM Tris, 270 mM glycine, 14 mM MgSO4, 0.2% Pb(NO3)2, and 8 mM ATP, pH 
7.8 (13). 
 
Molecular genetic analysis 
 
Whole exome sequencing  
 
We sequenced the exomes (Sure Select v2, 50Mb, Agilent, Santa Clara, CA, USA) of the 
two affected relatives, patient 2 (DDNA10-0926) and patient 1 (DDNA10-0976) on a SOLiD 4 
system (Life Technologies, Carlsbad, CA, USA). We sequenced a total of 157,698,947 and 
126,253,568 50 base pair (bp) reads, respectively. Sequence data were mapped to the hg19 
reference genome with the SOLiD bioscope software version 1.3 (Table 1a). This resulted in 
83% and 80% of the targets being covered at least 10 times, and a median coverage of 71- 
and 55-fold respectively (see Table 1a).  
Variants were called by Bioscope v1.3 and annotated using a custom-made bioinformatics 
pipeline (15-16). Variants were prioritized based on predicted amino acid consequences and 
overlap with common variation (dbSNP, in-house variant database) (Table 1b). All private 
non-synonymous and splice site variants that were present in both affected individuals are 
shown in Table 1c (see at the end of this article). 
 
Table 1a: Exome sequencing performance 
DDNA10-0926 DDNA10-0976 
Total mapped bases in regions: 4.999Gb (80.3%) 3.987Gb (75.3%) 
Total mapped bases near regions: 0.488Gb (7.8%) 0.492Gb (9.3%) 
Total mapped bases outside regions: 0.740Gb (11.9%) 0.812Gb (15.3%) 
Total reads: 157,698,947 126,253,568 
Total mapped reads: 129,880,994 109,891,958 
Median target coverage  71.0 55.2 
% Targets covered >=10x 83% 80% 
% Targets covered >=20x 76% 72% 
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Table 1b: Variant prioritization 
 DDNA10-0926 DDNA10-0976 
# Variants called 29,063 28,434 
Exonic and splice sites 14,700 14,141 
Non-synonymous and splice 
sites 8,101 7,951 
Novel dbSNP v134 625 614 
Novel in-house database 127 108 
Of those: Shared variants 22 (Table 1c) 
 
ATP5A1 genomic and coding DNA analysis 
 
Total DNA from blood and cultured fibroblasts was extracted using the salting out procedure 
for human DNA extraction (17). The coding region in genomic DNA of the ATP5A1 gene was 
polymerase chain reaction (PCR) amplified using ten primer pairs (Table 2a). PCR 
conditions were 95°C for 10 minutes (denaturation), 95°C for 30 seconds, 60°C for 30 
seconds and 72°C for 1 min for a total of 35 cycles. The promotor region in of the ATP5A1 
gene was amplified under the same PCR conditions using seven primer pairs (Table 2b). 
Sequence analysis of PCR amplified products was performed on an ABI3730 automatic 
capillary sequencer using BigDye® terminator chemistry (Applied Biosystems). RNA from 
blood and cultured fibroblasts was extracted as described (17). Reverse Transcriptase PCR 
(RT-PCR) was performed to produce cDNA followed by PCR amplification (Table 2c). 
Sequence analysis was subsequently performed as described above. 
 
Table 2a: Primers for PCR amplification of the genomic DNA 
Exon(s) Forward primer Reverse primer Comment
2 5'-CAGTACTTCCGGGTCAGGTG-3' 5'-ATTCTGCCTCTGCGCAGGTGAC-3' Conventional 
PCR 
3 5'-GATCACACTAAGCTGGCATTTG-3' 5'-CAACTCACCACAGTTATACGATG-3' Conventional 
PCR 
4 5'-AAGTGCTGGGATTACAGCTGTGAG-3' 5'-GAATAACTGAGAAGACTTAGATCC-3' Conventional 
PCR 
5-6 5'-TTGGTGTATGGGGAGGAGTG-3' 5'-ACCATTCCAAGACTAAAATATAATCC-3' Conventional 
PCR 
7 5'-TGCATAGACACAGTAACAGTCTG-3' 5'-CTACAATCAGCAGCAATGGGAC-3' Conventional 
PCR 
8-9* 5'-TTTTATAGTAGCCTCCAATTTAAAACC-
3' 
5'-CGGTAAGCAACAGCCTATGGTAC-3' Conventional 
PCR 
9* 5'-GTACCATAGGCTGTTGCTTACCG-3' 5'-CAACCAATGCCTTAGAATTATCC-3' Conventional 
PCR 
10 5'-TTGGGGTACTGATGCTTTGC-3' 5'-GTACTGTAACTCAGTGACACAGAGC-3' Conventional 
PCR 
11 5'-GCTCTGTGTCACTGAGTTACAGTAC-3' 5'-TGTGATGCAGCTCTGTAGGC-3' Conventional 
PCR 
12-13 5'-GACCTTGGTAACATGGCATTC-3' 5'-CTGGTATTTGATGTGAATCC-3' Conventional 
PCR 
*Exon 9 is amplified in two overlapping fragments 
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Table 2b: Primers for PCR amplification of the promoter region 
Fragment Forward primer Reverse primer Comment 
1 5'-CCAGGTAAGCATAGAAAGTG-3' 5'-CCCATCTGGTGCTAGAGGA-3' Conventional 
PCR 
2 5'-CCAGGTAAGCATAGAAAGTG-3' 5'-ATATTCCGGCTTTGGTCCTG-3' Conventional 
PCR 
3 5'-CTATCATCCCATCACCTAGG-3' 5'-CCCATCTGGTGCTAGAGGA-3' Conventional 
PCR 
4 5'-CTATCATCCCATCACCTAGG-3' 5'-ATATTCCGGCTTTGGTCCTG-3' Conventional 
PCR 
5 5'-CACGGTCTAACACTACCGAC-3' 5'-ATATTCCGGCTTTGGTCCTG-3' Conventional 
PCR 
6 5'-CACGGTCTAACACTACCGAC-3' 5'-ATTCTGCCTCTGCGCAGGTGAC-3' Conventional 
PCR 
7 5'-GACACAGGTGCCCTTTTGCTC-3' 5'-GGGTATTAATCCTTACAGCC-3' Conventional 
PCR 
 
Table 2c: Primers for PCR amplification of the cDNA 
Fragment Forward primer Reverse primer
1 5'-CTCCTTACTCTGGCTGTTCC-3' 5'-CTGGCAAAGCAGTCAAGGAG-3' 
 
 
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis 
 
To detect exon deletions or duplications in ATP5A1, MLPA analysis was performed as 
described (18). 
 
Comparative genomic hybridization (CGH) array 
 
Affymetrix CytoScan HD array was performed to search for genome-wide deletions or 
duplications with a median resolution of 20 kilo base (Human Genome Build hg19, UCSC 
genome browser February 2009). 
 
Cloning of human ATP5A1 gene and lentiviral complementation 
 
The full length ORF for ATP5A1 was amplified by PCR from I.M.A.G.E. cDNA clone 
IRATp970G0784D (Source BioScience) using specific primers with Gateway AttB flanking 
sites without a stop codon. The product was cloned into pDONR201 using the Gateway BP 
Clonase II Enzyme Mix (Invitrogen). The resulting entryclone was verified by sequence 
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analysis and subsequently recombined with the pLenti6.2V5-DEST destination vector 
(Invitrogen) using the Gateway LR Clonase II Enzyme Mix (Invitrogen). The Gateway BP and 
LR reactions were performed according to the manufacturer’s instructions. The resulting 
pLenti6.2-V5-ATP5A1 or the control construct pLenti6.2-V5-AcGFP were transfected into 10 
cm dishes 293FT cells together with a packaging mix consisting of pLP1, pLP2, and 
pLP/VSVG using Lipofectamine 2000 (Invitrogen). At 24 hours after transfection the medium 
was refreshed and supernatants containing the viral particles were harvested at 72 hours 
after transfection. Supernatants were cleared by centrifugation (5 min. 300 g) and the viral 
particles were stored at -80°C prior to use. Infections were performed on fibroblasts in 75 cm2 
flasks with 2 ml of virus containing supernatant in the presence of 6 µg/ml polybrene (Sigma). 
At 24 hours after infection the medium was refreshed and at 48 hours after transfection the 
selection medium was added (M199, 20 % fetal calf serum, penicillin/streptomycin 
(respectively 100 U/ml and 100 µg/ml), 2 µg/ml blasticidin (InvivoGen)). Cells were selected 
for 14 days, in which time the mock infected cells (without virus) died. Blasticidin resistant 
cells were used for biochemical analysis within six passages after transduction. 
 
Three-dimensional (3D) Modeling 
 
A 3D model of the human F1-ATPase, including the Arg329Cys mutation, was created using 
the automatic homology modeling script in the YASARA & WHAT IF Twinset (19-20). As a 
template for this model we used PDB structure 1BMF (21), containing the structure of the 
bovine F1-ATPase, of which the alpha-subunit is 98% identical to the human one. 
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RESULTS 
 
Biochemical assays 
 
Oxygen consumption measurements in fibroblasts as described by (8) showed a decreased 
oxygen consumption rate in cells of both patients (Figure 1a,b) compared to control cells 
(Figure 1c). A substantial increase was seen after addition of an uncoupler (2 µM carbonyl 
cyanide 3-chlorophenyl hydrazone: CCCP) in the fibroblasts of both patients (Figure 1a,b). 
This is not observed in control cells (Figure 1c) and indicates a complex V deficiency (8).  
 
 
Figure 1 Oxygen consumption rate in fibroblasts. A decreased oxygen consumption rate is 
seen in both patients (a, b) compared to the control (c). A clearly higher rate is observed in the 
cells of both patients (a, b) after addition of an uncoupler (2 μM carbonyl cyanide 3-
chlorophenyl hydrazone (CCCP)). This phenomenon is not observed in control cells (c) and 
indicates a complex V deficiency. (Normalized time profile of fluorescence intensity; RFU = 
relative fluorescence units; CS = citrate synthase; fibroblasts of (a) patient 1 and (b) patient 2; 
● = +ADP ○ = -ADP; ▼= +ADP + CCCP; ∆ = -ADP + CCCP). 
 
 
 
 
 
Measurements of the mitochondrial respiratory chain enzyme activities were performed in 
cultured fibroblasts (no muscle tissue was available for both patients) and displayed an 
isolated complex V deficiency in both cases (Table 3).  
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Table 3: Enzymatic analysis of the activities of complex V (mtATPase), the respiratory chain 
enzymes and CS in fibroblasts of patients 1 and 2. 
 
 Patient 1 Patient 2 
Complex V, mU/U COX a 116 (209-935) c 76 (209-935) 
Complex I, mU/U COX  140 (110-260) 126 (110-260) 
Complex II, mU/U COX 661 (536-1027) 698 (536-1027) 
Complex III, mU/U COX 2311 (1270-2620) 2431 (1270-2620) 
Complex IV, mU/U CS b 929 (680-1190) 918 (680-1190) 
CS, mU/mg 171 (144-257) 179 (144-257) 
a COX: cytochrome c oxidase; b CS: citrate synthase; c figures between brackets are reference ranges. 
 
Complex V assembly and activity 
 
We performed 1D and 2D BN-PAGE analysis on fibroblasts of the two patients and a healthy 
control. 1D BN-PAGE showed that the amount of complex V was strongly reduced in the 
patients compared to the control (Figure 2a) The in-gel activity assay (IGA) of ATP 
hydrolysis demonstrated a reduced complex V activity (Figure 2a, top panel). 2D BN-PAGE 
analysis showed holocomplex V, with no accumulation of subcomplexes (Figure 2b). 1D 
SDS-PAGE showed that the levels of individual complex V subunits were decreased (Figure 
2c), which is in accordance with (22) describing proteolytic removal of unassembled F1 
subunits in HeLa cells depleted in the β subunit of complex V. In conclusion, these data 
indicate a disturbed complex V assembly in an early stage (at the F1 level). 
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Figure 2 Complex V assembly and activity in fibroblasts. (a) BN-PAGE shows a reduced 
amount and activity (top panel, in-gel activity (IGA)) of complex V in both patients. (b) Two 
dimensional BN-PAGE analysis shows holocomplex V, with no accumulation of subcomplexes. 
(c) Immunoblot after SDS-PAGE shows decreased levels of complex V subunits. Note that blots 
stained with different antibodies can only be compared qualitatively since exposure times are 
not the same. Antibodies used are against complex V subunits α, β, OSCP and d, complex I 
subunit NDUFA9, and complex II-70 kDa (loading control). (8834: patient 2 and 8618: patient 1 
fibroblasts; H: holocomplex). 
 
 
Molecular genetic analysis 
 
Genetic analysis did not reveal mutations in the mtDNA or nuclear genes known to cause 
complex V deficiency (ATP12, TMEM70, ATP5E). Therefore, whole exome sequencing was 
performed and revealed a heterozygous mutation at c.985C>T (p.Arg329Cys) (Ref Seq 
accession number NM_001001937) in exon 9 of ATP5A1 (chromosome 18q21, MIM 
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*164360). Father was also heterozygous, whereas mother did not have this mutation (Figure 
3, left panel). The mutation was not present in more than 120 healthy Caucasian controls. 
Next, cDNA was checked and revealed a homozygous c.985C>T mutation in both patients, 
father was heterozygous and mother showed the wild-type coding sequence (Figure 3, right 
panel).  
Figure 3 Molecular genetic 
analysis in fibroblasts. Left panel: 
genomic (g)DNA analysis shows a 
heterozygous mutation at 
c.985C>T (pArg329Cys) in exon 9 
of ATP5A1 in both patients and in 
the father. Mother shows no 
mutations. Right panel: coding 
(c)DNA analysis shows a 
homozygous mutation in both 
patients. Father is heterozygous, 
and mother does not have this 
mutation.  
 
 
 
 
 
 
This means that one allele of mother is not expressed and that, in fact, both patients are 
hemizygous for the mutation at cDNA level. The loss of this transcript was not due to 
promoter region mutations (checked from g.41931368 – g.41933253 (Chr18, NCBI Build 
36)). MLPA analysis did not show deletions or duplications in ATP5A1 alleles (data not 
shown). CytoScan HD array showed no alterations (data not shown). 
 
Complementation of complex V deficiency by wild type ATP5A1 
 
To confirm the pathogenicity of the mutation, we transduced the index patients and a healthy 
control using the lentiviral system. Complementation of patient fibroblasts with wild-type 
ATP5A1 completely normalized complex V amount (Figure 4) and activity (Table 4). 
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Figure 4 Complementation with wild type ATP5A1. (a) BN-PAGE shows that complex V amount 
normalizes in patient fibroblasts after complementation with wild type ATP5A1. Incubation with 
anti-V5 antibody demonstrates that the wild type ATP5A1 construct is incorporated correctly. 
Other OXPHOS complexes are expressed normally. Of note, complementation of the control 
fibroblasts is less clear since these cells don’t need the complemented construct (competitive 
inhibition with wild type complex V). (b) Immunoblot after SDS-PAGE again demonstrates that 
the wild type ATP5A1 construct is incorporated correctly. Incubation with subunit α antibody 
shows two bands, the lower band is native subunit α, the upper band is subunit α tagged with 
V5. Antibodies used are against V5, complex V subunits α and β, complex IV subunit IV, 
complex III core 2, complex I NDUFA9, and complex II-70 kDa (loading control). (8834: patient 2 
and 8618: patient 1 fibroblasts; WT: wild type; GFP: negative control construct pLent6.2-V5-
AcGFP; 5A: wild type ATP5A1 construct pLent6.2-V5-ATP5A1). 
 
Table 4: Complementation with wild type ATP5A1 restores complex V activity in patient 
fibroblasts. 
 
 Complex V activity (mU/U CS, reference 
range 193-819)c 
Patient 1 - GFPa 118 
Patient 1 – ATP5A1b  337 
Patient 2 - GFP 118 
Functional assays preceding exome sequencing 
175 
 
Patient 2 – ATP5A1 381 
Control - GFP 748 
Control – ATP5A1 665 
a Patient 1 - GFP: negative control construct pLent6.2-V5-AcGFP; b Patient 1 – ATP5A1: wild type 
ATP5A1 construct pLent6.2-V5-ATP5A1. 
 
Modeling of p.Arg329Cys in ATP5A1 
 
The pathogenicity of the mutation was also corroborated by protein modeling. The arginine 
329 of the α subunit that is mutated in the patients is predicted to normally form a hydrogen 
bond with a carbonyl group of the glycine 323 of the β subunit (Figure 5). As the F1-ATPase 
has three α subunits and three β subunits, the Arg329Cys mutation would break three 
stabilizing interactions in the complex. This predicted loss of stability of the complex is in line 
with the Western blot results that show degradation of unassembled subunits. Furthermore, 
the arginine 329 is very well conserved, even among bacterial orthologs of ATP5A1 (data not 
shown), underlining its importance for the functioning of the complex. 
 
 
Figure 5 Impact of the ATP5A1 c.985C>T mutation at the protein structure level. p.Arg329Cys 
disturbs the interaction of the α subunit with the β subunit. Normally arginine 329 is predicted 
to interact with a carbonyl group of glycine 323 in the backbone of the β subunit. The 
Arg329Cys mutation is thus predicted to interfere with the stability of complex V. (R: arginine; 
C: cysteine; G: glycine) 
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DISCUSSION 
 
Clinical phenotype 
 
The severe neonatal encephalopathy of the patients described here resembles the clinical 
picture of the patient with a mutation in the complex V assembly gene ATP12 (1). The latter 
patient however also presented with dysmorphic features, an enlarged liver and hypoplastic 
kidneys, features that were not present here. It should be noted that postmortem 
anatomopathological examination of the eldest sibling revealed renal cysts and hypoplastic 
lungs. Remarkably, there is a predominance of the cerebral lesions in the right hemisphere in 
the patients described here. Additional patients with mutations in ATP5A1 are needed to 
confirm this clinical phenotype. Hypertrophic cardiomyopathy, which is often seen in complex 
V deficiency (2, 9), was not documented. A 4 base pair duplication in exon 3 of ATP5A1 
leading to a stopcodon in exon 4 and therefore an instable transcript, has been described in 
an animal model and this resulted in death in utero (23). 
 
Pathogenicity 
 
Several lines of evidence point to the pathogenicity of the ATP5A1 mutation. Clinically, there 
is a severe and fatal neonatal encephalopathy, while biochemically, an isolated complex V 
deficiency was found. Modeling of the mutation showed a disturbed interaction of the α and β 
subunit of complex V. This leads to instability of the complex which is in line with the Western 
blot results, showing a severely decreased holocomplex V and degradation of unassembled 
subunits. Complementation of the ATP5A1 defect normalized the amount and activity of 
complex V. Finally, the mutation is situated in a conserved region of the protein. 
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Value of functional assays before and after whole exome sequencing 
 
In the routine diagnostic setting for mitochondrial disorders, we first perform functional 
(mitochondrial energy-generating system (MEGS) capacity, oxygen consumption and 
enzymatic activity) assays. Genetic analysis is subsequently performed, oriented on these 
results. This approach was successful here, since the heterozygous mutation in ATP5A1 
which was found in both patients and in their father was only investigated further because of 
the known complex V deficiency in the patients. Therefore we want to emphasize the 
importance of functional assays preceding exome sequencing. Biochemical data can help to 
identify causative mutations which would have been filtered out when only WES data were 
considered. Indeed, the patients described here nicely show that also heterozygous 
mutations found in the index patient(s) and in one of the parents warrant further investigation 
if the mutation is suspected to be pathogenic. This differs from whole exome sequencing 
strategies which include homozygosity as a filter criterion when a recessive mode of 
inheritance is suspected (6-7). After WES, defining the true impact of genomic variants by 
functional follow-up (cDNA analysis, complementation studies) is mandatory. This is also 
emphasized in (24), where a branch-site mutation instead of a homozygous missense 
mutation in the NUBPL gene was shown to cause complex I deficiency. 
Together, we currently recommend functional studies before and after WES analysis to 
identify and confirm the pathogenicity of a mutation. As genetic knowledge and technology is 
rapidly evolving, time will tell whether functional assays remain valuable in a whole exome or 
whole genome sequencing setting. 
 
Implications 
 
In summary, we report the first mutation in ATP5A1, which codes for complex V subunit α 
and gives rise to an isolated complex V deficiency with a distinct clinical phenotype, i.e. a 
severe neonatal encephalopathy leading to early death. Moreover, this study demonstrated 
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that functional assays preceding (enzyme activity analysis) and following WES (cDNA 
analysis, complementation studies) are indispensable for the correct interpretation of these 
data. 
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Table 1c: Summary of all private non-synonymous and splice site variants identified in both 
affected individuals by WES 
Patien
t ID 
Chr
. 
Genomic 
position 
[hg19] 
Refere
nce 
Vari
ant 
Tota
l 
read
s 
Vari
ant 
read
s 
% 
variati
on 
Gene 
name Gene id 
Referenc
e Amino 
Acid 
Mutation 
Amino 
Acid 
AminoA
cid 
changes 
mRNA 
chang
es 
phyl
oP 
Granth
am 
Score 
DDNA-
100976 
chr
1 23,409,678 C T 75 34 45.3 KDM1A 
NM_001009
999 P S 
P818S 
P794S 
2380C
>T 5.83 74 
DDNA-
100926 
chr
1 23,409,678 C T 110 44 40.0 KDM1A 
NM_001009
999 P S 
P794S 
P818S 
2452C
>T 5.83 74 
DDNA-
100976 
chr
11 113,215,017 A T 55 22 40.0 TTC12 NM_017868 I L I337L 
1009A
>T -0.73 5 
DDNA-
100926 
chr
11 113,215,017 A T 117 47 40.2 TTC12 NM_017868 I L I337L 
1009A
>T -0.73 5 
DDNA-
100976 
chr
11 9,501,029 A G 47 23 48.9 ZNF143 NM_003442 D G D194G 
581A>
G 3.70 94 
DDNA-
100926 
chr
11 9,501,029 A G 60 28 46.7 ZNF143 NM_003442 D G D194G 
581A>
G 3.70 94 
DDNA-
100976 
chr
11 73,714,986 G A 15 5 33.3 UCP3 NM_003356 P L P237L 
710G>
A 5.87 98 
DDNA-
100926 
chr
11 73,714,986 G A 14 4 28.6 UCP3 NM_003356 P L P237L 
710G>
A 5.87 98 
DDNA-
100976 
chr
11 93,431,592 A G 155 74 47.7 
KIAA17
31 NM_033395 I V I1172V 
3514A
>G 0.54 29 
DDNA-
100926 
chr
11 93,431,592 A G 198 86 43.4 
KIAA17
31 NM_033395 I V I1172V 
3514A
>G 0.54 29 
DDNA-
100976 
chr
14 96,730,192 T C 16 8 50.0 
BDKRB
1 NM_000710 V A V58A 
173T>
C 2.26 64 
DDNA-
100926 
chr
14 96,730,192 T C 28 14 50.0 
BDKRB
1 NM_000710 V A V58A 
173T>
C 2.26 64 
DDNA-
100976 
chr
17 43,308,025 G A 22 13 59.1 FMNL1 NM_005892 E K E62K 
184G>
A 4.95 56 
DDNA-
100926 
chr
17 43,308,025 G A 52 26 50.0 FMNL1 NM_005892 E K E62K 
184G>
A 4.95 56 
DDNA-
100976 
chr
17 40,052,881 G A 25 11 44.0 ACLY NM_001096 S F S484F 
1451G
>A 2.28 155 
DDNA-
100926 
chr
17 40,052,881 G A 43 17 39.5 ACLY NM_001096 S F S484F 
1451G
>A 2.28 155 
DDNA-
100976 
chr
18 43,667,165 G A 28 12 42.9 
ATP5A
1 NM_004046 R C R329C 
985G>
A 5.70 180 
DDNA-
100926 
chr
18 43,667,165 G A 25 12 48.0 
ATP5A
1 NM_004046 R C R329C 
985G>
A 5.70 180 
DDNA-
100976 
chr
19 44,681,807 - A 17 13 76.5 ZNF226 
NM_001032
373 E 
potential 
fs E798EX 
2392>
A 1.36 NA 
DDNA-
100926 
chr
19 44,681,807 - A 15 9 60.0 ZNF226 
NM_001032
373 E 
potential 
fs E798EX 
2392>
A 1.36 NA 
DDNA-
100976 
chr
2 152,534,137 C A 396 155 39.1 NEB 
NM_001164
508 S I S1239I 
3716C
>A 5.93 142 
DDNA-
100926 
chr
2 152,534,137 C A 582 248 42.6 NEB 
NM_001164
508 S I S1239I 
3716C
>A 5.93 142 
DDNA-
100976 
chr
2 8,888,010 
TACTT
AC - 21 13 61.9 
KIDINS
220 NM_020738 
splice 
site    NA NA 
DDNA-
100926 
chr
2 8,888,010 
TACTT
AC - 52 21 40.4 
KIDINS
220 NM_020738 
splice 
site    NA NA 
DDNA-
100976 
chr
22 30,887,620 G A 39 25 64.1 
SEC14
L4 NM_174977 R C R341C 
1021G
>A 1.22 180 
DDNA-
100926 
chr
22 30,887,620 G A 39 24 61.5 
SEC14
L4 NM_174977 R C R341C 
1021G
>A 1.22 180 
DDNA-
100976 
chr
3 88,189,002 A G 99 37 37.4 ZNF654 NM_018293 N S N181S 
542A>
G 2.41 46 
DDNA-
100926 
chr
3 88,189,002 A G 91 46 50.5 ZNF654 NM_018293 N S N181S 
542A>
G 2.41 46 
DDNA-
100976 
chr
3 185,146,790 G A 38 16 42.1 
MAP3K
13 NM_004721 V I V141I 
421G>
A 6.10 29 
DDNA-
100926 
chr
3 185,146,790 G A 77 29 37.7 
MAP3K
13 NM_004721 V I V141I 
421G>
A 6.10 29 
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DDNA-
100976 
chr
4 113,436,601 T G 11 3 27.3 
NEURO
G2 NM_024019 K Q K11Q 31T>G 0.93 53 
DDNA-
100926 
chr
4 113,436,601 T G 50 20 40.0 
NEURO
G2 NM_024019 K Q K11Q 31T>G 0.93 53 
DDNA-
100976 
chr
4 155,530,867 A G 170 106 62.4 FGG NM_021870 F S F194S 
581A>
G 2.16 155 
DDNA-
100926 
chr
4 155,530,867 A G 182 89 48.9 FGG NM_021870 F S F194S 
581A>
G 2.16 155 
DDNA-
100976 
chr
5 140,740,918 A T 82 28 34.1 
PCDHG
B2 NM_018923 T S T406S 
1216A
>T 2.45 58 
DDNA-
100926 
chr
5 140,740,918 A T 88 28 31.8 
PCDHG
B2 NM_018923 T S T406S 
1216A
>T 2.45 58 
DDNA-
100976 
chr
6 33,648,392 G A 23 21 91.3 ITPR3 NM_002224 V I V1471I 
4411G
>A 3.34 29 
DDNA-
100926 
chr
6 33,648,392 G A 42 32 76.2 ITPR3 NM_002224 V I V1471I 
4411G
>A 3.34 29 
DDNA-
100976 
chr
7 138,552,843 G A 60 23 38.3 
KIAA15
49 
NM_001164
665 R W R1603W 
4807G
>A 3.03 101 
DDNA-
100926 
chr
7 138,552,843 G A 37 12 32.4 
KIAA15
49 
NM_001164
665 R W R1603W 
4807G
>A 3.03 101 
DDNA-
100976 
chr
8 101,601,143 T C 76 33 43.4 SNX31 NM_152628 Q R Q348R 
1043T
>C 3.43 43 
DDNA-
100926 
chr
8 101,601,143 T C 94 39 41.5 SNX31 NM_152628 Q R Q348R 
1043T
>C 3.43 43 
DDNA-
100976 
chr
9 101,980,430 G A 66 26 39.4 ALG2 NM_033087 S L S346L 
1037G
>A 4.24 145 
DDNA-
100926 
chr
9 101,980,430 G A 57 27 47.4 ALG2 NM_033087 S L S346L 
1037G
>A 4.24 145 
 
  
  
 
 
 
 
 
PART IV 
 
 
GENERAL DISCUSSION 
  
  
 
  
8 
 
 
 
 
General discussion, future perspectives and conclusions 
  
  
 
General discussion and conclusions 
189 
 
PART II: CHARACTERIZATION OF HUMAN CELL LINES WITH MITOCHONDRIAL 
DYSFUNCTION 
 
Establishing a biochemical diagnosis in the mitochondrial medicine field is of utmost 
importance since it guides the search for the underlying genetic defect. Therefore, we 
extended current tools for biochemical diagnostics in patients suspected for mitochondrial 
disease in this thesis. Functional measurements in fresh muscle tissue, comprising substrate 
oxidation, ATP production and oxygen consumption measurements, evaluate the capacity of 
the whole mitochondrial energy-generating system (MEGS). It is important to be able to 
perform these functional measurements in other tissues than skeletal muscle. A decreased 
MEGS capacity in other tissues than skeletal muscle, and this is certainly the case for 
confirming a defect in cultured skin fibroblasts, points to a primary mitochondriopathy, which 
is mostly inherited. A decreased MEGS capacity solely in muscle tissue can be secondary 
due to poor feeding or inactivity and can normalize in muscle tissue taken after clinical 
improvement, or can still indicate a primary mitochondriopathy, which is not expressed in the 
other tissue(s) examined. This means that functional assays in several tissues can be helpful 
to determine if it concerns an inherited disease. This is important for patient counseling. 
Chapter 2 described a simple, high-throughput, high-content screening method for oxygen 
consumption analysis in different digitonin-permeabilized cell types. It was demonstrated that 
this assay provides a valuable tool in the diagnostics of mitochondrial disorders. It can 
differentiate between primary and secondary mitochondrial abnormalities. Patients with a 
primary mitochondriopathy that does not affect the complexes of the respiratory chain can be 
identified. At present, the method is validated in order to implement these measurements in 
the routine diagnostic setting. In a research context, the assay is used in the search for and 
characterization of new genetic defects, and can be applied to evaluate the effects of 
therapeutic interventions. 
In chapter 3, two OXPHOS-deficient myogenic cell lines were established. It was shown that 
the complete biochemical toolbox, including substrate oxidation, ATP production rate and 
Chapter 8 
190 
 
oxygen consumption measurements, as well as spectrophotometric enzyme analysis and 
BN-PAGE could be adapted successfully for the study of mitochondrial energy metabolism in 
myoblasts and myotubes. Mitochondrial disorders can thus be identified and characterized in 
muscle cells. This paves the way for multiple applications, e.g. the study of OXPHOS defects 
that are only expressed in muscle tissue, in-depth research for mitochondrial physiology 
using biological assays in living cells, and targeted pharmacological intervention studies. The 
immortalization of myoblasts can provide a back-up of muscle cells, which circumvents novel 
muscle biopsies. 
Together, these new tools expand current diagnostic and counseling possibilities. 
Mitochondrial biochemical assays are continuously being optimized, validated and extended. 
In Nijmegen a micro method has been developed to measure the substrate oxidation and 
ATP production rates in human muscle mitochondria requiring less than one-tenth of the 
original amount of muscle tissue. Spectrophotometric enzyme activity measurements are 
now automated and can be performed much faster, more accurate and also requiring less 
sample. This shortens completion time of diagnostic assays and therefore the time of 
uncertainty in patients and their families. Methods for the measurement of the pyruvate 
carrier, the glutamate carrier and the α-ketoglutarate carrier in muscle tissue using 
radioactive substrates have been developed. These assays will be adapted soon for 
fibroblasts. The development of methods to measure different carriers is important because it 
can identify patients with described defects (1-2), but also, when expanding the number of 
carrier assays, could lead to the discovery of novel defects, further unraveling the complexity 
of mitochondrial diseases. Finally, mitochondrial biochemical diagnostics does not only serve 
patients suspected for a mitochondriopathy, but also other patient groups e.g. Multiple 
Sclerosis (MS) patients (3), Complex Regional Pain Syndrome type I (CPRS I) patients (4), 
and patients with several other disorders. Multiple mtDNA deletions are present in the gray 
matter of MS patients. It was proposed that these deletions are an important contributor to 
neurodegeneration in MS (3). Mitochondrial dysfunction was seen in muscle tissue of CPRS I 
patients; it remains to be established whether this is a primary or secondary phenomenon 
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(4). So mitochondrial biochemical assays undoubtedly also serve research goals. 
Biochemical measurements can guide the search for genetic defects. In that way, the genetic 
search can be performed step-wise and directed to specific genes, e.g. complex V genes in 
case of a complex V deficiency. Afterwards, biochemical diagnostic assays are again needed 
to evaluate the pathogenicity of genetic variants. Together with bioinformatics tools, 
biochemical assays are mandatory in the interpretation of whole exome sequencing data.  
 
 
PART III: COMPLEX V IN HEALTH AND DISEASE 
 
Unraveling the underlying genetic mutation and studying the functional impact of the defect in 
patients with a complex V deficiency was the second goal in this thesis. 
Chapter 4 reviewed the architecture, function and assembly of complex V. The role of 
complex V di- and oligomerization and its relation with mitochondrial morphology was 
discussed. Finally, pathology related to complex V deficiency and current therapeutic 
strategies were highlighted. Thanks to the extensive research over the last decades, 
nowadays much is known regarding the structure and function of the world’s smallest rotary 
nanomotor. Most of the structure of the bovine mitochondrial enzyme has been resolved. The 
structures of the membrane domain of subunit b, subunit a, and the accessory subunits e, f, 
g, and A6L remain to be determined (5). The mechanism of the rotary F1Fo ATP synthase 
has been described by Boyer (6). Still, understanding the enzyme fully at a molecular level 
will require further efforts, both experimental and theoretical (for a review, see (7)). Next to 
structure and function of the monocomplex, also the role of di- and oligomerization of 
complex V, shaping the inner mitochondrial membrane, has been addressed in many studies 
both in yeast and in mammalian mitochondria (8-9). The role of IF1 in this process has been 
shown to be important (10-11). 
In chapter 5, we studied the clinical features and molecular pathophysiology in a patient with 
the first described mitochondrial ATP8 gene mutation. The clinical picture was characterized 
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by apical hypertrophic cardiomyopathy and neuropathy. At the molecular level, we found an 
improper assembly and reduced activity of complex V. 
In chapter 6, we studied mitochondrial morphology in a patient with a deletion in the 
TMEM70 gene, causing complex V deficiency. We saw a fragmented mitochondrial network 
and swollen and irregularly shaped mitochondria with partial to complete loss of the cristae in 
fibroblasts of this patient, which could be completely restored by complementation of the 
TMEM70 genetic defect. Comparative genomics analysis predicted the topology of TMEM70 
in the inner mitochondrial membrane, which could be confirmed by immunogold labeling 
experiments, and showed that the TMEM70 gene is not restricted to higher multi-cellular 
eukaryotes. This study demonstrated that the role of complex V in mitochondrial cristae 
morphology applies to human mitochondrial disease pathology. 
In chapter 7, we described two siblings with intractable epilepsy and complex V deficiency 
due to a mutation in ATP5A1, coding for complex V subunit α. The mutation gave rise to a 
disturbed interaction of the α subunit with the β subunit of complex V, which interfered with 
the stability of the complex. This study also demonstrated that biochemical diagnostics 
preceding and following whole exome sequencing are indispensable for the correct 
interpretation of these data, since heterozygous mutations found in the index case and in one 
of the parents warrant cDNA analysis if the mutation is suspected to be pathogenic. 
 
Lots of questions regarding complex V remain to be answered. The assembly of the different 
subunits into the holocomplex continues to be puzzling. Most of the research has been done 
in yeast. But the yeast assembly process probably differs from the one in mammalian 
mitochondria, since there are substantial differences between higher and lower eukaryotes 
such as the number of Fo subunit c-genes, ATP synthase-specific assembly factors, and 
factors regulating transcription of ATP synthase genes (12). To gain further insight into the 
assembly of complex V, techniques like blue native and clear native PAGE, combined with 
incorporation and knock-down experiments of different subunits as described in (13) could 
refine our current knowledge. Further, only two assembly factors, ATP11 and ATP12, are 
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hitherto known in mammalian ATP synthase. They both have a role in F1 assembly. TMEM70 
maintains normal expression levels of complex V, and has been suggested to have a role in 
complex V biogenesis (14). The exact mechanism however still remains to be elucidated. 
Tandem-affinity purification (TAP) experiments can be performed to identify TMEM70 co-
purifying proteins. This information can be used to set up additional experiments in order to 
gain further insight into the TMEM70 mechanism. Moreover, the existence of specific factors 
involved in mammalian Fo formation is probable (12). A possible approach could be to study 
the evolution of complex V subunits and complex V chaperones by comparative genomics. 
For example, the yeast Fo assembly factor Atp23p has a human homolog for which, however, 
no involvement in ATP synthase assembly could be demonstrated (15). Also a homology of 
complex V chaperones with other human proteins could be of interest in the search of 
specific assembly factors. Another intriguing fact is that to date, mutations have only been 
found in two nuclear encoded structural complex V genes (16). It could be possible that 
mutations in some of the structural subunits are incompatible with life. On the other hand, 
given the lower frequency of complex V deficiency compared to the other OXPHOS 
deficiencies, routine screening of all nuclear structural genes is rarely implemented in a 
diagnostic setting. Whole genome or whole exome screening (WES) could possibly solve 
some of the hitherto unknown genetic defects causing complex V deficiency. A current 
drawback of WES is an incomplete coverage of the whole exome (17). Furthermore, WES 
misses structural variation and variants situated in highly conserved non-coding regions of 
the genome (17). Whole genome sequencing (WGS) can overcome these issues. However, 
since the amount of data generated from WGS is 100 times more than WES, data analysis 
is, next to the cost of this assay, still a major challenge. Already for WES, an overwhelming 
set of data is obtained. In this context, functional biochemical characterization of newly 
discovered genetic variants or of genes with unknown function is, next to bioinformatical 
analysis, mandatory to define their pathogenicity and pathophysiological consequences. This 
means that biochemical diagnostic assays are needed both in the search for genetic defects 
and in defining the impact of found genetic variants in an individual patient. This is well 
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illustrated in chapter 7, where the knowledge of an isolated complex V deficiency in the 
patients stimulated further study of the heterozygous mutation found in the ATP5A1 gene by 
whole exome sequencing, even if the same mutation was also found in the father. The 
pathogenicity of the mutation was confirmed by complementing the patient cells with wild 
type ATP5A1. Finally, the biggest challenge will be to find a tailored curative therapy for this 
patient group. Compound screening can be applied to find a possible pharmacological 
approach. For example, the compound 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR) activates mitochondrial biogenesis via activation of the AMPK/PGC1α axis (18). 
Stimulation of mitochondriogenesis nevertheless implies some residual activity of the 
deficient complex. If this is not the case, mitochondrial targeted delivery of the protein of 
interest via a liposome-based carrier system could be an alternative (19). For mtDNA 
defects, gene-shifting and germline techniques are promising. Nevertheless, much more and 
thorough experimental research is needed before these approaches can be implemented in 
the patient setting. In conclusion, mitochondrial ATP synthase has been and still is a popular 
research topic. Thanks to sustained effort, many aspects of this intriguing protein have been 
elucidated. This knowledge will guide further physio(patho)logical studies, paving the way for 
future therapeutic interventions. 
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BRIEF SUMMARY AND IMPLICATIONS OF THIS THESIS 
 
New tools for the biochemical characterization of cell lines of patients with a 
(suspected) mitochondriopathy are described (see PART II). Providing the most 
accurate biochemical diagnosis is important for the identification of new genetic 
defects. PART III of this thesis focused on complex V deficiency, and again used 
biochemical functional assays e.g. complementation studies to determine the 
pathogenicity of the genetic defect. Furthermore, (patho)physiology was studied using 
BN-PAGE, microscopy for mitochondrial morphology and for immunogold labeling 
(TMEM70 mutation), and biomolecular informatics (TMEM70 and ATP5A1 mutations). 
In conclusion, mitochondrial biochemistry and genetic analysis are complementary in 
the search for and in the characterization of novel mutations. Well-characterized 
defects are important for the development and testing of targeted therapeutic agents. 
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Summary 
 
Metabolism is the buildup and degradation of nutrients by chemical reactions at the cellular 
level. The degradation of nutrients generates metabolites, which can be used for energy 
production in the form of ATP. ATP is needed for growth, development and maintaining the 
living state of the cell. The main source of ATP production is the oxidative phosphorylation 
(OXPHOS) system. The OXPHOS system is situated in the mitochondria, double membrane 
cell organelles harboring their own DNA. This system consists of five multiprotein complexes 
(complex I to V). The first four complexes form the respiratory chain and are responsible for 
electron transfer and proton pumping. Complex V uses the energy created by the proton 
electrochemical gradient to synthesize ATP from ADP. Part of the OXPHOS proteins (called 
subunits) is encoded by the mitochondrial (mt) DNA, part by the nuclear (n) DNA, except for 
complex II which is entirely encoded by the nDNA. mtDNA depends on enzymes encoded by 
the nDNA for replication, repair, transcription and translation. Moreover, a set of assembly 
factors, encoded by the nDNA, is needed to assemble the complexes. As a consequence, 
many gene defects can lead to mitochondrial dysfunction. Mitochondrial diseases are 
therefore common and heterogeneous genetic disorders. Because of this complexity, the 
diagnosis of these diseases is not straightforward. The first step in this process is to define 
the defect biochemically as precise as possible. This can guide the search for the underlying 
genetic defect. Therefore, the first aim in this thesis was to expand current tools for 
biochemical diagnostics in patients suspected for a mitochondrial disease. 
Chapter 2 described a simple, high-throughput, high-content screening method for oxygen 
consumption analysis in different digitonin-permeabilized cell types. It was demonstrated that 
this assay provides a valuable tool in the diagnostics of mitochondrial disorders. It can 
differentiate between primary and secondary mitochondrial abnormalities. Patients with a 
primary mitochondriopathy that does not affect the complexes of the respiratory chain can be 
identified. This is important for patient counseling and genetic advice. 
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In chapter 3, two OXPHOS-deficient myogenic cell lines were established. It was shown that 
the complete biochemical toolbox, including substrate oxidation, ATP production rate and 
oxygen consumption measurements, as well as spectrophotometric enzyme analysis and 
BN-PAGE could be adapted successfully for the study of mitochondrial energy metabolism in 
myoblasts and myotubes. Mitochondrial disorders can thus be identified and characterized in 
muscle cells. This paves the way for multiple applications, e.g. the study of OXPHOS defects 
that are only expressed in muscle tissue, in-depth research for mitochondrial physiology 
using biological assays in living cells, and targeted pharmacological intervention studies. 
Taken together, biochemical assays can help in understanding the (patho)physiology of 
mitochondria and mitochondrial diseases and can guide the identification of the underlying 
genetic defect e.g. mutation analysis of complex V genes in case of an isolated complex V 
deficiency. 
 
The human mitochondrial ATP synthase, or complex V is the last multi subunit OXPHOS 
complex. Complex V comprises 16 subunits. Five of them (α, β, γ, δ, and ε) form the F1 
sector, situated in the mitochondrial matrix, the other subunits (a, c-ring, b, d, F6, OSCP, e, f, 
g, and A6L) belong to the Fo sector, embedded in the inner mitochondrial membrane. Only 
two subunits, a and A6L, are encoded by the mtDNA ATP6 and ATP8 genes, respectively. 
The other subunits are nuclear encoded. 
Unraveling the underlying genetic mutation and studying the functional impact of the defect in 
patients with a complex V deficiency was the second goal in this thesis. To this end, genetic 
mutation analysis was performed step-wise. First, the mtDNA was checked in all patients. 
Second, the complex V genes with reported mutations were examined. Third, whole exome 
sequencing was applied.  
As an introduction, chapter 4 reviewed the architecture, function and assembly of complex V. 
The role of complex V di- and oligomerization and its relation with mitochondrial morphology 
was discussed. Finally, pathology related to complex V deficiency and current therapeutic 
strategies were highlighted. 
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Chapter 5 described the first patient with a mutation in the mitochondrial encoded ATP8 gene 
(step 1). He presented with apical hypertrophic cardiomyopathy and neuropathy. At the 
molecular level, we found an improper assembly and reduced activity of complex V. 
In chapter 6, we described a patient with complex V deficiency due to a deletion in the 
TMEM70 gene (step 2). We saw a fragmented mitochondrial network and swollen and 
irregularly shaped mitochondria with partial to complete loss of the cristae in fibroblasts of 
this patient, which could be completely restored by complementation of the TMEM70 genetic 
defect. Comparative genomics analysis predicted the topology of TMEM70 in the inner 
mitochondrial membrane, which could be confirmed by immunogold labeling experiments, 
and showed that the TMEM70 gene is not restricted to higher multi-cellular eukaryotes. This 
study demonstrated that the role of complex V in mitochondrial cristae morphology applies to 
human mitochondrial disease pathology. 
In chapter 7, we performed whole exome sequencing to discover the mutation in two siblings 
with intractable epilepsy and complex V deficiency (step 3). We found a heterozygous 
mutation in ATP5A1, coding for complex V subunit α. This mutation was also found in the 
father, but because of the clear clinical picture and biochemical results, we decided to 
continue this study and checked the coding (c) DNA, revealing that the patients expressed 
the mutation homozygous while the father remained heterozygous. The mutation gave rise to 
a disturbed interaction of the α subunit with the β subunit of complex V, which interfered with 
the stability of the complex. This study demonstrated that biochemical diagnostics are 
indispensable for the correct interpretation of whole exome sequencing data.  
 
In conclusion (chapter 8), mitochondrial biochemistry is needed to define mitochondrial 
dysfunction. It guides the search for the genetic defect. Mitochondrial biochemistry is also 
needed to confirm the pathogenicity of (a) found genetic variant(s). As both biochemical and 
genetic assays are continuously evolving, this powerful combination of approaches to 
unravel mitochondrial defects will undoubtedly enhance the physiopathological knowledge of 
mitochondrial diseases. This knowledge is crucial for the development of targeted therapies.
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Samenvatting 
 
Stofwisseling is de aanmaak en afbraak van bouwstoffen in ons lichaam op celniveau. Bij 
afbraak ontstaan metabolieten, die gebruikt worden als brandstof om het lichaam te voorzien 
van energie onder de vorm van ATP. ATP is nodig voor groei, ontwikkeling en voor het 
dagelijkse metabolisme. De belangrijkste bron van ATP productie is het oxidatieve 
fosforyleringssysteem (OXFOS). Het OXFOS ligt in de mitochondriën, dit zijn celorganellen 
met een dubbele membraan die hun eigen DNA bevatten. Het OXFOS systeem bestaat uit 
vijf complexen (complex I tot en met V), elk bestaande uit meerdere eiwitten, subunits 
genaamd. Complex I tot en met IV vormen de respiratoire keten en zorgen voor de transfer 
van elektronen naar O2 en het pompen van protonen. Complex V gebruikt de energie die 
door deze proton electrochemische gradiënt gecreëerd wordt om ADP om te zetten tot ATP. 
Een deel van de OXFOS subunits wordt gecodeerd door het mitochondriële (mt) DNA, een 
deel door het nucleaire (n) DNA, met uitzondering van complex II wat volledig nucleair 
gecodeerd is. Het mtDNA hangt voor replicatie, herstel, transcriptie en translatie af van 
enzymen gecodeerd door het nDNA. De assemblage van de verschillende subunits tot 
complexen is eveneens afhankelijk van nucleair gecodeerde eiwitten. Dit betekent dat 
mutaties in veel verschillende genen kunnen leiden tot mitochondrieel disfunctioneren. 
Mitochondriële ziekten komen daarom vrij frequent voor en zijn heterogeen van karakter. 
Omwille van deze complexiteit is de diagnosestelling in deze groep van ziekten niet 
eenvoudig. De eerste stap in dit proces is de zo precies mogelijke biochemische 
karakterisatie van het defect. Dit is van belang bij het zoeken naar het verantwoordelijke 
gendefect. Het eerste doel in dit proefschrift was dan ook het uitbreiden van de huidig 
beschikbare mitochondrieel biochemische diagnostiek. 
In hoofdstuk 2 werd een snelle en eenvoudige methode beschreven om zuurstofconsumptie 
te meten in verschillende celtypes na lysis van de celmembraan met digitonine. Er werd 
aangetoond dat dit een waardevolle methode is om mitochondriële disfunctie aan te tonen. 
Door de zuurstofconsumptie te meten in verschillende celtypes of weefsels kan er een 
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onderscheid gemaakt worden tussen primaire en secundaire mitochondriële afwijkingen. Een 
primaire mitochondriële aandoening zonder complexdeficiëntie kan aangetoond worden. Dit 
is van belang voor (erfelijkheids)advies aan de patiënt. 
In hoofdstuk 3 werden twee OXFOS-deficiënte spiercellijnen geïsoleerd uit spierweefsel. 
Verschillende mitochondrieel biochemische methodes konden succesvol worden toegepast 
op myoblasten en myotubes. Dit betekent dat mitochondriële aandoeningen kunnen 
geïdentificeerd en gekarakteriseerd worden in spiercellen. Dit geeft de mogelijkheid tot tal 
van toepassingen, zoals het bestuderen van OXFOS defecten die enkel tot expressie komen 
in spierweefsel, de studie van mitochondriële fysiologie in de levende cel, en het testen van 
doelgerichte therapeutische interventies. 
Samenvattend kunnen biochemische testen helpen om inzicht te verwerven in de 
(patho)fysiologie van mitochondriën en mitochondriële ziekten. Bovendien zijn ze zeer zinvol 
om het onderliggende genetische defect te helpen identificeren, bijvoorbeeld bij een 
geïsoleerde complex V deficiëntie kan de aandacht in een eerste tijd gericht worden op de 
bekende complex V genen. 
 
 
Het humane mitochondriële ATP synthase, of complex V, is het vijfde OXFOS complex. Het 
bestaat uit 16 subunits. Vijf subunits (α, β, γ, δ, and ε) vormen het F1 deel. De andere 
subunits (a, c-ring, b, d, F6, OSCP, e, f, g, and A6L) vormen het Fo deel. Fo ligt verankerd in 
de mitochondriële binnenmembraan en zorgt voor de transfer van protonen naar F1, gelegen 
in de matrix, waar ATP wordt gesynthetiseerd. Slechts twee van de complex V subunits, 
subunit a en subunit A6L, worden gecodeerd door het mtDNA, namelijk respectievelijk door 
de ATP6 en ATP8 genen. De andere subunits worden nucleair gecodeerd.  
De identificatie en functionele impact van de onderliggende mutatie bij patiënten met een 
geïsoleerde complex V deficiëntie ontrafelen was het tweede doel in dit proefschrift. 
Hiervoor werd de genetische mutatie analyse stapsgewijs uitgevoerd. Eerst werd het mtDNA 
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nagekeken (stap 1). Vervolgens werden alle “bekende” complex V genen onderzocht (stap 
2). Tenslotte werd whole exome sequencing toegepast (stap 3).  
Als introductie gaf hoofdstuk 4 een overzicht van de architectuur, functie en assemblage van 
complex V. De rol van di- en oligomerizatie van complex V in de mitochondriële morfologie 
werd besproken. Tenslotte werden de aan complex V gerelateerde pathologie en de huidige 
therapeutische denkpistes belicht. 
In hoofdstuk vijf vond de eerste beschrijving plaats van een patiënt met een complex V 
deficiëntie ten gevolge van een mutatie in het mitochondrieel gecodeerde ATP8 gen (stap 1). 
Klinisch werd er een apicaal hypertrofe cardiomyopathie en een neuropathie vastgesteld. Op 
moleculair niveau vonden we een verstoorde assemblage en een verminderde activiteit van 
complex V. 
Hoofdstuk 6 behandelde een patiënt met een complex V deficiëntie ten gevolge van een 
deletie in het TMEM70 gen (stap 2). Bij deze en ook andere complex V deficiënte patiënten 
die een structurele afwijking in het complex hebben, werd in huidcellen een verstoorde 
mitochondriële morfologie gezien, gekenmerkt door gezwollen mitochondriën met een verlies 
van cristae. Het mitochondriële netwerk was gefragmenteerd. Deze afwijkingen konden 
hersteld worden door complementatie (toevoegen van het normale gen) van het TMEM70 
gendefect. Comparatieve genoom analyse voorspelde dat TMEM70 ook voorkomt bij lagere 
eukaryoten en dat het eiwit gelegen is in de mitochondriële binnenmembraan. Deze 
lokalisatie kon bevestigd worden met behulp van immunogold labeling en 
electronenmicroscopie. Deze studie toonde aan dat de rol van complex V in de 
mitochondriële morfologie ook geldt voor humane complex V pathologie. 
In hoofdstuk 7 werd whole exome sequencing toegepast bij twee broers met onbehandelbare 
epilepsie en complex V deficiëntie (stap 3). Er werd een heterozygote mutatie gevonden in 
het ATP5A1 gen, wat codeert voor de structurele complex V subunit α. Diezelfde mutatie 
werd ook gevonden bij vader, maar omdat het klinische beeld gecombineerd met de complex 
V deficiëntie zo overtuigend waren bij de patiënten, werd besloten de mutatie verder te 
onderzoeken. En inderdaad, op coderend (c) DNA niveau werd de mutatie homozygoot 
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teruggevonden bij beide kinderen en heterozygoot bij vader. Functioneel resulteerde dit 
defect in een verstoorde interactie van de α met de β subunit, wat aanleiding geeft tot 
instabiliteit van het complex. Deze studie toonde mooi aan dat een biochemische diagnose 
onontbeerlijk is voor de juiste interpretatie van whole exome sequencing data. 
 
In conclusie (hoofdstuk 8) kan gesteld worden dat mitochondriële biochemie nodig is om 
mitochondriële disfunctie te definiëren. Het helpt de zoektocht naar het verantwoordelijke 
gendefect. Mitochondriële biochemie is eveneens nodig om de pathogeniciteit van (een) 
gevonden genetische variant(en) te bevestigen. Gezien zowel de biochemische als 
genetische technieken voortdurend in ontwikkeling zijn, zal deze sterke combinatie 
ongetwijfeld leiden tot het verder ontrafelen van oorzaken van mitochondriële ziekten. Dit 
draagt bij tot de fysiopathologische kennis van deze aandoeningen, wat cruciaal is voor het 
ontwikkelen van gerichte behandelingen. 
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